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Renal and Cardiovascular Outcomes Associated with Cannabis Use in Veterans
with Advanced Chronic Kidney Disease Transitioning to Dialysis
Abstract
Background: Legalization of cannabis and its constituents may lead to increased exposure of a higher
number of consumers to cannabis use, including those with chronic kidney disease (CKD). We expect
increase in cannabis use, especially, in patients with compromised kidney function. However, there is
sparse literature on the effects of cannabis use on cardiorenal and mortality outcomes among patients
with advanced CKD. Objectives: The main goal of the current study was to examine the effect of cannabis
use on renal and cerebrovascular outcomes as well as mortality in patients with advanced CKD. Using a
nationwide cohort of US veterans with advanced CKD transitioning to dialysis, we were guided by the
following aims: Aim 1) Evaluate the effect of cannabis exposure on kidney function by 1a) examining the
association of cannabis exposure with progression of CKD, and 1b) investigating the association of
cannabis exposure with the incidence of acute kidney injury (AKI); Aim 2) Investigate the association of
cannabis exposure with the incidence of stroke; and Aim 3) Examine the association of cannabis
exposure with mortality (mortality due to any reason and cardiovascular mortality). Methods: We used a
retrospective cohort study design in a nationally representative cohort of US veterans with incident EndStage Renal Disease (ESRD) who transitioned to renal replacement therapy from October 1, 2007 through
March 31, 2015. The Transition of Care in Chronic Kidney Disease (TC-CKD) cohort consisted of 102,477
US veterans with incident ESRD identified from the US Renal Data System (USRDS). Urine toxicology tests
(UTOX) determined the use of cannabis, opioids, other drugs, and combinations of the same in the
patients who had undergone a UTOX test within the year prior to dialysis initiation. After applying
inclusion and exclusion criteria, 7,146 patients comprised our study population. Chapter 2 discusses our
examination of the association between UTOX groups and renal outcomes, including both long-term
changes in estimated glomerular filtration rate (eGFR) and the incidence of AKI. We used mixed-effects
models with random intercepts and slopes and logistic regression to examine the association between
UTOX groups and the risk of change in eGFR and AKI, respectively. Chapter 3 describes our investigation
of the association between UTOX groups and cerebrovascular accident (CVA) events using Cox
proportional hazard models. Finally, Chapter 4 presents our research on the association between UTOX
groups and mortality using Cox proportional hazard models (mortality due to any reason) and Fine and
Grey’s competing risk regression (cardiovascular mortality). Results: Cannabis users were more likely to
be younger (57 years cannabis users vs. 60 years no drug use), less likely to be white (45% cannabis
users vs. 55% no drug use), and more likely to be smokers (69% cannabis users vs. 38% no drug use). We
observed that cannabis use alone or combined with opioids or other drugs (vs. no drug use) was not
significantly associated with steeper eGFR slopes or risk of AKI (P-value 0.4-1.0). We also found that the
use of cannabis alone, opioids, other drugs alone, or a combination of these (vs. no drug use) was not
significantly associated with the risk of CVA events (P-value 0.4-1.0). Finally, cannabis use alone or
combined use of cannabis with opioids or with other drugs (vs. no drug use) was not significantly
associated with mortality due to any reason or CV mortality (P-value 0.4-1.0). Conclusion: This study is
the first, to our knowledge, to ascertain use of cannabis, opioids, or other drugs via UTOX tests to
examine the association between various combinations of exposures and renal/cardiovascular/mortality
outcomes in patients with advanced CKD transitioning to dialysis. The study findings suggest the
absence of a harmful association between exposure to cannabis and renal/cerebrovascular/mortality
outcomes. Future clinical trials and further epidemiological studies are needed to confirm these findings
and further expand our understanding of the health effects of cannabis use in the general population as
well as in patients with compromised kidney function.
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Abstract

Praveen Kumar Potukuchi
Renal and Cardiovascular Outcomes Associated with Cannabis Use
in Veterans with Advanced Chronic Kidney Disease Transitioning to
Dialysis
BACKGROUND: Legalization of cannabis and its constituents may lead to increased exposure of a higher number of consumers to cannabis use, including those with
chronic kidney disease (CKD). We expect increase in cannabis use, especially, in patients
with compromised kidney function. However, there is sparse literature on the effects of
cannabis use on cardiorenal and mortality outcomes among patients with advanced CKD.
OBJECTIVES: The main goal of the current study was to examine the effect of
cannabis use on renal and cerebrovascular outcomes as well as mortality in patients with
advanced CKD. Using a nationwide cohort of US veterans with advanced CKD transitioning to dialysis, we were guided by the following aims: Aim 1) Evaluate the effect of
cannabis exposure on kidney function by 1a) examining the association of cannabis exposure with progression of CKD, and 1b) investigating the association of cannabis exposure with the incidence of acute kidney injury (AKI); Aim 2) Investigate the association
of cannabis exposure with the incidence of stroke; and Aim 3) Examine the association of
cannabis exposure with mortality (mortality due to any reason and cardiovascular mortality).
METHODS: We used a retrospective cohort study design in a nationally representative cohort of US veterans with incident End-Stage Renal Disease (ESRD) who transitioned to renal replacement therapy from October 1, 2007 through March 31, 2015. The
Transition of Care in Chronic Kidney Disease (TC-CKD) cohort consisted of 102,477 US
veterans with incident ESRD identified from the US Renal Data System (USRDS). Urine
toxicology tests (UTOX) determined the use of cannabis, opioids, other drugs, and combinations of the same in the patients who had undergone a UTOX test within the year prior
to dialysis initiation. After applying inclusion and exclusion criteria, 7,146 patients comprised our study population. Chapter 2 discusses our examination of the association between UTOX groups and renal outcomes, including both long-term changes in estimated

v
glomerular filtration rate (eGFR) and the incidence of AKI. We used mixed-effects models with random intercepts and slopes and logistic regression to examine the association
between UTOX groups and the risk of change in eGFR and AKI, respectively. Chapter 3
describes our investigation of the association between UTOX groups and cerebrovascular
accident (CVA) events using Cox proportional hazard models. Finally, Chapter 4 presents
our research on the association between UTOX groups and mortality using Cox proportional hazard models (mortality due to any reason) and Fine and Grey’s competing risk
regression (cardiovascular mortality).
RESULTS: Cannabis users were more likely to be younger (57 years cannabis users
vs. 60 years no drug use), less likely to be white (45% cannabis users vs. 55% no drug use),
and more likely to be smokers (69% cannabis users vs. 38% no drug use). We observed
that cannabis use alone or combined with opioids or other drugs (vs. no drug use) was not
significantly associated with steeper eGFR slopes or risk of AKI (P-value 0.4-1.0). We also
found that the use of cannabis alone, opioids, other drugs alone, or a combination of these
(vs. no drug use) was not significantly associated with the risk of CVA events (P-value 0.41.0). Finally, cannabis use alone or combined use of cannabis with opioids or with other
drugs (vs. no drug use) was not significantly associated with mortality due to any reason
or CV mortality (P-value 0.4-1.0).
CONCLUSION: This study is the first, to our knowledge, to ascertain use of cannabis, opioids, or other drugs via UTOX tests to examine the association between various
combinations of exposures and renal/cardiovascular/mortality outcomes in patients with
advanced CKD transitioning to dialysis. The study findings suggest the absence of a harmful association between exposure to cannabis and renal/cerebrovascular/mortality outcomes. Future clinical trials and further epidemiological studies are needed to confirm
these findings and further expand our understanding of the health effects of cannabis use
in the general population as well as in patients with compromised kidney function.
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Chapter 1
INTRODUCTION

Chronic Kidney Disease
Over 850 million individuals worldwide suffer from various stages of Chronic Kidney
Disease (CKD) (ASN, ISN, and ERA-EDTA, 2018). In 2019, approximately 37 million (15%)
of United States (US) adults had CKD (CDC, 2019b). CKD is a public health problem
(Coresh et al., 2014; Coyne and Kovesdy, 2017) but remains a somewhat silent condition,
i.e., 90% of adults with CKD are unaware of their renal disease (ASN, ISN, and ERAEDTA, 2018; Gatwood et al., 2018; CDC, 2019b). The kidneys play a role in a multitude of
functions, including the homeostasis of fluids, electrolytes, and proteins, as well as excretion of toxins (Chua et al., 2019). Structural and functional damage to the kidneys or the
renal system results in the development of CKD. The Kidney Disease Improving Global
Outcomes (KDIGO) defines CKD as persistent alterations in renal structure and function
that are present for more than 90 days. CKD is classified into one of five stages based on
glomerular filtration rate (GFR) and albuminuria (Romagnani et al., 2017).

Diagnosis
The nephron is the functional unit of the kidney, and there are approximately 200 thousand
to 2.5 million nephrons in the kidney to maintain normal biological function. The nephron
is composed of a glomerulus and distinct segments of the tubular system, including the
proximal convoluted tubule, descending loop of Henle, ascending loop of Henle, distal
tubule, and collecting duct (Wikimedia, 2019) (Figure 1.1).
GFR can be expressed as the GFR of a single nephron multiplied by the number of
nephrons (Romagnani et al., 2017). Albuminuria is a useful marker of glomerular injury
(renal barrier dysfunction), while GFR is a reliable marker of renal excretory function (Romagnani et al., 2017) and is expressed in milliliters per min (ml/min), i.e., the quantity
of plasma filtered per minute by the kidneys. GFR can be quantified in multiple ways,
such as measured GFR (mGFR), urinary creatinine clearance (CrCl), and estimated GFR
(eGFR). The gold standard method to evaluate GFR is mGFR. However, obtaining mGFR
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Figure 1.1: Anatomy of nephron. Reprinted with open access permission.
Wikimedia, 2019.
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is expensive and invasive (Jain and Susan Hedayati, 2013; Rule and Kremers, 2016; Alaini
et al., 2017). Alternatively, GFR can be estimated from the measurement of 24-hour urinary
CrCl. However, urinary CrCl is confounded by the tubular secretion of creatinine, which
results in overestimation of true GFR, especially at lower GFR levels (Jain and Susan Hedayati, 2013; Rule and Kremers, 2016; Alaini et al., 2017). Finally, GFR can be calculated
as eGFR, based on patient characteristics including serum creatinine or cystatin C concentration, age, sex, and race (Jain and Susan Hedayati, 2013; Rule and Kremers, 2016; Alaini
et al., 2017).
eGFR can be calculated by several equations, the most commonly used ones being the Modification of Diet in Renal Disease (MDRD) study equation and the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, which were developed
to reduce the bias in estimates of different levels of eGFR (Jain and Susan Hedayati, 2013;
Rule and Kremers, 2016; Alaini et al., 2017). As GFR decreases, patients with CKD progress
from stage 1 to stage 5 (Romagnani et al., 2017). Based on the eGFR, KDIGO classifies CKD
stages as stage 1 (kidney damage with normal or increased GFR, >90 ml/min/1.73m2 ),
stage 2 (kidney damage with mild decrease in GFR, 60-89 ml/min/1.73m2 ), stage 3a (mild
to moderate decrease in GFR, 45-59 ml/min/1.73m2 ), stage 3b (moderate to severe decrease in GFR, 30-44 ml/min/1.73m2 ), stage 4 (severe decrease in GFR, 15-29 ml/min/
1.73m2 ), and stage 5 (kidney failure <15 ml/min/1.73m2 ). Stage 5 is also called end-stage
renal disease (ESRD) (Figure 1.2) (Romagnani et al., 2017).

Epidemiology and Management of CKD
The prevalence of CKD stages 1-5 is estimated at 14.8% (2016) based on data from The National Health and Nutrition Examination Survey (NHANES). In 2016, there were 726,331
prevalent and 124,675 incident ESRD patients in the US based on data from the United
States Renal Data Systems (USRDS) (Saran et al., 2019). A conceptual model developed
by the National Kidney Foundation’s (NKF) Kidney Disease Outcomes Quality Initiative (KDOQI) portrays the development, progression, and complications of CKD (Levey,
Stevens, and Coresh, 2009). According to this model, the development of CKD starts with
damage to the kidneys, resulting in a gradual decrease in GFR, which ultimately leads to
progressive kidney failure. Development and progression of CKD are emphasized in the
(Figure 1.3) model by the horizontal bi-directional arrows, starting from normal kidney
function and leading to kidney failure .
Early stages of CKD may be reversible; however, progression to kidney disease
more frequent than remission. Progression of CKD may lead to complications, such as
cardiovascular disease as shown by the vertical arrows, and may result in death due to
kidney disease (Levey, Stevens, and Coresh, 2009). Furthermore, CKD imposes a substantial economic burden on the healthcare system. Costs for CKD/ESRD comprise nearly
23% of Medicare expenditures (the biggest payer for CKD/ESRD) or approximately $114
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Figure 1.2: KDIGO classification of CKD by GFR and albuminuria. This
KDIGO 2D matrix incorporates the level of albuminuria (given as a ratio to
creatinine (in mg per g) divided into three categories) and the glomerular
filtration rate (GFR) (that is, the level of kidney function) to describe the
risk of patients with chronic kidney disease (CKD) progressing to
end-stage renal disease (ESRD). Reprinted with permission from Springer
Nature. Romagnani et al., 2017.

billion, which includes $35 billion for ESRD (Saran et al., 2019). The only available treatment for ESRD is renal replacement therapy (RRT). RRT can be dialysis or transplantation
(Levey, Stevens, and Coresh, 2009). Worldwide, organ transplantation plays a crucial role
in saving and prolonging lives in a wide variety of clinical conditions. Especially, transplantation has a proven survival advantage over dialysis with also an improvement in
quality of life. However, the shortage of organs is a significant problem worldwide (Beyar,
2011). Also, it is difficult to obtain a transplant because there are many fewer individuals
who donate compared to individuals who suffer from ESRD. Due to many such barriers
for transplantation, most Americans rely on dialysis (Beyar, 2011; Saran et al., 2019). The
mainstay in CKD management is early detection and prevention, especially treating the
underlying cause to curb its progression.

Risk Factors and Complications of CKD
Risk factors that may aid in the development of CKD and its progression include being
born with low nephron numbers, sex, race, loss of nephrons as one ages, or kidney injuries
that may be acute or chronic and are typically a result of chronic diseases or toxic exposures. CKD and progression to ESRD is common in people aged above 65 years. Diabetes
and hypertension are the most significant causes/risk factors of CKD, accounting for 3 out
of 4 new cases. Also, risk factors like obesity, heart disease, family history of CKD, and
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Figure 1.3: Conceptual model of CKD development and progression by
KDOQI. This diagram presents the continuum of the development,
progression, and complications of CKD. Green circles, stages of CKD; aqua
circles, potential antecedents of CKD; lavender circles, consequences of
CKD; thick arrows between ellipses, risk factors associated with the
development and progression and remission of CKD. “Complications”
refers to all complications of CKD and its treatment, including
complications of decreased glomerular filtration rate (GFR) and
cardiovascular disease. Stages of prevention are shown along the
continuum. Reprinted with permission from Elsevier. Levey, Stevens, and
Coresh, 2009.
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acute kidney injury (AKI, transient kidney damage) are associated with the development
and progression of CKD (Kazancioglu, 2013; CDC, 2019b; Saran et al., 2019). Patients with
CKD are at high risk of adverse events and high burden of comorbidities such as chronic
pain, cardiovascular disease (CVD), AKI, and death (Ishani et al., 2009; Tonelli et al., 2015;
Grams et al., 2016a; Kovesdy et al., 2018; Strausser, Nakano, and Souma, 2018).
Risk factors of CKD can be classified as sociodemographic or non-modifiable factors
such as age, sex, race, family history/genetics, low birth weight, and life style or modifiable behavioral factors like smoking, alcohol, physical inactivity, diet, and obesity. There
are also clinical factors including diabetes, hypertension, cardiovascular diseases, and AKI
that increase the risk of CKD. Furthermore, exposure to nephrotoxic drugs is another clinical/risk factor (Saker, 2000; Kazancioglu, 2013; Pazhayattil and Shirali, 2014; Tsai et al.,
2016; Kovesdy et al., 2017; Mallappallil et al., 2017; Mansoor et al., 2017; Obrador et al.,
2017; Romagnani et al., 2017; Perazella, 2018).
Sociodemographic factors (non-modifiable)
Age. Kidney function decreases with age, either due to loss of the number of functioning nephrons or structural changes like decreased podocyte density in the nephron
(Romagnani et al., 2017). While age-related loss of kidney function is believed by most to
be a physiologic process, it also puts the elderly at more risk of CKD, especially the earlier
stages. Indeed, progression to ESRD is higher in adults 65 years and older whose disease
process is often driven by true pathological disease states (Kazancioglu, 2013; Romagnani
et al., 2017)
Sex. The prevalence of earlier stages of CKD is higher in women. However, progression to ESRD is higher in men (Hill et al., 2016; Romagnani et al., 2017; Carrero et al.,
2018). Once on RRT, the gender differences mitigate, and both men and women are at
similar risk of mortality. However, in predialysis CKD, mortality is higher among men
than women (Hill et al., 2016; Romagnani et al., 2017; Carrero et al., 2018).
Race. Advanced stages of CKD and ESRD are more prevalent in African Americans than Caucasians. African Americans are at approximately four times higher risk of
developing ESRD in comparison to Caucasians (Kovesdy et al., 2015; Saran et al., 2019). Although African Americans represent 13 percent of the US population, they make up more
than one-third of people with ESRD in the US. Paradoxically, Caucasians have poorer outcomes compared to African Americans with CKD and ESRD (Kovesdy et al., 2015; Saran
et al., 2019).
Family history/genetics. Heredity or family history of CKD is a significant independent risk factor for CKD and ESRD. Genetic abnormalities or polymorphisms can cause
CKD due to mutations in genes like apolipoprotein L1 (APOL1) or uromodulin (UMOD)
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and are one of the reasons that African Americans are at higher risk of CKD than Caucasians (McClellan et al., 2012; Kazancioglu, 2013; Grams et al., 2016b; Romagnani et al.,
2017).
Low birth weight. Babies born with low birth weight display partial kidney development. In addition, low birth weight may lead to low nephron numbers. Research
has demonstrated that an increase in 1 kg of birth weight increases the nephron number
approximately by 257,000. If born with weight less than 2,500 g, children are at fourfold
increased risk of developing CKD by the time they are 17 years old in comparison to children born with at least 2,500 g weight (Kazancioglu, 2013; Romagnani et al., 2017). A low
number of functioning nephrons (due to low birth weight or nephron loss) results in increased glomerular hyperfiltration leading to glomerular hypertension. Also, low nephron
numbers result in increased risk of arterial hypertension, development of CKD, and rapid
progression to ESRD (Kazancioglu, 2013; Romagnani et al., 2017).
Life style behavioral factors (modifiable)
Smoking. Cigarette smoking is a significant independent risk factor for the development and progression of chronic diseases like CKD. Smoking has a dose-dependent relationship with development and progression of CKD due to its association as a causative
factor in the development of kidney fibrosis. This is mediated via various mechanisms,
including adverse effect of nephrotoxic chemicals in cigarette smoke on the kidneys (Orth
and Hallan, 2008; Xia et al., 2017; Ng et al., 2019) by exerting vasoconstrictive properties
that could lead to a transient increase in blood pressure and decrease of kidney function
(Van Laecke and Van Biesen, 2017; Xia et al., 2017; Schrauben et al., 2019). As a modifiable lifestyle or behavioral factor, smoking is among the major causes of preventable
deaths(Van Laecke and Van Biesen, 2017; Xia et al., 2017; Schrauben et al., 2019).
Physical inactivity. Physical activity is one of the modifiable behavioral factors
for better health and management of chronic conditionss (Chudasama et al., 2019). On
the other hand, physical inactivity is a risk factor for the development of various chronic
diseases like obesity, diabetes, hypertension, and CKD. Physical inactivity is escpeically
common among patients with CKD. Physical exercise positively effects several metabolic
factors and lowers CVD risk factors like triglycerides, hypertension, and insulin resistance,
and, subsequently, these may reduce the risk of CVD and CKD (Johansen, 2005; Stump,
2011).
Diet. Diet also ranks in the top tier of modifiable behavioral factors for maintaining proper health and for the management of the development and progression of chronic
diseases. Unhealthy/poor dietary behaviors is associated with increased burden of comorbidities such as diabetes, hypertension, CVD, and poor outcomes (Ruel et al., 2014). Diet
plays a significant role in both the development and progression of CKD. Healthy diet by
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itself may serve as an intervention, as observed in the Dietary Approaches to Stop Hypertension (DASH) study (Kovesdy and Kalantar-Zadeh, 2017). DASH is a type of diet intervention whose protective effects have been observed in patients with stroke, metabolic
syndrome, and CVD. A similar protective effect is observed in CKD. DASH diet comprises
fruits, vegetables, nuts, and it is low in salt. The DASH diet is composed of 18% protein, 27% fats, and 55% carbohydrates (Asghari et al., 2017; Kovesdy and Kalantar-Zadeh,
2017). Associated with renoprotection the DASH diet can be used as an intervention in the
management of CKD.
Obesity. In the last four decades, the burden of obesity has tripled, effecting more
than 1.9 billion adults worldwide (≥ 18 years) who are overweight and more than 650
million who are obese (WHO, 2018b). In the US, approximately 93 million adults were
obese in 2016. In 2008, the estimated cost to treat obesity was $147 billion (CDC, 2019a).
Obesity is a risk factor for CVD, diabetes, certain types of cancer, and CKD. Obesity is also
one of the top tier modifiable behavioral risk factors for the development and progression
of CKD. Obesity may be harmful to the kidneys by increasing the burden of inflammation,
endothelial dysfunction and oxidative stress. Body mass index (BMI) > 30 (moderate to
morbid obesity) may also lead to proteinuria and rapid progression of CKD (Kazancioglu,
2013; Kovesdy et al., 2017). However, a paradoxical association between BMI and mortality
in advanced CKD/ESRD is observed, with those having high BMI experiencing better
outcomes, as compared to their lower BMI counterparts (Kazancioglu, 2013; Kovesdy et
al., 2017; Romagnani et al., 2017).
Clinical factors
Acute kidney injury (AKI). AKI is a syndrome characterized by a rapid (hours to
days) deterioration of kidney function (Ostermann and Joannidis, 2016). It is often diagnosed in the context of other acute illnesses (especially in those who are hospitalized)
and is particularly common in critically ill patients (Koza, 2016). AKI is associated with a
substantial increase in morbidity, mortality and financial burden (Mehta et al., 2015; Ostermann and Cerda, 2018). Every year approximately 2 million individuals die due to
AKI (Mehta et al., 2015; Ostermann and Cerda, 2018). Approximately 20% of hospitalized
patients develop AKI overall, and about 45% of patients in the intensive care unit (ICU)
develop AKI. Hospitalized patients with AKI experience a higher mortality rate of around
20-50%. In ICU patients, approximately 5-6% develop AKI requiring dialysis. These patients experience an in-hospital mortality rate as high as 60% (Uchino et al., 2005; Fang et
al., 2010; Lafrance and Miller, 2010; Bellomo, Kellum, and Ronco, 2012). AKI may range in
severity from mild renal impairment to overt loss of kidney function requiring RRT. AKI
is a risk factor for development of CKD and having AKI in advanced CKD patients may
further worsen CKD progression to ESRD (Ishani et al., 2009; Grams et al., 2016a; Kovesdy
et al., 2018; Strausser, Nakano, and Souma, 2018)
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Diabetes mellitus. In the last four decades, there has been an enormous leap in
the number of patients with diabetes mellitus. Diabetes can be, type 1 (when the pancreas fails to produce insulin), type 2 (resistance to insulin, or the inability of the body
to use produced insulin). Insulin is a vital hormone which controls glucose metabolism.
Diabetes mellitus is a chronic condition and is a significant cause of diseases like CVD (hypertension, heart attacks, stroke, and amputations) and CKD (WHO, 2018a). In 2017, 9.4%
of the US population (30.3 million people) was effected by diabetes mellitus, out of which
23.1 million were aware of their diabetes or diagnosed. Diabetes mellitus was the seventh
leading cause of death in the US in 2015. The estimated costs of diabetes management was
$327 billion in 2017 (CDC, 2017). Diabetes mellitus is one of the major causes of CKD and
ESRD, followed by hypertension (CDC, 2019b). Approximately one-third of people with
diabetes develop CKD (Gatwood et al., 2018). In 2016, diabetes was deemed responsible
for the development of ESRD in 38% of ESRD patients (CDC, 2017).
Hypertension. Hypertension is the high pressure exerted by circulating blood on
the walls of blood vessels, especially pressure against the arteries. Blood pressure is measured as systolic (pressure in blood vessels when the heart contracts) and as diastolic (pressure in the blood vessels between heart beats). Hypertension is a chronic condition and
also a risk factor for CKD. Hypertension is the leading cause of premature deaths worldwide (WHO, 2019). Blood pressure is considered normal if systolic blood pressure is < 120
mm Hg and diastolic blood pressure is ≤ 80 mm Hg. Elevated blood pressure is diagnosed
when systolic blood pressure is between 120-129 mm Hg and diastolic blood pressure is
< 80 mm Hg (Arnett et al., 2019). Stage 1 hypertension is diagnosed when systolic blood
pressure is between 130-139 mm Hg or diastolic blood pressure is between 80-89 mm Hg.
Stage 2 hypertension is diagnosed when systolic ≥ 140 mm Hg or diastolic ≥ 90 mm Hg
(Arnett et al., 2019). In patients with hypertension and CKD the treatment goal is to maintain blood pressure < 130/80(Arnett et al., 2019). Hypertension was the cause of death for
410,000 US adults in 2014 or more than 1000 deaths each day. The yearly cost of hypertension to the US is estimated at $48.6 billion (CDC, 2019c). Hypertension, importantly, is
the second leading cause of CKD in the US, behind diabetes mellitus. High blood pressure
leads to the development of CKD, which in turn further increase blood pressure, resulting
in a vicious cycle of damage (NIDDK, 2014; CDC, 2019b).
Cardiovascular diseases (CVD). CVD is the leading cause of death in US adults,
with more than 840,768 deaths in 2016 attributable to it. Annual cost of CVD to the US was
approximately $351 billion in 2015(Benjamin et al., 2019). It is estimated that every 40 seconds one US adult may have a myocardial infarction (MI) or stroke. Approximately, 90%
of strokes are due to modifiable risk factors such as hypertension (Benjamin et al., 2019). In
2016, 1 in every 19 deaths were due to stroke. Stroke ranks 5th among the top reasons for
mortality in the US. Worldwide, cerebrovascular disease by itself (which includes ischemic
stroke and hemorrhagic stroke) led to 5.5 million deaths (Benjamin et al., 2019). In 2019, it
is expected that more than 1 million US adults may have a coronary event. Furthermore,

Chapter 1. INTRODUCTION

10

Table 1.1: Comorbidities associated with CKD with a high burden of
hospitalization or death.
Concordant

Discordant

Mental health
and chronic pain

Atrial fibrillation
Chronic heart failure
Diabetes
Hypertension
Peripheral vascular disease
Stroke or TIA

Asthma
Cancer, lymphoma
Cancer, metastatic
Cancer, non-metastatic
Chronic pulmonary disease
Constipation
Severe Dementia
Inflammatory bowel disease
Rheumatiod arthritis

Alcohol misuse
Chronic pain
Depression
Schizophrenia

Reprinted with permission from Elsevier. Tonelli et al., 2015.

approximately 6.2 million individuals had heart failure (HF) and nearly 5.3 million had
atrial fibrillation (AFib) in 2013-2016 (Benjamin et al., 2019). Heart disease (which includes
coronary heart disease, hypertension, and stroke) was the leading cause of death in 2016,
accounting for 13% of deaths in the US, and heart attacks were among the ten most expensive conditions to treat in 2013 (Benjamin et al., 2019). The prevalence of CVD in CKD
patients is two times higher than that in the general population, with an increased risk of
CVD with decreasing kidney function. Notably, a linear relationship exists between the
risk of stroke and decreasing GFR. The relative risk of stroke is 1.4 times higher in patients
with advanced stages of CKD (stages 3-4) than in the general population. However, the
relative risk of stroke increases 5-10 times in patients with ESRD in comparison to the general population. In CKD patients, not only morbidity but also mortality due to CVD are
higher compared to the general population. Notably, patients with ESRD are at higher
risk of death due to stroke (Levin, 2003; Lainscak, 2009; Herzog et al., 2011; Gansevoort
et al., 2013; Liu et al., 2014; Dad and Weiner, 2015; Masson et al., 2015; De La Mata et al.,
2019a; De La Mata et al., 2019b). Similar to hypertension, the relationship between CKD
and CVD is bidirectional, with CKD being both a cause and a consequence of CVD. This is
best exemplified in the various forms of the so-called cardiorenal syndrome (Gansevoort
et al., 2013).
Other comorbidities. CKD imposes significant comorbidity and financial burden,
resulting in poor health outcomes and quality of life. In a study by Tonelli et al. (Tonelli et
al., 2015), comorbidities of CKD were classified as concordant, discordant, mental health,
and chronic pain comorbidities (Table 1.1).

Chapter 1. INTRODUCTION

11

Research efforts are focused on concordant comorbidities like diabetes, hypertension, and stroke. These concordant comorbidities share risk factors with CKD. Discordant
comorbidities like cancer, lung diseases, and dementia, etc. are those which are not directly
related to CKD pathophysiology. In spite of the high prevalence of many of these comorbidities in CKD, their role as risk factors for the development and progression of CKD is
less well studied (Tonelli et al., 2015).
Chronic pain. Pain is common among patients with CKD. The prevalence of pain
in patients with advanced stages of CKD and ESRD ranges from 60-70% (Pham et al.,
2017), and pain in patients with early stages of CKD is associated with decreasing kidney
function (Ravel et al., 2016). Causes of chronic pain in patients with CKD are multifactorial. Pain can be due to comorbidities (diabetic neuropathy), polycystic kidney disease,
syndromes unique to CKD (like renal bone disease), syndromes common in CKD (like
arthritis), and complications from the dialysis procedure (Davison and Davison, 2011). The
severity of pain can be classified as mild, moderate, or severe. The World Health Organization (WHO) has provided a 3-step analgesic ladder for treating the different severities
of pain in the general population, which are classified as mild, moderate, and severe. The
first step for mild pain includes non-opioids like non-steroidal anti-inflammatory drugs
(NSAIDS). The second step of treatment for moderate pain includes opioids with low potency in addition to step 1 drugs. The third step of treatment for severe pain includes
potent opioids in addition to step 1 and 2 drugs. Special consideration has to be given
in treating pain in CKD/ESRD patients when using the analgesic ladder, due in part to
altered pharmacokinetics of certain analgesics and in part to the nephrotoxicity of others
such as NSAIDs (Saker, 2000; Pazhayattil and Shirali, 2014; Wu et al., 2015; Mallappallil
et al., 2017; Mansoor et al., 2017; Pham et al., 2017; Perazella, 2018). In ESRD patients, a
further consideration is the removal of some analgesics by the dialysis procedure (Davison
and Davison, 2011; Pham et al., 2017; Coluzzi, 2018; Ishida et al., 2018; White, 2018).
Nephrotoxic drugs. Some drugs may adversely effect renal function in people with
normal kidneys or further worsen the kidneys in patients with CKD (Saker, 2000). A list
of nephrotoxic medications is shown in Table 1.2.
Nephrotoxic drugs are composed of therapeutic drugs like antimicrobials, chemotherapy drugs, analgesics, immunosuppressants, angiotensin-converting enzyme inhibitors
(ACE), angiotensin receptor blockers (ARBs), statins, herbal remedies, diagnostic agents,
and environmental intoxicants (Perazella, 2018)NSAIDs, which are primarily used for
treating pain, are one of the major nephrotoxic drugs. Prostaglandins are chemicals that
play a role in pain. Prostaglandins and the renin-angiotensin system play a vital role in
maintaining intrarenal circulation by regulating hemodynamics through vasoconstriction
and vasodilation to ensure constant normal intraglomerular pressure and glomerular filtration. NSAIDs inhibit prostaglandins, leading to increased vasoconstriction, which could
result in decreased glomerular filtration leading to AKI (Saker, 2000). Additional adverse
renal effects of NSAIDs include allergic reactions that could result in AKI from interstitial
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Table 1.2: Nephrotoxic drugs and toxicants.
Type
Therapeutic medications
Antimicrobial

Chemotherapy

Analgesics
Immunosuppressives
Other

Alternative/health products
Herbal remedies

Adulterants
Diagnostic agents
Radiocontrast
Other agents
Environmental toxicants
Heavy metals
Solvents
Other toxins

Nephrotoxic drugs and toxicants
Aminoglycosides, Antiviral agents, Amphotericin B, Colistin, Polymixin B, Sulfadiazine, Quinolones, Vancomycin
Platins, Ifosfamide, Mitomycin, Gemcitabine,
Methotrexate,
Pentostatin,
Interleukin-2 (high dose), Antiangiogenesis agents, Immunotherapies (immune
checkpoint inhibitors, chimeric antigen
receptor T cells)
NSAIDs, Selective COX-2 inhibitors,
Phenacetin, Analgesic combinations
Calcineurin inhibitors, Sirolimus, Everolimus
ACE inhibitors/ARBs/renin inhibitors,
SGLT-2 inhibitors (canagloflozin, dapagliflozin), Methoxyflurane, Sucrose
(IVIg excipient), Hydroxyethyl starch,
Mannitol, Dextran, Pamidronate, Zolendronate, Topiramate, Zonisamide, Orlistat,
Statins, Mesalamine
Aristolochic acid, Ephedra sp., Glycyrrhiza sp., Datura sp., Taxus celebica,
Uno degatta, Cape aloes
Mefenamic acid, Dichromate, Cadmium,
Phenylbutazone, Melamine
High osmolar, Low osmolar, Iso-osmolar
Gadolinium (in high dose), Oral NaP solution (colonoscopy prep)
Lead, Mercury, Cadmium, Uranium, Copper, Bismuth
Hydrocarbons
Silicon, Germanium

NSAIDs, nonsteroidal anti-inflammatory drugs; COX, cyclo-oxygenase; ACE,
angiotensin-converting enzyme; ARBs, angiotensin-receptor blockers; SGLT-2, sodium
glucose transporter-2; NaP, sodium phosphate; IVIg, intravenous immunoglobulin; sp.,
species. Reprinted with permission. Perazella, 2018.
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nephritis, a negative effect on electrolyte balance. Such an imbalance can lead to complications such as hyperkalemia, sodium retention with hypertension, edema, (Saker, 2000) and
the development of CKD in patients exposed to NSAIDS for prolonged periods of time.
Due to the numerous adverse renal effects of NSAIDs, opioids are often the treatment of
choice for individuals with CKD who suffer from moderate to severe pain. Opiates and
their metabolites are renally excreted (Coluzzi, 2018). However, in patients with compromised kidney function opiates may be retained in the body, which may lead to adverse
effects like constipation, nausea, dry mouth, changes in mental health, fall risk, and fractures (Davison and Davison, 2011; Coluzzi, 2018). Due to the multiple difficulties posed by
both NSAIDs and opioid analgesic use in patients with CKD, alternative means of analgesia would be preferable. A possible alternative is cannabis-based analgesics, which could
be very useful for treating pain in patients with CKD and ESRD if their efficacy and safety
can be proven (Davison and Davison, 2011; National Academies of Sciences and Medicine,
2017; Abrams, 2018).

Cannabis
History and Legalization
Use of cannabis and its products dates back to 4000 B.C. in ancient days, cannabis was used
for medicinal and/or recreational purposes. In 1896, cannabinol was the first cannabinoid to be isolated, and it was synthesized in 1940. In 1964, delta-9-tetrahydrocannabinol
(THC) was another primary cannabinoid isolated,which later led to the discovery of the
endocannabinoid system (EC) comprising of cannabinoid receptors (CB) and multiple circulating endocannabinoids (Park et al., 2017). For centuries, cannabis was used for treating
a variety of ailments. The legal status of marijuana changed in 1937 with the Marijuana Tax
Act, which led to federal prohibition. Due to criminalization and the subsequent war on
drugs, marijuana was placed in the most restricted schedule I category of drugs, defined
as being a drug with no probable medical use and high abuse potential. The legal status of
marijuana changed again in the 1990s when the state of California approved medical uses
of marijuana for certain conditions such as as cancer, glaucoma , multiple sclerosis. Moreover, in 2012, Colorado and Washington legalized recreational marijuana use ( (Park et al.,
2017). In 2019, 33 other states legalized medical marijuana, and 11 states and Washington
D.C., legalized the recreational use of marijuana in the United States (Cerda et al., 2019),
as shown in Figure 1.4.
In 2013, Uruguay became the first country to legalize marijuana nationwide, followed by Canada in October 2018 (Seltenrich, 2019). Changes in the legalization status
of cannabis, starting from prohibition to criminalization and subsequently to decriminalization/legalization, has led to an increase in the rate of utilization of this substance. The
FDA has also approved two synthetic cannabinoids, nabilone and dronabinol, for clinical
use. These are schedule II and III drugs, respectively (Park et al., 2017).
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Figure 1.4: Legalization of cannabis in the United States for medical and
recreational use. Reprinted with open access permission. Wikipedia, 2019.
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Epidemiology
Utilization of cannabis for recreational purposes is widespread. According to the United
Nations Office of Drugs and Crime data (UNODC), it is estimated that 188 million people
worldwide and 57 million in the US in the age group 15-64 used cannabis at least once
in 2017. Based on UNODC data, the prevalence of cannabis use was 3.9% globally and
15.3% in the USA in 2017 (Report, 2019). Based on the current legalization environment,
it is expected that cannabis use will continue to increase. The expected boom in cannabis
use calls for a deeper understanding of the health effects associated with cannabis use,
including the effect on renal function and kidney disease (Park et al., 2017).

Role of Endocannabinoid (EC) System in Physiology and Pathophysiology
Even though the effect of cannabis consumption on the central nervous system by acting on cannabinoid (CB) receptors (CB1 or CB2) has been well-documented, its use may
also effect (i.e., protective or deleterious effects) on various other organ systems. CB receptors are expressed in multiple tissues and can be activated by exocannabinoids (THC,
Cannabinol, etc.) or by endocannabinoids like N-arachidonoyl ethanolamide, also known
as anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Activation of these receptors
plays a vital role in numerous physiologic processes, including memory, mood, pain sensation, sleep patterns, energy metabolism, and immune function. Cannabis can be used
medicinally to treat various diseases like anxiety, cachexia, obesity, metabolic syndrome,
atherosclerosis, depression, emesis and nausea, epilepsy, hypertension, multiple sclerosis
(especially for spasms), and rheumatoid arthritis (Park et al., 2017). Previous studies suggested that cannabis users may encounter cardiovascular, pulmonary, dental, and other
adverse effects (Park et al., 2017; Rein and Wyatt, 2018). However, we do not have a comprehensive understanding of its long-term risks and benefits on multiple organ systems,
especially the kidneys. Both CB receptors are expressed in the kidneys, and findings from
experimental studies suggest that cannabis use can have both adverse and protective effects on the kidneys. However, there are few human studies that examined the effect of
cannabis use on human kidneys in healthy individuals or in patients with compromised
kidney function (Park et al., 2017).

The EC System in the Kidney
Both CB receptors (CB1 and CB2) are G-protein coupled receptors (Park et al., 2017), which
are expressed to varying degrees in different parts of the kidneys (Munro, Thomas, and
Abu-Shaar, 1993; Howlett, Blume, and Dalton, 2010). CB receptors expression and localization in the kidneys of mice, rats, and humans has been provided in Figure 1.5.
CB1 receptor protein has been detected in proximal convoluted tubules, distal tubules, and intercalated cells of the collecting duct in human kidneys. CB2 receptor expression has been reported in cultured in a proximal tubule or glomerular mesangial cells and
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Figure 1.5: Expression of cannabinoid receptors in the normal kidney.
Affer A, afferent arteriole; CD, collecting duct; EC, endothelial cells; Effer
A, efferent arteriole; G, glomerulus; IHC, immunohistochemistry; PCR,
polymerase chain reaction; Podo, podocytes; TAL, thick ascending limb;
TD, distal tubule; TP, proximal tubule; WB, Western blotting. Reprinted
with permission. Barutta et al., 2018b.
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sporadically in glomerular podocytes. Activation of the renal CB receptors or dysregulation of various components of the EC system may have pathophysiologic consequences
(Park et al., 2017; Barutta et al., 2018a; Chua et al., 2019).

Cannabinoid (CB) Receptors and EC System in Renal Physiology
Based on the research from experimental studies of EC system, the activation of CB1 receptors plays a significant role in maintaining renal homeostasis and tubular biology under
normal physiologic conditions. However, while research has shed light on systemic cardiovascular effects of endocannabinoids, it has not done so as extensively on the specific
effect of endocannabinoids in renal hemodynamics and tubular function (Park et al., 2017;
Barutta et al., 2018a; Rein and Wyatt, 2018; Chua et al., 2019).
Renal hemodynamics
When rats were injected with intravenous AEA, an increase in renal blood flow with a
decrease in glomerular filtration was observed. Increase in renal blood flow was associated
with increased urine flow, but the changes in renal blood flow have not shown an effect
on systemic blood pressure (Park et al., 2017). Studies examining the activation of CB1
receptors in blood vessels and tubular cells have shown increase in urine flow and sodium
excretion. Research has shown that infusion of 2-AG is associated with reduced blood
pressure and may be partly medicated by CB receptors. Further studies are needed to
confirm whether exo-cannabinoids activation of CB receptors and subsequent changes in
renal hemodynamics may have an effect on changes in blood pressure (Park et al., 2017;
Chua et al., 2019). Biological and genetic changes in CB receptors of healthy animals led
to a better understanding of their role and EC system in the glomerulus. Activation of
CB1 receptors in kidneys, especially in the glomerulus using transgenic mice or by CB1
receptor agonists led to increased urinary protein excretion or proteinuria. Based on these
results, it was postulated that dysregulation of CB1 receptor or its increased activity can
lead to pathological effects in the kidney (Park et al., 2017; Barutta et al., 2018a; Chua et al.,
2019).
Tubular biology
Administration of AEA may lead to an increase in renal blood flow, which may be associated with an increase in urine flow and sodium output. The association between increased
renal and urine flow may be mediated by both vascular and tubular components of the kidney through CB1 receptors. Previous research has observed that manipulation of sodium
excretion by desensitization of CB1 receptors with AEA in isolated thick ascending limbs
of Henle’s loop (TAL) lead to an increase in urine flow. Also, this indicates that activation
of CB 1 receptors in tubular and vascular components of the kidney may regulate renal
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blood flow and tubular management of electrolytes, which can effect renal water and salt
clearance (Park et al., 2017; Chua et al., 2019).

CB Receptors and the EC System in Renal Pathophysiology
Perturbations in CB receptors have been observed in various types of acute and chronic
kidney disease. Increased expression of CB1 mRNA has been found in biopsied kidneys
of patients with diabetic nephropathy or IgA nephropathy. On the other hand, a decrease
in CB2 receptor levels, in addition to increased CB1 receptor levels, was observed in diabetic nephropathy of experimental mice and in humans (Park et al., 2017; Barutta et al.,
2018a; Chua et al., 2019). Based on this information, we can hypothesize that changes in
CB receptor expression and function and activity of the endocannabinoid system play a
vital role in renal physiology and pathophysiology and therefore may be a viable potential
therapeutic target for treatment of renal diseases. Experimental studies conducted on genetic models of rats and mice with CKD have suggested that inhibiting CB1 receptors and
activating CB2 receptors using selective pharmacological agents results in improvement in
renal structure and function. When CB1 receptor antagonists were administered to mouse
models with diabetic nephropathy, reduction in proteinuria was observed, which may be
the result of a safeguarding effect on the glomerular podocytes (Jourdan et al., 2014; Nam
et al., 2012). On the other hand, stimulation of CB2 receptors using an agonist (AM1241)
resulted in improvement in albuminuria and podocyte protein expression in diet-induced
obese rats (Jenkin et al., 2016). Also, similar results were observed in diet-induced obese
rats by using antagonists of CB1 receptors (Jenkin et al., 2015). Reduction in protein excretion as a result of CB1 receptor blockade may be mediated through VEGF production
(Jenkin et al., 2015).
Similar results were found in animal models of AKI, where activation of CB2 and
inhibition of CB1 receptors were shown to result in a reduction in markers of kidney injury
(Park et al., 2017; Barutta et al., 2018b; Chua et al., 2019). Previous research based on invitro and preclinical studies has shown the respective role of CB1 and CB2 receptors and
the changes in the receptors in the pathogenesis of a variety of AKI etiologies. Research has
shown harmful effects of CB1 receptors and protective effects of CB2 receptors in cisplatininduced renal injury (Nettekoven et al., 2016). In a recent study, use of CB2 receptors
agonist (triazolpyrimidine derived) had a protective effect in renal injury (Nettekoven et
al., 2016). These results highlight the importance of further understanding the components
of the EC system, given that it most likely plays a crucial role in the effect of cannabis on
the kidneys in both healthy patients and patients with compromised kidney function (Park
et al., 2017; Barutta et al., 2018a; Chua et al., 2019).
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Cannabis Effects on Kidney Function
The current legalization environment suggests that there will be increased use of cannabis
both for medical and recreational purposes. Based on the evidence of the role of the EC system in renal physiology and pathophysiology, individuals using cannabis can potentially
experience detectible effects on the kidneys. These may include deleterious effects, such
as the development and/or worsening of AKI and CKD, or potentially an improvement
of these conditions, depending on factors such as the type and location of CB receptors activated. Previous studies have reported increased incidence of AKI with recreational use
of synthetic cannabinoids (Park et al., 2017; Barutta et al., 2018a; Chua et al., 2019). Few
studies have investigated the association between cannabis use and kidney function, and
mortality (all-cause and cause-specific) (Vupputuri et al., 2004; Grubbs et al., 2016; Ishida
et al., 2017; Bundy et al., 2018; Lu et al., 2018). Bundy et al. examined the association between marijuana use and CKD progression, and all-cause mortality in adults (21-74 years)
with mild to moderate CKD. They observed that marijuana use was not associated with
CKD progression and all-cause mortality (Bundy et al., 2018).
Ishida et al. (2017) investigated the association between marijuana use and kidney
function in young adults (18-30 years) with preserved kidney function, using both a crosssectional and longitudinal design. They observed a modest association between higher
marijuana use and lower kidney function in the cross-sectional design, but no association
in the longitudinal design
Lu et al. (2018) assessed the association between marijuana use and kidney function in healthy adults (18-59 years) and did not find any clinically significant association
between marijuana use and kidney function.
Vupputuri et al. (2004) examined the association between illicit drug use (including
marijuana) and kidney function in adult men with hypertension, and found a significant
association between marijuana use (by itself) and a decline in kidney function. These available observational studies were based on self-reported use of cannabis (Vupputuri et al.,
2004; Grubbs et al., 2016; Ishida et al., 2017; Bundy et al., 2018; Lu et al., 2018), which
can result in suboptimal validity and reliability, and under-reporting of its use (Magura
and Kang, 1996; Richter and Johnson, 2001). Also, these studies did not investigate the
cardiovascular/cerebrovascular events, even though the risk of stroke is high in patients
with CKD/ESRD (Power, 2013; Dad and Weiner, 2015; Nayak-Rao and Shenoy, 2017), and
cannabis use can aggravate stroke risk (Thanvi and Treadwell, 2009; Singh et al., 2012;
Reece, Norman, and Hulse, 2016; Goyal, Awad, and Ghali, 2017; Wolff and Jouanjus, 2017;
Pacher et al., 2018; Sierra, Luquin, and Navarro-Otano, 2018). In addition, none of the
previous studies examined the association between cannabis use and incidence of AKI in
patients with compromised kidney function.
As mentioned above, the major limitation of the previous studies was the use of
self-reported exposure to cannabis/opioids/illicit drugs, which is prone to reporting bias
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and which may explain the inconsistent results described by these studies. Furthermore,
the effects of cannabis and cannabinoids may be different depending on the studied population, and none of the former studies examined patients with advanced CKD, who may
be more vulnerable to deleterious effects of nephrotoxic agents, or who may benefit more
from putative salutary effects of cannabinoids. In the current study, we have used urine
toxicology tests to accurately identify the exposure to cannabis/opioids/illicit drugs, and
we examined the association between these exposures with clinically relevant outcomes
like AKI/ cardiovascular/cerebrovascular events.

Goal of the Study
The overarching goal of the current study was to shed more light on the effect of cannabis
use on clinical end points, indicating kidney injury, progression of kidney disease, and association with relevant outcomes such as mortality and CV events. We have focused on
patients with preexisting CKD, given that they are the highest risk group for complications
described. This is an epidemiological study of US veterans with advanced CKD. To more
accurately ascertain exposure to cannabis, we used urine toxicology tests to compare outcomes in patients with positive and negative tests. We investigated the population-wide
association of cannabis use with progression of CKD, the incidence of stroke, and mortality
(all-cause and cause-specific).

Study Signficance
Legalization of cannabis and its constituents may lead to increased exposure of a higher
number of consumers, including those with chronic kidney disease (CKD). Patients with
advanced CKD are a vulnerable population at high risk for complications associated with
toxic exposures, and in whom there are few effective therapeutic interventions aimed at
kidney disease or cardiovascular disease . Little is known about the effects of cannabis on
kidney function at a population level, and especially in patients with advanced CKD. The
lack of epidemiological studies examining the association between cannabis use and renal
outcomes, such as the progression of CKD and the risk of AKI in advanced CKD patients,
highlights the need for the current study.
Besides a lack of information about renal outcomes, little is known about the association between cannabis use and the incidence of other major clinical outcomes such as
mortality or stroke in advanced CKD patients. To the best of our knowledge, none of the
previous studies examined the effects of cannabis use on mortality and stroke incidence
in patients with advanced CKD and ESRD. More epidemiological studies like the current
study are imperative to investigate these associations of cannabis use in patients with advanced kidney disease. This proposal is, to our knowledge, the first to examine clinically
relevant associations of cannabis use by using urine toxicology tests (UTOX) to confirm the

Chapter 1. INTRODUCTION

21

exposure. The current study findings may further aid in better understanding the effect of
cannabis use on renal and cardiovascular outcomes in patients with advanced CKD and
ESRD.

Research Aims
We had three specific aims, as follows:
Aim 1. Evaluate the effect of cannabis exposure on kidney function in a nationwide
cohort of US veterans with advanced CKD.
1a. Examine the association of cannabis exposure with progression of CKD.
Hypothesis: Cannabis use is associated with more pronounced loss of kidney
function over time, expressed as steeper slopes of eGFR.
1b. Investigate the association of cannabis exposure with the incidence of AKI.
Hypothesis: Cannabis use is associated with higher AKI incidence.
Aim 2. Investigate the association of cannabis exposure with the incidence of stroke
in a nationwide cohort of US veterans with incident ESRD.
Hypothesis: Cannabis use is associated with higher stroke incidence.
Aim 3. Examine the association of cannabis exposure with mortality (all-cause &
cause-specific) in a nationwide cohort of US veterans with incident ESRD.
Hypothesis: Cannabis use is associated with higher risk of mortality.

22

Chapter 2
ASSOCIATION OF CANNABIS USE WITH RENAL
OUTCOMES IN VETERANS WITH ADVANCED
CHRONIC KIDNEY DISEASE (CKD)
TRANSITIONING TO DIALYSIS

Introduction
Chapter 2 describes the research undertaken for Aim 1, mentioned in the Research Aims
section of chapter 1, that examined the association between cannabis use and kidney function in the study population.
Chronic kidney disease (CKD) is a worldwide health problem (Coresh et al., 2014;
Coyne and Kovesdy, 2017). Pain is common among patients with CKD and end-stage
renal disease (ESRD) (Pham et al., 2017). Therefore, special consideration should be given
to treating pain in CKD and ESRD patients, partly due to altered pharmacokinetics and
nephrotoxicity of certain analgesics such as NSAIDs (Saker, 2000; Pazhayattil and Shirali,
2014; Wu et al., 2015; Mallappallil et al., 2017; Mansoor et al., 2017; Pham et al., 2017;
Perazella, 2018).
As a result of the numerous adverse renal effects of NSAIDs, opioids are often the
treatment of choice for individuals with CKD who suffer from moderate to severe pain
(Wyne et al., 2011; Kimmel et al., 2017; Ishida et al., 2018). In order to monitor the adherence to chronic or long-term opioid therapy LTOT), guidelines drafted by various medical
societies and by federal/state regulatory agencies have recommended urine drug testing
(UDT) (Reisfield, Salazar, and Bertholf, 2007; Mahajan, 2017). UDT is also used to monitor
concurrent or combined use of non-opioid substances. This monitoring aids providers in
assessing the risk-benefit ratio to further prescribe opioids, decrease the dose, or discontinue prescribing (Wyse et al., 2018).
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LTOT is common in patients with CKD (Kimmel et al., 2017). Use of both NSAIDs
and opioid analgesics in patients with CKD poses multiple difficulties, and hence alternative means of analgesia would be preferable. This need is exacerbated by the current
public health crisis from the opioid epidemic (Mahajan, 2017; Murray et al., 2019).The
spread of legalization/decriminalization of cannabis for medical or recreational use (Park
et al., 2017) has created a possible alternative mode of analgesia, which could be especially
useful for treating pain in patients with CKD and ESRD if their efficacy and safety can be
proven (Davison and Davison, 2011; National Academies of Sciences and Medicine, 2017;
Abrams, 2018; Coluzzi, 2018; Ishida et al., 2018).
Although cannabis has been used for recreational and/or medicinal purposes for
a long time, there is a paucity of conclusive evidence regarding the short- and long-term
health effects (harmful/beneficial) of cannabis use (National Academies of Sciences and
Medicine, 2017; Park et al., 2017). Previous research has observed that cannabis users may
encounter adverse effects like pulmonary, cardiovascular, dental, and other adverse effects
(Park et al., 2017). However, only a few studies have examined the impact of cannabis
use on the kidneys, especially in patients with compromised kidney function (Vupputuri
et al., 2004; Grubbs et al., 2016; Ishida et al., 2017; Bundy et al., 2018; Lu et al., 2018).
The current legalization environment and the expected increase in cannabis use calls for
a deeper understanding of its health effects, including the effect on renal function and
kidney disease (Park et al., 2017).
Cannabis exerts its effects by acting on cannabinoid (CB) receptors CB1 or CB2 (Park
et al., 2017). CB receptors are expressed in multiple tissues throughout the body, including
the kidneys, and can be activated by many active ingredients present in cannabis (tetrahydrocannabinol [THC], cannabinol [CBN], etc.). Endogenous ligands and the machinery
involved in their synthesis and breakdown comprise the endocannabinoid system, which
plays a significant role in maintaining normal renal homeostasis (Park et al., 2017). Perturbations in this system have been shown to be involved in chronic kidney disease and acute
kidney injury.
In pathophysiological conditions, increased expression of CB1 receptors has been
observed in the brain, cardiovascular, and renal systems. Research has shown that activation of CB1 receptors may lead to oxidative stress, inflammation, and fibrosis (Mukhopadhyay et al., 2010b; Rajesh et al., 2012; Chua et al., 2019). In this regard, there is evidence
that blocking CB1 receptors and activating CB2 receptors using selective pharmacological
agents can result in improvement in renal structure and function in some experimental
models of acute kidney injury (Park et al., 2017; Chua et al., 2019).
When CB1 receptor antagonists were administered to mouse models with diabetic
nephropathy, reduction in proteinuria was observed, which may be the result of a safeguarding effect on the glomerular podocytes (Nam et al., 2012; Jourdan et al., 2014). Also,
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similar results were observed in diet-induced obese rats by using antagonists of CB1 receptors (Jenkin et al., 2015). Furthermore, in animal models of AKI, activation of CB2 receptors
and inhibition of CB1 receptors resulted in a reduction in markers of kidney injury (Park
et al., 2017; Barutta et al., 2018b; Chua et al., 2019). Previous research based on in vitro and
preclinical studies has shown the respective roles of CB1 and CB2 receptors and the role
of their alterations in the pathogenesis of AKI in a variety of settings. For instance, studies
have shown the harmful effects of CB1 receptors and the protective effects of CB2 receptor
activation in cisplatin-induced renal injury. Also, in a recent study, use of a CB2 receptor
agonist (triazolpyrimidine-derived) played a protective role in renal injury (Mukhopadhyay et al., 2010c; Mukhopadhyay et al., 2010a; Mukhopadhyay et al., 2016). It is therefore
imperative to understand whether chronic and consistent cannabis use has an impact on
CKD progression/kidney injury in humans.
Few studies have examined the association between cannabis/illicit drug use and
CKD progression in healthy patients and in patients with compromised kidney function
(Vupputuri et al., 2004; Grubbs et al., 2016; Ishida et al., 2017; Bundy et al., 2018; Lu
et al., 2018). Previous reports have shown increased incidence of AKI with use of synthetic cannabinoids (Park et al., 2017; Barutta et al., 2018b; Chua et al., 2019). However,
these observational studies were based on self-reported use of cannabis, and research has
shown that self-reported illicit drug use in patients with chronic pain is not reliable (Reisfield, Salazar, and Bertholf, 2007). Also, no studies observed the association of AKI with
natural/non-synthetic cannabinoids. In addition, previous studies have not examined the
association of combined use of opioids/other drugs with cannabis on renal outcomes in
patients with compromised kidney function (Vupputuri et al., 2004; Grubbs et al., 2016;
Ishida et al., 2017; Bundy et al., 2018; Lu et al., 2018).
Besides self-reporting, drug use (cannabis/opioids/illicit drugs) can be ascertained
through biological specimens, including urine, blood, breath, oral fluid, nails, and hair.
Biological specimens have several disadvantages, however: 1) A urine sample can be diluted; 2) blood sampling involves an invasive procedure; 3) hair sampling may be difficult
if the hair is too short and not suitable for acute drug use; 4) sweat samples can be affected
by drug diffusion to the sweat glands; 5) in the case of saliva, the window of detection
is measured in hours; and finally, 6) nail samples are not reliable for recent or infrequent
drug use (Moeller, Lee, and Kissack, 2008; Moeller et al., 2017). However, the most commonly used drug testing specimen is urine. Advantages of urine specimens include the
noninvasive nature of specimen collection, a higher concentration of the parent drug and
its metabolites, and longer drug detection times compared to blood samples ((Moeller,
Lee, and Kissack, 2008; Moeller et al., 2017). In the current study, we ascertained the exposure to cannabis, opioids, and other drug use (also combined use of opioids/other drugs
with cannabis) using UDTs and classified individuals into urine toxicology groups (UTOX
groups).
The primary aim of the current study was to examine the association between UTOX
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groups and renal outcomes, including both long–term changes in estimated glomerular
filtration rate (eGFR) and the incidence of AKI. Given the predominant expression of CB1
receptors in the different cells of the kidney and data indicating that activation of CB1
receptors is associated with inflammation, oxidative stress, renal injury, and fibrosis, we
hypothesized that cannabis use is associated with more pronounced loss of kidney function over time (via activation/blocking of CB receptors by cannabinoids in cannabis), expressed as steeper slopes of eGFR. Also, we hypothesized that cannabis use is associated
with higher AKI incidence.

Methods
Study Population
We examined a nationally representative cohort of US veterans with incident end stage
renal disease (ESRD) who transitioned to renal replacement therapy from October 1, 2007
through March 31, 2015 (Transition of Care in Chronic Kidney Disease (TC-CKD)) (Gaipov
et al., 2018). The TC-CKD cohort consisted of 102,477 US veterans with incident ESRD
identified from the US Renal Data System (USRDS) (Saran et al., 2019). We excluded patients without a UDT/urine toxicology test (n=82,106). Subsequently, we excluded patients
with a urine toxicology test only after dialysis initiation (n=5,949) or only before one year
prior to dialysis initiation (n=6,807). This resulted in urine samples from 7,615 patients
who had at least one UDT within a year of dialysis initiation. Out of the 7,615 patients,
6,945 patients tested negative for cannabis, out of which we excluded patients with a positive test for cannabis any time prior to the one-year period preceding dialysis initiation
or after dialysis initiation (n=469, potential false negatives). This resulted in a sample of
7,146 (6,476 tested negative for cannabis and 670 patients tested positive for cannabis). For
the analyses focused on eGFR change, we further excluded patients without eGFR data
(n=312; Figure 2.1). For the analysis focused on AKI, we excluded patients without AKI
data (n=4,895; Figure 2.2).

Exposure Ascertainment
Out of the 7,146 patients who had undergone a urine toxicology test in the year prior
to dialysis initiation, cannabis status (positive vs negative) was ascertained by the validated algorithm by Morasco et al. (2018). We excluded past users of cannabis from the
ones who tested negative in the year prior to dialysis initiation, as mentioned above.
Among those who tested negative for cannabis, we identified patients who tested positive for opioids only (buprenorphine, codeine, hydrocodone, methadone morphine, oxycodone, propoxyphene, and opiates), for other drugs (amphetamines, barbiturates, benzodiazepines, cocaine, heroin, phencyclidine (PCP), and lysergic acid diethylamide (LSD)),
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Figure 2.1: Study population for eGFR slope outcome. *469 patients
tested positive for cannabis any time before 365 days of dialysis initiation
or after dialysis initiation.
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Figure 2.2: Study population for AKI outcome. *469 patients tested
positive for cannabis any time before 365 days of dialysis initiation or after
dialysis initiation.
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Figure 2.3: Color matrix for the urine toxicology (UTOX) groups.

and for combined use of opioids and other drugs. Out of these, 3,394 patients had negative test results for all the toxicology tests. There were 670 patients whose test results
were positive for cannabis, but only 201 patients tested positive for cannabis only. Also,
we identified combined use of opioids and other drugs in patients who tested positive for
cannabis. These patients were further categorized as positive for cannabis and opioids,
positive for cannabis and other drugs, and finally positive for cannabis, opioids, and other
drugs. This categorization yielded 8 UTOX exposure groups (Figure 2.1, Figure 2.2, and
Figure 2.3).
For cannabis use, we only considered never users or current users, and excluded
past users. Past users were excluded to avoid misclassification of long-term users as negative users within a year of dialysis initiation. Cannabinoids can be detected in the urine as
long as 3 days after a single use, 7 days after multiple uses, 14 days in frequent users, and 30
days in heavy daily users (Moeller, Lee, and Kissack, 2008; Moeller et al., 2017). However,
in the case of opioids and other drugs, we included past/long-term users with current
users to identify the lifetime use of opioids and other drugs. For example, if a patient’s
UDT was negative for opioids (n=577 out of 1,751)/other drugs (n=291 out of 566) within
the year of dialysis initiation but they tested positive for opioids/other drugs any time
before or after (within a year of dialysis initiation), the patient was considered positive for
opioids/other drugs. We assume misclassification may not be a problem in this scenario
for two reasons. Firstly, the majority of these patients had undergone UDTs as a part of
COT/LTOT. Second, USRDS/Center for Medicare and Medicaid Services (CMS) records
illicit/other drug use as current and/or use anytime within the last 10 years (Grubbs et al.,
2016).
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Outcome Ascertainment
The co-primary outcomes were eGFR slopes and incidence of AKI. VA Corporate Data
Warehouse-LabChem data files were used to extract data, as previously described (Gaipov
et al., 2018; Kovesdy et al., 2018).
Several indices are available to examine eGFR change over time, i.e., percentage
change relative to a baseline value and slope (annual change in eGFR). Previous research
suggests eGFR slope is a better predictor for long-term CKD outcomes (Coresh et al., 2014;
Sumida et al., 2016; Streja et al., 2017); therefore, we used eGFR slopes as an outcome. We
used outpatient serum creatinine values and demographic data to estimate eGFR values
with the CKD-EPI formula (Levey et al., 2009). Outpatient serum creatinine values were
used to avoid potential fluctuation of serum creatinine levels in inpatient settings.
AKI was identified from hospitalization-associated serial serum creatinine measurements in the year before dialysis initiation. We identified the incidence of in-hospital AKI
observed within 7 days after a urine toxicology test. We defined AKI only within 7 days
of UTOX test as we needed at least 3 to 7 days of inpatient creatinine measures to identify
AKI. AKI was categorized as present/absent (Kellum, Lameire, and Group, 2013; Grams
et al., 2016a). In the current study, due to categorization of UTOX groups and low numbers in certain groups, we only used the binary definition (presence or absence) of AKI as
an outcome. Baseline serum creatinine was defined as the most recent outpatient serum
creatinine measured prior to hospitalization (Grams et al., 2016a).

Confounders/Covariates
Multivariable models were adjusted for a priori specified confounders. The following confounders were included, based on literature/previous observational studies identifying
their association with/known effects on renal function and/or UTOX groups (Vupputuri
et al., 2004; Grubbs et al., 2016; Ishida et al., 2017; Bundy et al., 2018; Lu et al., 2018).
Demographic characteristics
Data from the USRDS Patient and Medical Evidence file was used to determine patients’
baseline information on age, sex, and race at a year before dialysis initiation (Vupputuri
et al., 2004; Grubbs et al., 2016; Ishida et al., 2017; Bundy et al., 2018; Lu et al., 2018).
Comorbidities
The following comorbidities were included:
• Chronic pulmonary disease (CPD) (Chen and Liao, 2016; National Academies of Sciences and Medicine, 2017).
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• Diabetes (Ishida et al., 2017; National Academies of Sciences and Medicine, 2017;
Bundy et al., 2018; Lu et al., 2018).
• Liver disease (Gonwa and Wadei, 2013; National Academies of Sciences and Medicine,
2017).
• Hyperlipidemia (Ishida et al., 2017).
• Hypertension (Vupputuri et al., 2004; Grubbs et al., 2016; Ishida et al., 2017; Bundy
et al., 2018; Lu et al., 2018).
• Post-traumatic stress disorder (PTSD) (National Academies of Sciences and Medicine,
2017).
• Charlson comorbidity index (CCI) scores. CCI scores were estimated using the Deyo
modification for administrative datasets without including kidney disease (Deyo,
Cherkin, and Ciol, 1992).
For the following reasons, we did not include cardio/cerebro/ peripheral vascular disease
as confounders in the comorbidities. Firstly, CCI score estimation includes cardio/cerebro/
peripheral vascular disease information. Finally, use of medications was considered a
proxy for presence of these comorbidities. Information about prevalent comorbidities at
the time of dialysis initiation was extracted from the VA Inpatient and Outpatient Medical
SAS datasets and CMS datasets using ICD-9 diagnostic and procedure codes and Current
Procedural Terminology codes.
Tobacco smoking status
Tobacco smoking status is a crucial confounder to adjust for in examining the association
between UTOX groups and renal outcomes (Vupputuri et al., 2004; Ishida et al., 2017;
National Academies of Sciences and Medicine, 2017; Lu et al., 2018). Smoking information
was extracted from VA health factors data (McGinnis et al., 2011; Soohoo et al., 2019).
Vascular access
Creation of vascular access is associated with slower progression of CKD (Sumida et al.,
2017). Also, cannabis use may have an impact on blood vessels (Steffens et al., 2005; Lu et
al., 2018) and may effect vascular access. It was therefore important to adjust for vascular
access (Grubbs et al., 2016).
Medications
Information about potentially nephrotoxic medication use during the year prior to dialysis initiation was collected from both the VA pharmacy dispensation records and CMS
Medicare Part D files (Perazella, 2018; Overholser and Foster, 2011; Lindsey, Stewart, and
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Childress, 2012; Alsherbiny and Li, 2018). The following medications were considered
potentially nephrotoxic and hence acting as confounders:
• Analgesics (aspirin, acetaminophen, NSAIDs and opioid analgesics).
• Psychiatric medications (amitriptyline, doxepin, fluoxetine, lithium, haloperidol).
• Antimicrobials (acyclovir, aminoglycosides, amphotericin B, penicillins,
cephalosporins, foscarnet, ganciclovir, pentamidine, quinolones, rifampin, sulfonamides, vancomycin).
• Antiretrovirals (adefovir, cidofovir, tenofovir, indinavir).
• Cardiovascular drugs (angiotensin-converting enzyme inhibitors,
angiotensin-receptor blockers, direct renin inhibitors, clopidogrel, ticlopidine, statins).
• Chemotherapeutics (carmustine, cisplatin, interferon-alfa, methotrexate, mitomycinC).
• Diuretics.
• Proton pump inhibitors and H2 receptor blockers.
• Anticoagulants and warfarin.
• Antihistamines (diphenhydramine, doxylamine).
• Benzodiazepines.
Vital signs
Vital signs data were obtained from the VA Vital Status file. The following vital signs were
considered confounders (Ravel et al., 2016) and were included in our analyses: systolic
blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI) and pain
score. We used the mean value of all measurements performed within a year before dialysis initiation for each of these variables (Vupputuri et al., 2004; Lu et al., 2014; Grubbs et al.,
2016; Ishida et al., 2017).
Baseline eGFR
Baseline eGFR was defined as the intercept estimated from the mixed-effects models (proxy
of residual kidney function).

Statistical Analysis
Baseline data are presented for the entire cohort and by UTOX group as a number (percent)
for categorical variables and mean ± SD or median (interquartile range [IQR]), as appropriate. Based on retrospective cohort design of the study and nonrandomized data, we
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used inverse probability of treatment weighting (IPTW) to adjust for baseline differences
between the patients in the eight UTOX groups. We used IPTW to re-weight and balance each UTOX group based on pretreatment variables/confounders, which includes demographics, comorbidities, smoking status, vascular access, medications, and vital signs.
We used generalized boosted modeling (GBM), a nonparametric method to calculate the
weights. GBM is flexible and outperforms logistic regression in estimating weights from
IPTW (McCaffrey et al., 2013; Schuler et al., 2014). We used GBM for estimating weights
with more than two treatment groups (using the “twang” package in R (McCaffrey et al.,
2013)), which is referred to as Multinomial Propensity Score (MNPS) weights. In GBM,
IPTW weights were estimated from the MNPS. As it is difficult to show the balance of
weighted variables with eight treatment groups, we opted for doubly robust models as
a sensitivity analysis. Doubly robust models include the UTOX groups, all the variables
used to calculate the MNPS weights, and the MNPS weights (Steffens et al., 2005; McCaffrey et al., 2013). Even though the possibility of extreme weights for the treatment groups is
low in GBM (McCaffrey et al., 2013), we conducted a sensitivity analysis with winsorized
weights. In order to correctly interpret IPTW weights as probability weights, we used
survey packages/methods (McCaffrey et al., 2013).
Change in estimated glomerular filtration rate (eGFR slope) outcome
Slopes of eGFR (annual change in eGFR) and the effect of inter-individual UTOX groups on
intraindividual slopes was assessed in mixed-effects models with random intercepts and
slopes. We used the XTMIXED command in STATA to assess eGFR slopes, which accounts
for the differences in number, spacing, and different follow-up time in eGFR measurements
for each patient while also estimating eGFR slopes. An additional advantage of XTMIXED
is that it can handle IPTW (from MNPS) weights as probability weights. We performed
various levels of adjustment as follows:
1. Main analysis:
(a) Unadjusted model/Model 1: Only UTOX groups (UTOX group 0 reference).
(b) Adjusted model: Model 1 + IPTW weights.
2. Sensitivity analyses:
(a) Incremental analysis:
i. Model 2-Model 1 + demographic variables.
ii. Model 3-Model 2 + comorbidities + smoking status + vascular access.
iii. Model 4- Model 3 + medications.
iv. Model 5- Model 4 + vital signs (without baseline eGFR as random intercepts
were included).
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(b) Doubly robust model: Model 5 + IPTW weights.
(c) Adjusted model with winsorized weights: Model 1 + winsorized IPTW weights.
(d) Doubly robust model with winsorized weights: Model 5 + winsorized IPTW
weights.
Acute kidney injury outcome
We assessed the odds ratios of AKI associated with UTOX groups using logistic regression
models (crude and multivariable adjusted). Specifically, we used the survey logistic procedure in SAS software with UTOX group 0 as reference. We performed various levels of
adjustment as follows:
1. Main analysis:
(a) Unadjusted model/ Model 1: Only UTOX groups (UTOX group 0 reference).
(b) Adjusted model: Model 1 + IPTW weights.
2. Sensitivity analyses:
(a) Incremental analysis:
i. Model 2-Model 1 + demographic variables.
ii. Model 3-Model 2 + comorbidities + smoking status + vascular access.
iii. Model 4- Model 3 + medications.
iv. Model 5- Model 4 + vital signs + baseline eGFR .
(b) Doubly robust model: Model 5 + IPTW weights.
(c) Adjusted model with winsorized weights: Model 1 + winsorized IPTW weights.
(d) Doubly robust model with winsorized weights: Model 5 + winsorized IPTW
weights.
A two-sided p-value of <0.05 was used as a threshold of statistical significance for all
statistical analyses. We also performed additional analyses to control for multiple comparisons between the 8 UTOX groups. First, we applied Bonferroni correction to avoid type
I error (Armstrong, 2014). The Bonferroni correction sets the significance at a more conservative value, which is represented by α/n. In the current study α=0.05 and n= 8 UTOX
groups, which involved seven between-group comparisons and resulted in α-threshold
of 0.007 (0.05/7). Second, we performed multiple pair-wise comparisons among the 8
UTOX groups (total of 28 pair-wise comparisons) using Tukey’s method. We considered
these analyses as additional analyses since Bonferroni‘s correction is not routinely recommended and Tukey’s method is a post hoc analysis (Lee and Lee, 2018). All analyses were
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conducted in SAS Enterprise Guide v7.1 (SAS Institute; Cary, NC), STATA/MP Version 15
(STATA Corporation, College Station, TX), and R-Studio 1.0.153. The study was approved
by the Institutional Review Boards of the Memphis and Long Beach, VA, Medical Centers,
with exemption from informed consent.

Results
Change in Estimated Glomerular Filtration Rate (eGFR Slope) Outcome
Baseline characteristics
The mean (SD) age of the sample was 60 (10) years; 97% were males, 46% were African
Americans, 97% had hypertension, 78% had hyperlipidemia, 73% were diabetic, 51% were
current smokers, 88% were analgesics users, 85% were diuretics users, and 51% were psychiatric medication users. Except for patients in UTOX groups 0 and 5, patients in other
groups (1-4 & 6, 7) were more likely to be younger, less likely to be white and more likely
to be smokers (Table 2.1).
UTOX groups 1-4 vs group 0
The median (IQR) eGFR slope was -9.4 (-17.6, -5.0) ml/min/1.73m2/year. In the unadjusted model, compared to UTOX group 0, UTOX groups 1, 3 and 4 were associated with
significantly steeper decreasing eGFR slopes. Similar patterns of steeper decreasing slopes
were observed in the adjusted model with weights, however, these differences did not
reach statistical significance (Table 2.2 and Figure 2.4):
The unadjusted difference in eGFR slopes of UTOX groups (95% CI, p-values for
comparison with the UTOX group 0 reference) were:
• Group 1 [-0.83 (-1.6, -0.06), P=0.03].
• Group 2 [-0.63 (-1.27, 0.02), P=0.06].
• Group 3 [-0.72 (-1.43, 0), P=0.05].
• Group 4 [-0.46 (-0.91, -0.01), P=0.05].
The adjusted difference in eGFR slopes of UTOX groups (95% CI, p-values for comparison with the UTOX group 0 reference) were:
• Group 1 [-0.89 (-1.85, 0.06), P=0.07].
• Group 2 [-0.13 (-0.98, 0.72), P=0.8].
• Group 3 [-1.25 (-2.71, 0.2), P=0.09].
• Group 4 [-0.41 (-0.89, 0.07), P=0.09].
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Table 2.1: Baseline characteristics of the overall eGFR outcome cohort
and urine toxicology (UTOX) groups.
Variables

Demographics
Mean age (SD), years
Males, n (%)
Race, n (%)
Whites
African Americans
Other
Comorbidities, n (%)
Chronic pulmonary disease
Liver disease
Diabetes
Hyperlipidemia
Hypertension
PTSD
CCI Score (IQR)
Access type, n (%)
AVF
AVG
Catheter
Other
Missing
Smoking, n (%)
Never
Current
Past
Missing
Medication use, n (%)
Analgesics
Psychiatric meds
Antimicrobials
Antiretrovirals
Cardiovascular meds
Chemotherapeutics
Diuretics
Proton pump inhibitors
H2 receptor blockers
Warfarin
Anticoagulants
Antihistamines
Benzodiazepines
Vital signs, Mean (SD)
SBP
DBP
BMI
Pain

All
(N=6,834)

Tested negative
for all tests
(N=3,251)

Cannabis
(N=193)

Cannabis
+ opioids
(N=174)

Cannabis
+ other drugs
(N=96)

Cannabis
+ opioids
+ other drugs
N=(179)

Opioids
(N=1,698)

other drugs
(N=518)

Opioids
+ other drugs
(N=725)

61 (10)
6633 (97)

62 (10)
3148 (97)

57 (8)
184 (95)

57 (8)
171 (98)

57 (6)
95 (99)

56 (7)
174 (97)

62 (9)
1663 (98)

58 (8)
498 (96)

57 (7)
700 (97)

3469 (51)
3154 (46)
211 (3)

1808 (56)
1296 (40)
147 (5)

86 (45)
104 (54)
3 (2)

93 (53)
74 (43)
7 (4)

25 (26)
71 (74)
0 (0)

54 (30)
121 (68)
4 (2)

1066 (63)
597 (35)
35 (2)

131 (25)
380 (73)
7 (1)

206 (28)
511 (71)
8 (1)

3407 (50)
1869 (27)
4966 (73)
5361 (78)
6658 (97)
1451 (21)
4 (3-6)

1449 (45)
666 (21)
2432 (75)
2647 (81)
3174 (98)
534 (16)
4 (3-6)

73 (38)
66 (34)
114 (59)
131 (68)
187 (97)
43 (22)
3 (2-5)

93 (53)
70 (40)
108 (62)
122 (70)
166 (95)
54 (31)
4 (3-6)

39 (41)
36 (38)
58 (60)
59 (62)
93 (97)
21 (22)
4 (2-6)

90 (50)
84 (47)
111 (62)
114 (64)
172 (96)
58 (32)
4 (3-7)

1034 (61)
482 (28)
1290 (76)
1407 (83)
1652 (97)
388 (23)
5 (3-7)

224 (43)
172 (33)
353 (68)
369 (71)
509 (98)
138 (27)
4 (2-6)

405 (56)
293 (40)
500 (69)
512 (71)
705 (97)
215 (30)
5 (3-7)

1291 (19)
142 (2)
4692 (69)
35 (1)
674 (10)

687 (21)
51 (2)
2134 (66)
20 (1)
359 (11)

49 (25)
8 (4)
119 (62)
2 (1)
15 (8)

29 (17)
2 (1)
129 (74)
2 (1)
12 (7)

21 (22)
1 (1)
64 (67)
0 (0)
10 (10)

19 (11)
4 (2)
143 (80)
1 (1)
12 (7)

290 (17)
34 (2)
1196 (70)
5 (0)
173 (10)

78 (15)
15 (3)
382 (74)
5 (1)
38 (7)

118 (16)
27 (4)
525 (72)
0 (0)
55 (8)

1820 (27)
3470 (51)
1522 (22)
22 (0)

1118 (34)
1235 (38)
882 (27)
16 (0)

23 (12)
134 (69)
35 (18)
1 (1)

25 (14)
120 (69)
28 (16)
1 (1)

7 (7)
82 (85)
7 (7)
0 (0)

13 (7)
154 (86)
12 (7)
0 (0)

440 (26)
835 (49)
420 (25)
3 (0)

112 (22)
337 (65)
69 (13)
0 (0)

82 (11)
573 (79)
69 (10)
1 (0)

6006 (88)
3499 (51)
1749 (26)
24 (0)
5682 (83)
40 (1)
5785 (85)
4003 (59)
1315 (19)
598 (9)
3799 (56)
1156 (17)
1461 (21)

2706 (83)
1413 (44)
808 (25)
7 (0)
2769 (85)
17 (1)
2764 (85)
1765 (54)
609 (19)
271 (8)
1758 (54)
473 (15)
588 (18)

158 (82)
90 (47)
37 (19)
2 (1)
146 (76)
3 (2)
162 (84)
109 (57)
29 (15)
16 (8)
98 (51)
32 (17)
39 (20)

163 (94)
118 (68)
49 (28)
1 (1)
136 (78)
3 (2)
144 (83)
112 (64)
30 (17)
13 (7)
108 (62)
36 (21)
54 (31)

86 (90)
41 (43)
13 (14)
1 (1)
78 (81)
0 (0)
77 (80)
57 (59)
9 (9)
6 (6)
50 (52)
20 (21)
19 (20)

170 (95)
114 (64)
47 (26)
2 (1)
138 (77)
2 (1)
143 (80)
121 (68)
37 (21)
12 (7)
114 (64)
40 (22)
43 (24)

1607 (95)
998 (59)
472 (28)
2 (0)
1417 (84)
14 (1)
1444 (85)
1081 (64)
341 (20)
208 (12)
911 (54)
307 (18)
442 (26)

436 (84)
248 (48)
120 (23)
3 (1)
420 (81)
0 (0)
436 (84)
283 (55)
95 (18)
27 (5)
296 (57)
79 (15)
76 (15)

680 (94)
477 (66)
203 (28)
6 (1)
578 (80)
1 (0)
615 (85)
475 (66)
165 (23)
45 (6)
464 (64)
169 (23)
200 (28)

146 (17)
79 (11)
29 (7)
2 (2)

146 (17)
78 (10)
29 (6)
2 (2)

149 (17)
83 (11)
26 (5)
2 (2)

149 (17)
82 (10)
27 (6)
3 (2)

152 (18)
86 (12)
26 (5)
2 (2)

147 (16)
84 (9)
27 (6)
3 (2)

143 (16)
76 (10)
30 (7)
3 (2)

149 (16)
84 (10)
28 (7)
2 (2)

147 (16)
83 (10)
28 (6)
3 (2)

AVF: arteriovenous fistula; AVG: ateriovenous graft; BMI: body mass index; CCI Score:
Charlson comorbidity index; DBP: diastolic blood pressure; eGFR: estimated glomerular
filtration rate; H2 receptors: histamine 2 receptors; IQR: interquartile range; PTSD:
post-traumatic stress disorder; SBP: systolic blood pressure; SD: standard deviation.
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Table 2.2: Difference in eGFR slopes (ml/min/1.73m2 /year) associated
with urine toxicology groups in the main analysis.

UTOX groups
1-7 vs 0*
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

Unadjusted
slopes (95% CI)

P-value

Adjusted (IPTW wts)
slopes (95% CI)

P-value

-0.83 (-1.6, -0.06)
-0.63 (-1.27, 0.02)
-0.72 (-1.43, 0)
-0.46 (-0.91, -0.01)
-1.42 (-2.65, -0.2)
-1.13 (-2.11, -0.14)
-0.91 (-1.47, -0.34)

0.034
0.056
0.049
0.047
0.023
0.025
0.002

-0.89 (-1.85, 0.06)
-0.13 (-0.98, 0.72)
-1.25 (-2.71, 0.2)
-0.41 (-0.89, 0.07)
-1.2 (-2.65, 0.25)
-1.4 (-2.5, -0.29)
-1.11 (-1.83, -0.4)

0.068
0.8
0.092
0.093
0.1
0.013
0.002

*For description of UTOX groups 0-7, see Figure 2.2. CI: Confidence intervals.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 2.1.

Figure 2.4: eGFR slopes estimated from unadjusted/adjusted
mixed-effects models. (a): unadjusted mixed-effects models. (b):
multivariable-adjusted mixed-effects models adjusted for inverse
probability treatment weights (IPTW).
* = P-value ≤ 0.05 and # = P-value ≤ 0.005.
†For description of UTOX groups 0-7, see Figure 2.3.
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UTOX groups 5-7 vs group 0
In the unadjusted model, compared to UTOX group 0, UTOX groups 5-7 were associated
with significantly steeper decreasing eGFR slopes. The difference in eGFR slopes of UTOX
groups (95% CI, p-values for comparison with the UTOX group 0 reference) were:
• Group 5 [-1.3 (-2.52, -0.09), P=0.02].
• Group 6 [-1.13 (-2.11, -0.14), P=0.03].
• Group 7 [-0.91 (-1.47, -0.34), P=0.002].
Similar patterns of steeper decreasing slopes were observed in the adjusted model
with weights, with the associations of group 6 and 7 remaining statistically significant
(Table 2.2 and Figure 2.4):
• Group 5 [-1.2 (-2.65, 0.25), P=0.1].
• Group 6 [-1.4 (-2.5, -0.29) P=0.01].
• Group 7 [-1.11 (-1.83, -0.4), P=0.002].
In the analysis with Bonferroni correction, only group 7 (vs group 0 reference)
showed statistically significant association with decreasing slope in both unadjusted and
adjusted analysis (Table 2.2 and Figure 2.4), respectively. Also, the results of the model
with winsorized weights showed a similar pattern of steeper decreasing slopes for the
UTOX groups (groups 1-7 vs group 0 reference, Table 2.3).
The sensitivity analysis with both doubly robust models (with weights and with
winsorized weights) showed similar patterns of associations as those observed in the incremental analysis models (Table 2.3).
The sensitivity analysis with incremental adjustment showed a similar pattern of
steeper decreasing slopes, but the associations observed in models 2-5 were not statistically
significant (Table 2.4).

Acute Kidney Injury Outcome
Baseline characteristics
The mean (SD) age of the sample was 61 years (9); 97% were males, 51% were African
Americans, 97% had hypertension, 76% had hyperlipidemia, 75% were diabetic, 54% were
current smokers, 92% were analgesics users, 90% were diuretics users, and 56% were psychiatric medication users. Except for patients in UTOX groups 0 and 5, patients in the
other groups (1-4 and 6,7) were more likely to be younger, less likely to be white, and more
likely to be smokers (Table 2.5). Inpatient AKI occurred in 56% of the cohort.
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Table 2.3: Difference in eGFR slopes (ml/min/1.73m2 /year) associated
with urine toxicology groups in the DRE analysis.
UTOX groups
1-7 vs 0*

DRE
slopes (95% CI)

P-value

Adjusted
(winsorized IPTW wts)
slopes (95% CI)

P-value

DRE
(winsorized IPTW wts)
slopes (95% CI)

P-value

Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

-0.29 (-1.18, 0.6)
0.72 (-0.19, 1.62)
-0.76 (-2.14, 0.62)
0.31 (-0.18, 0.8)
-0.16 (-1.67, 1.34)
-0.25 (-1.35, 0.84)
0.11 (-0.64, 0.85)

0.5
0.1
0.3
0.2
0.8
0.6
0.8

-0.89 (-1.85, 0.07)
-0.15 (-0.99, 0.7)
-1.24 (-2.67, 0.2)
-0.41 (-0.89, 0.07)
-1.21 (-2.65, 0.23)
-1.39 (-2.49, -0.3)
-1.07 (-1.76, -0.38)

0.068
0.7
0.091
0.092
0.1
0.013
0.002

-0.28 (-1.16, 0.61)
0.7 (-0.2, 1.6)
-0.74 (-2.09, 0.62)
0.31 (-0.17, 0.8)
-0.17 (-1.66, 1.33)
-0.24 (-1.32, 0.84)
0.16 (-0.56, 0.88)

0.5
0.1
0.3
0.2
0.8
0.7
0.7

*For description of UTOX groups 0-7, see Figure 2.3. CI: Confidence intervals.
DRE: Doubly robust estimation; "doubly robust" means the model includes all variables
used to calculate IPTW weights, including the weights as well.
Winsorized weights: Weights adjusted at 90 percentiles, respectively, for each group.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 2.1.

UTOX groups 1-4 vs group 0
Table 2.6 shows the association between UTOX groups 1-4 and AKI risk. In the unadjusted
model, UTOX groups 1, 2 and 3 (vs group 0) showed lower odds of AKI, whereas higher
odds of AKI were observed in groups 4. However, these associations were not statistically
significant.
The unadjusted odds ratios (95% CI, p-values for comparison with the UTOX group
0 reference) in the respective exposure groups were:
• Group 1 [0.87 (0.53, 1.42) , P=0.6].
• Group 2 [0.92 (0.56, 1.53), P=0.7].
• Group 3 [0.97 (0.49, 1.93), P=0.9].
• Group 4 [1.3 (0.79, 2.12), P=0.3].
In the main adjusted analysis (with weights) a similar trend was observed. The adjusted
odds ratios (95% CI) of the respective exposure groups (vs group 0 reference) were:
• Group 1 [0.85 (0.38, 1.87), P=0.7].
• Group 2 [0.81 (0.44, 1.52), P=0.5].
• Group 3 [0.54 (0.22, 1.31, P=0.2)].
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Table 2.4: Difference in eGFR slopes (ml/min/1.73m2 /year) associated
with urine toxicology groups in the incrementally adjusted analysis.
UTOX groups

Model 2

Model 3

Model 4

Model 5

1-7 vs 0*

slopes (95% CI)

slopes (95% CI)

slopes (95% CI)

slopes (95% CI)

P-value

Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

-0.51 (-1.27, 0.26)
-0.36 (-0.99, 0.27)
-0.53 (-1.24, 0.18)
-0.25 (-0.7, 0.2)
-1.3 (-2.52, -0.09)
-0.79 (-1.77, 0.2)
-0.55 (-1.12, 0.02)

-0.28 (-1.04, 0.47)
-0.03 (-0.65, 0.6)
-0.34 (-1.03, 0.36)
0.02 (-0.43, 0.46)
-0.82 (-2.03, 0.38)
-0.4 (-1.37, 0.57)
-0.14 (-0.71, 0.43)

-0.31 (-1.05, 0.44)
0.07 (-0.56, 0.69)
-0.38 (-1.07, 0.31)
0.08 (-0.36, 0.53)
-0.78 (-1.99, 0.43)
-0.38 (-1.34, 0.58)
0.04 (-0.53, 0.6)

-0.27 (-1.01, 0.47)
0.22 (-0.41, 0.84)
-0.24 (-0.92, 0.45)
0.25 (-0.19, 0.7)
-0.3 (-1.56, 0.96)
0.01 (-0.96, 0.98)
0.36 (-0.23, 0.95)

0.5
0.5
0.5
0.3
0.6
1
0.2

*For description of UTOX groups 0-7, see Figure 2.3. CI: Confidence intervals.
Model 1: Unadjusted analysis shown in Table 2.2.
Models 2-5 presented here are incrementally adjusted, as follows : Model 2: Model 1 +
demographics (sex, race, age). Model 3: Model 2 + comorbidities (chronic pulmonary
disease, liver disease, diabetes, hyperlipidemia, hypertension, and post-traumatic stress
disorder) + access type + smoking. Model 4: Model 3+ use of medications (analgesics,
psychiatric drugs, antimicrobials, antiretrovirals, cardiovascular meds, chemotherapeutic
inhibitors, diuretics, proton pump inhibitors, H2 receptor blockers, warfarin,
anticoagulants, and benzodiazepines). Model 5: Model 4 + vital signs (mean systolic
blood pressure, mean diastolic blood pressure, mean body mass index, and mean pain
score).
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Table 2.5: Baseline characteristics of the overall AKI outcome cohort and
urine toxicology (UTOX) groups.
Variables

Demographics
Mean age (SD), years
Males, n (%)
Race, n (%)
Whites
African Americans
Other
Comorbidities, n (%)
Chronic pulmonary disease
Liver disease
Diabetes
Hyperlipidemia
Hypertension
PTSD
CCI Score (IQR)
Access type, n (%)
AVF
AVG
Catheter
Other
Missing
Baseline eGFR
(mL/min/1.73m2 /year),
Mean (SD)
Smoking, n (%)
Never
Current
Past
Missing
Medication use, n (%)
Analgesics
Psychiatric meds
Antimicrobials
Antiretrovirals
Cardiovascular meds
Chemotherapeutics
Diuretics
Proton pump inhibitors
H2 receptor blockers
Warfarin
Anticoagulants
Antihistamines
Benzodiazepines
Vital signs, Mean (SD)
SBP
DBP
BMI
Pain

All
(N=2,251)

Tested negative
for all tests
(N=1,061)

Cannabis
(N=66)

Cannabis
+ opioids
(N=64)

Cannabis
+ other drugs
(N=34)

Cannabis
+ opioids
+ other drugs
(N=70)

Opioids
(N=464)

other drugs
(N=204)

Opioids
+ other drugs
(N=288)

61 (9)
2184 (97)

63 (10)
1034 (98)

57 (7)
63 (96)

57 (7)
64 (100)

57 (7)
33 (97)

56 (7)
69 (99)

61 (9)
447 (96)

59 (8)
196 (96)

58 (7)
278 (97)

1045 (46)
1143 (51)
63 (3)

575 (54)
441 (42)
45 (4)

33 (50)
32 (49)
1 (2)

33 (52)
27 (42)
4 (6)

4 (12)
30 (88)
0 (0)

22 (31)
48 (69)
0 (0)

255 (55)
200 (43)
9 (2)

56 (28)
145 (71)
3 (1)

67 (23)
220 (76)
1 (0)

1206 (54)
634 (28)
1686 (75)
1700 (76)
2186 (97)
467 (21)
5 (3-7)

540 (51)
219 (21)
820 (77)
850 (80)
1030 (97)
160 (15)
5 (3-7)

25 (38)
24 (36)
39 (59)
39 (59)
62 (94)
15 (23)
4 (2-5)

36 (56)
33 (52)
40 (63)
42 (66)
61 (95)
17 (27)
4 (3-6)

14 (41)
15 (44)
23 (68)
23 (68)
32 (94)
6 (18)
5 (3-6)

39 (56)
35 (50)
47 (67)
54 (77)
68 (97)
21 (30)
5 (3-7)

273 (59)
126 (27)
366 (79)
355 (77)
449 (97)
118 (25)
5 (3-7)

104 (51)
63 (31)
140 (69)
142 (70)
199 (98)
48 (24)
4 (3-7)

175 (61)
119 (41)
211 (73)
195 (68)
285 (99)
82 (29)
5 (3-7)

304 (14)
51 (2)
1741 (77)
14 (1)
141 (6)

153 (14)
17 (2)
821 (77)
9 (1)
61 (6)

10 (15)
4 (6)
47 (71)
0 (0)
5 (8)

10 (16)
1 (2)
49 (77)
1 (2)
3 (5)

11 (32)
0 (0)
20 (59)
0 (0)
3 (9)

7 (10)
2 (3)
56 (80)
0 (0)
5 (7)

61 (13)
12 (3)
354 (76)
2 (0)
35 (8)

20 (10)
4 (2)
164 (80)
2 (1)
14 (7)

32 (11)
11 (4)
230 (80)
0 (0)
15 (5)

29 (21)

28 (21)

30 (23)

35 (25)

23 (14)

28 (17)

32 (23)

28 (19)

28 (20)

570 (25)
1212 (54)
462 (21)
7 (0)

342 (32)
432 (41)
282 (27)
5 (0)

6 (9)
50 (76)
9 (14)
1 (2)

10 (16)
44 (69)
10 (16)
0 (0)

0 (0)
31 (91)
3 (9)
0 (0)

4 (6)
61 (87)
5 (7)
0 (0)

136 (29)
232 (50)
95 (21)
1 (0)

39 (19)
131 (64)
34 (17)
0 (0)

33 (12)
231 (80)
24 (8)
0 (0)

2079 (92)
1255 (56)
885 (39)
5 (0)
1934 (86)
16 (1)
2029 (90)
1566 (70)
560 (25)
240 (11)
1793 (80)
543 (24)
580 (26)

958 (90)
499 (47)
407 (38)
1 (0)
934 (88)
6 (1)
949 (89)
692 (65)
263 (25)
122 (12)
838 (79)
222 (21)
236 (22)

57 (86)
36 (55)
18 (27)
1 (2)
50 (76)
1 (2)
60 (91)
48 (73)
12 (18)
5 (8)
46 (70)
15 (23)
15 (23)

60 (94)
49 (77)
26 (41)
0 (0)
50 (78)
2 (3)
58 (91)
54 (84)
11 (17)
5 (8)
49 (77)
20 (31)
25 (39)

33 (97)
14 (41)
8 (24)
0 (0)
27 (79)
0 (0)
27 (79)
24 (71)
3 (9)
3 (9)
26 (77)
10 (29)
5 (15)

66 (94)
46 (66)
27 (39)
0 (0)
57 (81)
1 (1)
60 (86)
58 (83)
17 (24)
7 (10)
60 (86)
15 (21)
17 (24)

443 (96)
300 (65)
211 (46)
0 (0)
406 (88)
6 (1)
426 (92)
350 (75)
129 (28)
65 (14)
375 (81)
115 (25)
147 (32)

187 (92)
102 (50)
73 (36)
2 (1)
178 (87)
0 (0)
186 (91)
128 (63)
44 (22)
15 (7)
155 (76)
43 (21)
38 (19)

275 (96)
209 (73)
115 (40)
1 (0)
232 (81)
0 (0)
263 (91)
212 (74)
81 (28)
18 (6)
244 (85)
103 (36)
97 (34)

146 (17)
79 (11)
28 (7)
2 (2)

146 (17)
77 (11)
29 (7)
1 (1)

150 (19)
83 (11)
26 (5)
2 (2)

149 (17)
82 (10)
27 (7)
3 (2)

153 (14)
85 (9)
25 (3)
2 (2)

147 (16)
83 (9)
27 (6)
3 (2)

144 (16)
77 (10)
29 (7)
3 (2)

147 (17)
83 (10)
28 (6)
2 (1)

149 (15)
83 (9)
27 (6)
3 (2)

AKI: acute kidney injury; AVF: arteriovenous fistula; AVG: ateriovenous graft; BMI: body
mass index; CCI Score: Charlson comorbidity index; DBP: diastolic blood pressure; eGFR:
estimated glomerular filtration rate; H2 receptors: histamine 2 receptors; IQR: interquartile range; PTSD: post-traumatic stress disorder; SBP: systolic blood pressure; SD:
standard deviation.
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Table 2.6: Association of AKI with urine toxicology groups in the main
analysis.

UTOX groups
1-7 vs 0*
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

Unadjusted
OR (95% CI)

P-value

Adjusted (IPTW wts)
OR (95% CI)

P-value

0.87 (0.53, 1.42)
0.92 (0.56, 1.53)
0.97 (0.49, 1.93)
1.3 (0.79, 2.12)
1.07 (0.86, 1.34)
1.37 (1.01, 1.86)
1.76 (1.34, 2.31)

0.6
0.7
0.9
0.3
0.5
0.045
<.0001

0.85 (0.38, 1.87)
0.81 (0.44, 1.52)
0.54 (0.22, 1.31)
1.26 (0.74, 2.14)
1 (0.77, 1.28)
1.46 (1.02, 2.09)
1.53 (1.07, 2.18)

0.7
0.5
0.2
0.4
1.0
0.040
0.020

*For description of UTOX groups 0-7, see Figure 2.3. OR: Odds ratios; CI: Confidence
intervals.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 2.5.

• Group 4 [1.26 (0.74, 2.14), P=0.4].
UTOX groups 5-7 vs group 0
Association between UTOX groups 5-7 and AKI risk is shown in Table 2.6. Both in the
unadjusted and adjusted (with weights) analysis, UTOX groups 5-7 (vs group 0 reference)
showed higher odds of AKI, out of which the associations of group 6 and 7 were statistically significant.
Unadjusted odds ratios (95% CI) were:
• Group 5 [1.07 (0.86, 1.34), P=0.7].
• Group 6 [1.37 (1.01, 1.86, P=0.045)].
• Group 7 [1.76 (1.34, 2.31), P=<0.0001].
Adjusted odds ratios (95% CI) were:
• Group 5 [1 (0.77, 1.28), P=1.0].
• Group 6 [1.46 (1.02, 2.09), P=0.040].
• Group 7 [1.53 (1.07, 2.18), P=0.020.
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Table 2.7: Association of AKI with urine toxicology groups in the
incrementally adjusted analysis.
UTOX groups

Model 2

Model 3

Model 4

Model 5

1-7 vs 0*

OR (95% CI)

OR (95% CI)

OR (95% CI)

OR (95% CI)

P-value

Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

0.84 (0.51, 1.39)
0.9 (0.54, 1.5)
0.91 (0.46, 1.82)
1.23 (0.75, 2.03)
1.06 (0.85, 1.32)
1.31 (0.96, 1.79)
1.67 (1.25, 2.21)

0.91 (0.55, 1.51)
0.93 (0.56, 1.57)
0.99 (0.49, 2)
1.27 (0.76, 2.12)
1.07 (0.85, 1.33)
1.33 (0.97, 1.82)
1.67 (1.24, 2.25)

0.93 (0.55, 1.57)
0.84 (0.49, 1.43)
1.05 (0.51, 2.15)
1.17 (0.69, 1.98)
0.96 (0.76, 1.21)
1.33 (0.96, 1.84)
1.54 (1.13, 2.1)

0.83 (0.48, 1.41)
0.77 (0.45, 1.34)
0.98 (0.48, 2.01)
1.28 (0.74, 2.23)
0.94 (0.73, 1.19)
1.32 (0.94, 1.84)
1.52 (1.1, 2.11)

0.5
0.4
1.0
0.4
0.6
0.1
0.012

*For description of UTOX groups 0-7, see Figure 2.3. OR: Odds ratios; CI: Confidence
intervals.
Model 1: Unadjusted analysis shown in Table 2.6.
Models 2-5 presented here are incrementally adjusted, as follows : Model 2: Model 1 +
demographics (sex, race, age). Model 3: Model 2 + comorbidities (chronic pulmonary
disease, liver disease, diabetes, hyperlipidemia, hypertension, and post-traumatic stress
disorder) + access type + smoking. Model 4: Model 3+ use of medications (analgesics,
psychiatric drugs, antimicrobials, antiretrovirals, cardiovascular meds, chemotherapeutic
inhibitors, diuretics, proton pump inhibitors, H2 receptor blockers, warfarin,
anticoagulants, and benzodiazepines). Model 5: Model 4 + vital signs (mean systolic
blood pressure, mean diastolic blood pressure, mean body mass index, and mean pain
score) + baseline eGFR (eGFR intercept).

Similar trends of associations were observed in all the sensitivity analyses (incremental analysis, winsorized weights, and doubly robust models (Table 2.7 and Table 2.8).
In analyses with Bonferroni correction, only UTOX group 7 was associated with
risk of AKI. This association was statistically significant in unadjusted (P=0.007) and in
adjusted (with winsorized weights) analysis. However, the associations between AKI and
pair-wise comparisons of UTOX groups were not statistically significant (Figure 2.5).

Discussion
In this nationally representative cohort of US veterans with advanced CKD who transitioned to dialysis, we observed a statistically significant association between cannabis use
(UTOX group 1 vs 0 reference) and steeper eGFR slope (change in eGFR) in the unadjusted
analyses. However, after multivariable adjustments, cannabis use was not associated with
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Table 2.8: Association of AKI with urine toxicology groups in the DRE
analysis.
UTOX groups
1-7 vs 0*
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

DRE
OR (95% CI)

P-value

Adjusted
(winsorized IPTW wts)
OR (95%CI)

P-value

DRE
(winsorized IPTW wts)
OR (95%CI)

P-value

0.79 (0.34, 1.83)
0.75 (0.38, 1.48)
0.62 (0.23, 1.71)
1.17 (0.66, 2.1)
0.87 (0.66, 1.15)
1.46 (0.96, 2.21)
1.33 (0.88, 2)

0.6
0.4
0.4
0.6
0.3
0.078
0.2

0.81 (0.46, 1.43)
0.78 (0.42, 1.43)
0.85 (0.42, 1.75)
1.25 (0.74, 2.11)
0.99 (0.78, 1.25)
1.41 (1, 1.99)
1.56 (1.13, 2.14)

0.5
0.4
0.7
0.4
0.9
0.053
0.007

0.79 (0.34, 1.83)
0.75 (0.38, 1.48)
0.62 (0.23, 1.71)
1.17 (0.66, 2.1)
0.87 (0.66, 1.15)
1.46 (0.96, 2.21)
1.33 (0.88, 2)

0.6
0.4
0.4
0.6
0.3
0.078
0.2

*For description of UTOX groups 0-7, see Figure 2.3. OR: Odds ratios; CI: Confidence
intervals.
DRE: Doubly robust estimation; "doubly robust" means the model includes all the
variables used to calculate IPTW weights and includes weights too.
Winsorized weights: Weights adjusted at 90 percentiles, respectively, for each group.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 2.5.

steeper slopes of eGFR decline. A similar association was observed between steeper slopes
and combined cannabis use with opioids or with other drugs or with opioids and other
drugs (UTOX groups 2-4 vs 0 reference) in the unadjusted and adjusted analysis. Furthermore, we observed a statistically significant association between steeper slopes and opioid
use, other drugs use, and combined opioid use and other drug use (UTOX groups 5-7 vs
0 reference) in unadjusted analyses. In the multivariable-adjusted analysis, only the association of UTOX groups 6 (other drug users) and 7 (opioids + other drugs users) (vs 0
reference) with steeper slopes remained statistically significant. The association between
UTOX group 7 and steeper slopes was statistically significant, especially after Bonferroni
correction.
We did not observe a statistically significant association between cannabis use (group
1 vs 0) and risk of AKI. Similar non-significant associations were observed between combined cannabis use/opioid use/other drug use and risk of AKI (groups 2-4, 5, 6 vs 0 reference). The association between UTOX group 7 (opioids + other drugs users vs 0 reference)
and AKI risk was statistically significant after Bonferroni correction.
Only four studies have thus far examined the association between self-reported
cannabis use and kidney function or change in eGFR (Vupputuri et al., 2004; Grubbs et
al., 2016; Ishida et al., 2017; Bundy et al., 2018; Lu et al., 2018). Ishida et al. (2017) examined the association between cannabis use and a decline in kidney function in 3,765 young

Chapter 2. ASSOCIATION OF CANNABIS USE WITH RENAL OUTCOMES IN
VETERANS WITH ADVANCED CHRONIC KIDNEY DISEASE (CKD)
TRANSITIONING TO DIALYSIS

44

Figure 2.5: Association of AKI with urine toxicology groups using
Tukey’s adjustment for pair-wise comparisons adjusted with IPTW
weights. *For description of UTOX groups 0-7, see Figure 2.3. CI:
Confidence intervals.The displayed confidence intervals have a 95%
family-wise confidence level and are corrected for the number of all
pair-wise comparisons using Tukey’s method. Point estimates/odds ratios
of respective pair-wise comparisons (vertical scale) are shown as solid
circles. Confidence intervals that include zero (dotted line) correspond to
statistically non-significant associations.

adults with preserved eGFR. They did not find any association with change in kidney function over time in a longitudinal design. In 13,995 US adults (18-59 years) with early stages
(1-2) of CKD, Lu et al. (2018) used a cross-sectional study design. They did not observe
any significant association between cannabis use and measures of kidney function (serum
creatinine concentration, change in eGFR, and odds of having stage 2 or greater CKD).
In a study using data from the Chronic Renal Insufficiency Cohort (CRIC, a prospective longitudinal cohort) composed of 3,939 patients with mild to moderate CKD, Barutta
et al. (2018a) observed that cannabis use was not associated with the progression of CKD.
Furthermore, in a single-center study (n=647) compossed of hypertensive men, cannabis
use was not associated with higher risk of kidney function decline when compared to
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nonusers (Vupputuri et al., 2004). Our study results are in line with previous research
showing that cannabis use is not associated with steeper eGFR slopes.
An association between cannabis use and AKI has only been reported in case reports (Ishida et al., 2017; Park et al., 2017). However, these associations were from cases
of synthetic cannabinoid use, and we are not aware of any reports examining associations
between nonsynthetic cannabinoid use and AKI. Synthetic cannabinoids are analogs of
tetrahydrocannabinol (THC), one of the several natural cannabinoids in cannabis. However, these analogs structurally differ from natural cannabinoids. Also, the synthetic
cannabinoids are distinct from FDA-approved therapeutic cannabinoids (dronabinol and
nabilone), given that they are unregulated drugs and have a higher potency than THC.
Also, these synthetic cannabinoids may have a higher binding affinity to CB receptors,
especially to CB1 receptor (Ho, Martinusen, and Lo, 2019). In addition, unregulated synthetic cannabinoids, which are mostly used illicitly, may contain other chemical solvents
that may mediate the toxic renal effects observed in cannabinoid-associated AKI. Even
though the association between cannabis use and AKI was not statistically significant, the
point estimates in the current study suggest that there may be a protective effect of natural cannabinoids, which could be uncovered in studies with a large sample size. The
difference in the chemical structure may be one of the reasons why we observed lower
odds of AKI with cannabis use in our study. In one of the preclinical studies, Moradi et
al. (2016) observed that increasing renal levels of 2-arachidonoylglycerol, an endogenous
endocannabinoid ligand, in an ischemia-reperfusion mouse model of AKI, was associated
with improved indices of renal function. As mentioned above, experimental studies have
observed that CB1 receptor blockade and activation of CB2 receptors may have beneficial
effects on renal structure and function. Therefore, a protective effect of natural cannabis
is possible through increased activation of renal CB2 receptors when compared to CB1
receptors (Moradi et al., 2016).
It should be noted that studies evaluating the role of CB receptor activation and
blockade heavily relied on pharmacologic means that are highly specific for each receptor
in isolation. In contrast, natural cannabinoids (such as THC) are capable of activating both
CB receptors. Therefore, the net renal effect can be indicative of the balance between the
activation of both receptors. Furthermore, it is well known that CB receptors are part of
the G-protein coupled family of receptors, and their activation results in the recruitment
of various G-proteins, thereby eliciting a cascade of cellular signals and effects through
specific transducers. There is now evidence that activation of CB receptors via different
ligands (i.e., endogenous ligands, THC, and pharmacologic agonists) can be associated
with recruitment/activation of different sets of G-proteins, thereby mediating downstream
effects that may be unique to each ligand. This concept, which is known as functional
selectivity or ligand bias, can explain the discrepancy between the results observed in experimental animal models that mainly utilized pharmacologic agonist/antagonists of CB
receptors when compared to natural ligands, such as THC (Ibsen, Connor, and Glass, 2017;
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Mallipeddi et al., 2017). In Tukey-adjusted pair-wise comparisons (Figure 2.5), we did not
find a significant association between risk of AKI and various pair-wise comparisons of
UTOX groups.
Association between the combined use of cannabis with opioids was not examined
by previous studies. The combined use of cannabis with opioids may result in potential
pharmacodynamic and pharmacokinetic interactions. Research has shown that an overlap
exists in expression and colocalization of CB1 receptors and mu-opioid receptors (MORs).
Also, a bidirectional association exists between these two receptors in the rewarding properties of drugs and the pharmacokinetic interaction between cannabis and opioids, which
results in synergistic analgesia (Wiese and Wilson-Poe, 2018). Administering a lower dose
of THC alone or morphine alone was not effective in treating pain. However, when the
same small doses of both THC and morphine were administered together, they produced
a significant reduction in pain (Wiese and Wilson-Poe, 2018). Also, similar synergistic
analgesic effects were observed in patients using opioids and inhaled vaporized cannabis,
while vaporized cannabis did not affect the pharmacokinetics of opioids (Abrams et al.,
2011; Wiese and Wilson-Poe, 2018). Besides the pharmacodynamic and pharmacokinetics
interactions, the legalization of cannabis has resulted in complex changes in how cannabis
and opioids are used. Previous research indicates that states in which medical marijuana
is legalized have experienced a reduction in utilization of prescribed opioids and deaths
due to opioid overdoses (Shah et al., 2019). In our study, we did not observe a significant
association between the combined use of cannabis with opioids and steeper eGFR slopes
(UTOX group 2 vs group 0 reference ).
Similarly, the association between the combined use of cannabis with other/illicit
drugs and renal outcomes was never previously investigated. Prior literature has shown
that the use of illicit drugs may increase the risk of CKD progression (Vupputuri et al.,
2004; Bundy et al., 2018). Also, research has shown an increased risk of AKI with the use
of illicit drugs (Lau Hing Yim et al., 2019). However, little is known about the effect of
the combined use of cannabis with other drugs. In the current study, we did not observe
a significant association between the combined use of cannabis with other drugs or with
opioids and other drugs (UTOX groups 3-4 vs 0 reference) and steeper eGFR slopes.
In the current study, opioid use alone (UTOX groups 5 vs. 0 reference) was not associated with steeper eGFR slope or with risk of AKI. However, an association between
lifetime opiate use and reduced eGFR has been previously described (Novick et al., 2016).
Also, the association between opioid overdose and higher incidence of AKI is known (Mallappallil et al., 2017). This discrepancy in the results may be due to differences in the
cohorts studied, especially the advanced CKD nature of our cohort and the potential for
shorter exposure to opioids. As mentioned above, illicit drug use was associated with
CKD progression and risk of AKI in previous studies (Vupputuri et al., 2004; Bundy et al.,
2018). In our study, other/illicit drug use alone (UTOX group 6 vs. group 0 reference)
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was associated with steeper eGFR slopes and with a higher risk of AKI, in line with previous research. However, the association between other/illicit drug use alone and steeper
slopes/risk of AKI was not statistically significant in Bonferroni correction analysis. Little
is known about the association of combined use of opioids and other/illicit drugs with
renal outcomes. Our study observed a significant association between combined use of
opioids and other/illicit drugs (UTOX group 7 vs. group 0 reference) and steeper slopes of
eGFR as well as with higher risk of AKI. This association was statistically significant after
Bonferroni correction. Our current study had several unique features that contributed to
our understanding of this topic. First, we used UDTs or urine toxicology tests to ascertain
the use of cannabis, opioids, other/illicit drugs, and the combination of these. Second, we
used a control group composed of patients who tested negative for all substances. Third,
we examined the association between nonsynthetic cannabis use, other UTOX groups, and
renal outcomes, including change in eGFR slope and risk of AKI. Fourth, we adjusted for a
variety of potential confounders. Finally, we used IPTW weights to balance all the groups
on potential confounders.
Our study also had several limitations. First, we used UDTs or urine toxicology
tests to ascertain the exposure to cannabis, opioids, other/illicit drugs, and a combination
of the same. Even though UDTs are better than self-reported use, still a possibility of misclassification exists. Misclassification can be of two types: 1) a false-positive test result and
2) a false negative because the UDTs were not performed within the window of detection
of particular use to cannabis (3 days for single-use, 14 for moderate use, and around 30
days for heavy use), opioids, or other drugs. To minimize misclassification, we assessed
the current use of cannabis and lifetime use of opioids and other drugs in the current study
population. Second, we were not able to assess the risk of AKI stages, as recommended
by Kidney Disease Improving Global Outcomes (KDIGO), due to low numbers in certain
exposure groups. Third, we also did not include interactions or subgroup analysis due to
the small number of patients. Fourth, as the study cohort was restricted to predominantly
male US veterans, our study findings may have limited generalizability. Fifth, as we used
observational data for this study, we cannot infer causality. Lastly, we adjusted for several
confounders, but there is a possibility of residual confounding. Regardless, our analysis
has some validity because we have categorized the study population into different UTOX
groups, and patients in each group are different from other groups, which may adjust for
unobserved confounders.
To our knowledge, this is the first study to ascertain cannabis, opioid or other drug
use via urine toxicology tests (UTOX) in order to examine the association between various
combinations of exposures and renal outcomes, including change in eGFR (change in eGFR
slope) and the risk of AKI. In addition, this is the first study to examine these associations
in patients with advanced kidney disease or compromised kidney function.
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Conclusion
In summary, this study shows that cannabis use alone or combined use of cannabis with
opioids or with other drugs was not significantly associated with steeper eGFR slopes or
with a risk of AKI. The preponderance of evidence in our study suggests a lack of detrimental associations between cannabis exposure and renal outcomes. Given the increasing
number of individuals exposed to cannabis in the current socio-legal environment, additional studies are needed to better characterize the renal effects of cannabis and cannabinoids. However, the exposure to opioids and other drugs was associated with a higher
risk of adverse renal outcomes. Future studies are needed to validate these findings and
further determine the mechanisms of action whereby various illicit drugs may affect the
kidneys.
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Chapter 3
ASSOCIATION OF CANNABIS USE WITH
CEREBROVASCULAR OUTCOMES IN VETERANS
WITH ADVANCED CHRONIC KIDNEY DISEASE
(CKD) TRANSITIONING TO DIALYSIS

Introduction
The research presented in chapter 3 is based on Aim 2, mentioned in the Research Aims
section of chapter 1, that examined the association between cannabis use and cerebrovascular outcomes in the study population.
Cardiovascular disease (CVD), a leading cause of death worldwide and in the US
(Benjamin et al., 2019), is composed of diseases of the heart and blood vessels, which
includes cerebrovascular disease or stroke. Stroke is the fifth leading cause of death in
the US (Benjamin et al., 2019). A stroke occurs due to perturbations in blood supply to
the brain resulting in the death of a portion of brain tissue. Strokes can be ischemic (insufficient blood or oxygen supply) or hemorrhagic (National Academies of Sciences and
Medicine, 2017). The majority of strokes are ischemic (approximately 80-90%) (Dad and
Weiner, 2015). Stroke can be incident or recurrent. An incident stroke may increase the
risk of recurrent strokes. Each year about 795,000 individuals experience strokes in the US,
out of which approximately 185,000 are recurrent strokes (National Academies of Sciences
and Medicine, 2017; Benjamin et al., 2019). About 74% of stroke risk can be attributed to
modifiable behavioral risk factors like smoking, lack of physical activity, and diet. About
90% of stroke risk can be associated with modifiable risk factors like hypertension, obesity,
metabolic syndrome, and chronic kidney disease (CKD) (Benjamin et al., 2019). A linear
relationship exists between the risk of stroke and decreasing kidney function. The relative
risk of stroke is 1.4 times higher in patients with advanced stages of CKD (stages 3-4) than
in the general population. However, the relative risk of stroke increases 5-10 times in patients with end-stage renal disease (ESRD) in comparison to the general population (Levin,
2003; Lainscak, 2009; Herzog et al., 2011; Gansevoort et al., 2013; Dad and Weiner, 2015).
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Both stroke and CKD share risk factors or comorbidities, one of which is chronic
pain. Pain is common among patients with CKD and ESRD (Pham et al., 2017), and it is
also common among patients with stroke. In general, patients with stroke suffer from pain
after a stroke event, a phenomenon that is referred to as central post-stroke pain (CPSP)
(Henon, 2006; O’Donnell et al., 2013; Watson and Sandroni, 2016; Treister et al., 2017).
Decreased kidney function results in altered pharmacokinetics of many medications, including several analgesics. Some analgesics, like nonsteroidal anti-inflammatory drugs
(NSAIDs), are also nephrotoxic. Special consideration should thus be given to treating
pain in patients with CKD and ESRD (Saker, 2000; Pazhayattil and Shirali, 2014; Wu et al.,
2015; Mallappallil et al., 2017; Mansoor et al., 2017; Pham et al., 2017; Perazella, 2018). Opioids are often the treatment of choice for individuals with CKD who suffer from moderate
to severe pain (Wyne et al., 2011; Kimmel et al., 2017; Coluzzi, 2018; Ishida et al., 2018).
However, guidelines recommend monitoring chronic opioid therapy (COT) by urine drug
testing (UDT) (Reisfield, Salazar, and Bertholf, 2007; Mahajan, 2017) to check adherence
to therapy. Also, UDT’s are used to monitor concurrent or combined use of non-opioid
substances.
NSAID and opioid analgesic use in patients with CKD poses multiple difficulties
due to the aforementioned pharmacokinetic and pharmacodynamic issues. Besides,
NSAIDs and opioids are not effective in treating CPSP in patients with stroke (Zorowitz et
al., 2005; Frese et al., 2006). This problem demands the use of alternative means of analgesia in treating pain in these patients. Current decriminalization of cannabis for medicinal
and/or recreational use (Park et al., 2017) may aid the use of cannabis as an alternative
analgesic to treat pain in these patients (Davison and Davison, 2011; National Academies
of Sciences and Medicine, 2017; Abrams, 2018; Coluzzi, 2018; Ishida et al., 2018). However, the efficacy and safety of cannabis should first be proven. According to the National Academies of Sciences and Medicine (NASM) report, cannabis is effective in treating chronic pain (National Academies of Sciences and Medicine, 2017). However, some
studies have also suggested that cannabis use may be associated with an increased risk of
stroke (Jouanjus et al., 2017; National Academies of Sciences and Medicine, 2017). The biological mechanisms behind the association between cannabis use and stroke are not clear.
Some of the theoretical causes mentioned in previous studies were hypotension, vasculitis,
vasospasm, and impairment of cerebral blood flow (Thanvi and Treadwell, 2009).
Studies that formed the basis of the NASM report described an increased risk of
stroke with cannabis use (Westover, McBride, and Haley, 2007; Hemachandra et al., 2016;
Rumalla, Reddy, and Mittal, 2016a; Rumalla, Reddy, and Mittal, 2016b). However, other
studies have shown no association between cannabis use and the incidence of stroke (Sidney et al., 1997; Sidney, 2002; Barber et al., 2013). In addition to the studies included in
the NASM report, two recent studies have also examined this issue and reported contradictory results: One study found no association between cannabis use and the incidence
of stroke (Reis et al., 2017), while another study observed an increased risk of incident
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stroke with cannabis use (Kalla et al., 2018). Complicating the picture, experimental studies have reported a neuroprotective effect for cannabinoids in ischemic stroke, including
a meta-analysis based on 34 studies, which concluded that cannabinoids can play a neuroprotective role (England et al., 2015). Cannabinoids like tetrahydrocannabinol (THC)
and cannabidiol (CBD) exert their effects by directly or indirectly acting on cannabinoid
(CB) receptors CB1 or CB2 (Park et al., 2017), which are expressed in multiple tissues. As
already discussed (in chapters 1 and 2), the endogenous ligands and the machinery involved in their synthesis and breakdown make up the endocannabinoid system (ECS). CB
receptors are expressed in a multitude of organ systems including the brain, cardiovascular, and renal systems (Park et al., 2017).
ECS plays a significant role in maintaining renal homeostasis (Park et al., 2017),
and experimental studies have observed disturbances in CB receptors in acute and chronic
kidney disease. Similar perturbations in CB receptors have been found in ischemic stroke
in both humans and animals. Also, evidence exists that blocking CB1 receptors and activating CB2 receptors in some experimental models of kidney disease and injury using
pharmacological agents can result in amelioration in renal structure and function (Park
et al., 2017). When CB1 receptor antagonists were administered to mouse models with
diabetic nephropathy, reduction in proteinuria was observed, which may be the result of
a safeguarding effect on the glomerular podocytes (Nam et al., 2012; Jourdan et al., 2014).
Also, similar results were observed in diet-induced rat obesity by using antagonists of CB1
receptors (Jenkin et al., 2015). Comparable evidence exists that blocking CB1 receptors and
activating CB2 receptors is neuroprotective in stroke in animal models and human autopsy
studies (Choi, Mou, and Silva, 2019; Kolb et al., 2019).
Previous research based on preclinical studies indicates that cannabinoids have a
remarkable therapeutic value in stroke. THC’s neuroprotective effects are thought to be
facilitated through its CB1 receptor-mediated inhibition of calcium channels leading to a
decrease in calcium influx, glutamate release, and hypothermia, which subsequently led
to increased cerebral blood flow. In addition, THC can act on CB2 receptors in the immune
system and lead to its protective effect in stroke (Choi, Mou, and Silva, 2019). Rats with
permanent middle cerebral artery occlusion, when administered dose-dependent CB1 receptor agonists, had a reduction in motor disability and infarct volume compared to controls. This effect remained present after 4 hours from stroke onset (Leker et al., 2003). The
contradictory evidence of the association between cannabis use and incidence of stroke in
the few preclinical/epidemiological studies mentioned above warrants further investigation, especially in patients with compromised kidney function in whom the risk of stroke
is higher than in the general population. Previous research has observed an association between self-reported cannabis use and stroke in young adults, using diagnostic codes. Only
one study has used urine drug tests as a means of confirming cannabis use (Barber et al.,
2013). In addition, these studies have not examined the association between the combined
use of cannabis with opioids/other drugs and stroke.
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To fill this evidence gap, in our study we identified the use of cannabis, opioids, and
other drugs (also the combined use of opioids/other drugs with cannabis) using UDTs and
classified individuals into urine toxicology groups (UTOX groups) based on their exposure status. The primary aim of the current study was to examine the association between
UTOX groups and cerebrovascular accident events (CVA), including ischemic stroke or
transient ischemic attack (TIA). Given the predominant expression of CB1 receptors in the
brain and data indicating that activation of CB1 receptors is associated with inflammation, oxidative stress, and fibrosis, we hypothesized that cannabis use is associated with
increased risk of CVA in patients with advanced kidney disease.

Methods
Study Population
Description of the study population was provided in the Methods section of chapter 2. For
the current analysis, out of the sample of 7,146 (6,476 who tested negative for cannabis and
670 who tested positive for cannabis), we further excluded patients who lacked information needed to identify cerebrovascular accident (CVA) events (n=134; Figure 3.1).

Exposure Ascertainment
Details of the exposure ascertainment were provided in the Methods section of chapter 2.
Exposure ascertainment lead to categorization into 8 urine toxicology (UTOX) exposure
groups (Figure 2.3 and Figure 3.1).

Outcome Ascertainment
Our outcomes of interest were ischemic CVA events (ischemic stroke or transient ischemic
attack). CVA events were defined using ICD-9 diagnostic codes extracted from the VA Inpatient and Outpatient Medical SAS datasets and CMS datasets. Only primary diagnostic
codes were considered for identifying CVA events. As death can be a competing event to
stroke, all-cause mortality was regarded as a competing event for ischemic CVA events.
The start of the follow-up period was from the first UTOX test (within a year of dialysis
initiation), and patients were followed up until kidney transplantation, loss to follow-up-,
last date of available CVA events (including recurrent CVA events), death, or last date of
available follow-up data (September 1, 2015), whichever occurred first. All-cause mortality data, censoring events, and associated dates were obtained from VA, CMS, and USRDS
data sources.
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Figure 3.1: Study population for CVA outcome. *469 patients tested
positive for cannabis any time before 365 days of dialysis initiation or after
dialysis initiation.

Confounders/Covariates
Description of the confounders/covariates was provided in the Methods section of chapter
2. In addition to the comorbidities mentioned in the chapter 2, history of TIA (Ramsey,
Burnett, and Cowperthwaite, 2012) was included in the current study. Dialysis initiation
was included as a time-dependent variable to control for the incidence of stroke before or
after dialysis.

Statistical Analysis
Overall description of the statistical analysis was provided in the Methods section of chapter 2. We estimated the association between UTOX groups and CVA events using Cox
proportional hazards models and Fine and Grey competing risk regression for the association of UTOX groups and CVA events competing with death. While it is recommended
to use survey packages/methods for analyzing IPTW weights calculated from MNPS, we
used normalized weights to correctly interpret IPTW weights as probability weights in
Cox proportional hazards models and also Fine & Grey competing risk regression models
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due to the limitation of using survey packages in both Cox and Fine & Grey regression
models.
We used conditional repeated measures in Cox regression to handle the incidence
of multiple strokes in the same patient. The assumption in this method is that it is not possible to be at risk of repeated strokes without having the first stroke (and hence the model
is referred to as a "conditional risk model") (Perera and Dwivedi, 2019). This model aids
in modeling the time between the recurrent events rather than the full time course of repeated strokes (UCLA, 2018). The proportionality assumption was tested by Kolmogorovtype Supremum Test (Hiller, Marshall, and Dunn, 2015). There was a violation of the proportionality hazard (PH) assumption for the primary exposure variable (UTOX groups)
in case of examining recurrent strokes. However, the PH assumption was satisfied when
examined at the incidence of the first stroke. One of the ways to account for nonproportional hazards is the stratified Cox proportional hazards model (Perera and Dwivedi,
2019). Stratification is based on time, and it is also called the restricted mean survival
time (RMST) (McCaw, Yin, and Wei, 2019). However, RMST models cannot account for
repeated measures or recurrent events. The conditional risk set model is a type of RMST
used to model the time between each recurring event instead of the full-time course of the
recurrent events (UCLA, 2018). The conditional risk model takes into account recurrent
events, even though the time between events varies between patients, as opposed to uniform periods for all the patients in RMST. We used robust sandwich variance estimates
in the conditional risk models to account for repeated measures (UCLA, 2018). Also, the
way the TC-CKD cohort was designed, death can happen only after dialysis initiation.
However, a patient can have a stroke before and/or after dialysis initiation.
Various levels of adjustment were performed, as mentioned below:
1. Main analysis:
(a) Unadjusted model/ Model 1: Only UTOX groups (UTOX group 0 reference).
(b) Adjusted model: Model 1 + IPTW weights.
2. Sensitivity analyses:
(a) Incremental analysis:
i. Model 2-Model 1 + demographic variables.
ii. Model 3-Model 2 + comorbidities + smoking status + vascular access.
iii. Model 4- Model 3 + medications.
iv. Model 5- Model 4 + vital signs + baseline eGFR .
(b) Doubly robust model: Model 5 + IPTW weights.
(c) Adjusted model with winsorized weights: Model 1 + winsorized IPTW weights.
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(d) Doubly robust model with winsorized weights: Model 5 + winsorized IPTW
weights.
We used a two-sided p-value of <0.05 as a threshold of statistical significance for
all statistical analyses. We also performed additional analyses to control for multiple comparisons between the 8 UTOX groups. First, we applied Bonferroni correction to avoid
type I error (Armstrong, 2014). The Bonferroni correction sets the significance at a more
conservative value, which is represented by α/n. In the current study, α=0.05 and n=8
UTOX groups. It involved 7 comparisons and resulted in α-threshold of 0.007 (0.05/7).
Second, we performed multiple pair-wise comparisons among the 8 UTOX groups (28
total pair-wise comparisons) using Tukey’s method. We considered these additional analyses, as Bonferroni’s correction is not routinely recommended and Tukey’s adjustment is
a post hoc analysis (Lee and Lee, 2018). All analyses were conducted in SAS Enterprise
Guide v7.1 (SAS Institute; Cary, NC), STATA/MP Version 15 (STATA Corporation, College
Station, TX), and R-Studio 1.0.153. The study was approved by the Institutional Review
Boards of the Memphis and Long Beach, VA, Medical Centers, with exemption from informed consent.

Results
Cerebrovascular Outcome
Baseline characteristics: The mean (SD) age of the sample was 61 (10); 97% were males;
46% were African Americans; 97% had hypertension; 78% had hyperlipidemia; 73% were
diabetic; 51% were current smokers; 87% were analgesics users; 84% were diuretics users;
and 51% psychiatric medication users. Except patients in UTOX groups 0 and 5, patients
in other groups (1-4 & 6, 7) were more likely to be younger, less likely to be white and more
likely to be smokers (Table 3.1).
A total of 1,232 CVA (18%) events occurred, out of which 616 were single CVA
events; 229 patients had two CVA events, and 387 had 3 or more CVA events (crude incidence rate 66 per 1,000 patient-years; 95% CI 62-68, with a total of 17,432 patient-years of
follow-up). Median (IQR) at-risk time was 2 (1, 3.4) years.

Association with CVA Events
UTOX groups 1-4 vs group 0
Table 3.2 shows the association between UTOX groups 1-4 and CVA events. In the unadjusted model, UTOX groups 1-4 were associated with lower risk of CVA events. However,
only the associations of UTOX groups 2 and 4 were statistically significant.
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Table 3.1: Baseline characteristics of the overall CVA outcome cohort and
urine toxicology (UTOX) groups.
Variables

Demographics
Mean age (SD), years
Males, n (%)
Race, n (%)
Whites
African Americans
Other
Comorbidities, n (%)
Chronic pulmonary disease
Liver disease
Diabetes
Hyperlipidemia
Hypertension
PTSD
History of TIA
CCI Score (IQR)
Access type, n (%)
AVF
AVG
Catheter
Other
Missing
Baseline eGFR
(mL/min/1.73m2 /year),
Mean (SD)
Smoking, n (%)
Never
Current
Past
Missing
Medication use, n (%)
Analgesics
Psychiatric meds
Antimicrobials
Antiretrovirals
Cardiovascular meds
Chemotherapeutics
Diuretics
Proton pump inhibitors
H2 receptor blockers
Warfarin
Anticoagulants
Antihistamines
Benzodiazepines
Vital signs, Mean (SD)
SBP
DBP
BMI
Pain

All
(N=7,012)

Tested negative
for all tests
(N=3,362)

Cannabis
(N=201)

Cannabis
+ opioids
(N=183)

Cannabis
+ other drugs
(N=102)

Cannabis
+ opioids
+ other drugs
(N=184)

Opioids
(N=1,715)

other drugs
(N=545)

Opioids
+ other drugs
(N=720)

61 (10)
6805 (97)

62 (10)
3253 (97)

57 (8)
192 (96)

57 (8)
180 (98)

57 (6)
100 (98)

56 (7)
179 (97)

62 (9)
1676 (98)

58 (8)
526 (97)

57 (7)
699 (97)

3552 (51)
3236 (46)
224 (3)

1864 (55)
1343 (40)
155 (5)

91 (45)
107 (53)
3 (1)

99 (54)
76 (42)
8 (4)

26 (26)
76 (75)
0 (0)

56 (30)
124 (67)
4 (2)

1074 (63)
606 (35)
35 (2)

137 (25)
398 (73)
10 (2)

205 (29)
506 (70)
9 (1)

3456 (49)
1897 (27)
5054 (72)
5440 (78)
6801 (97)
1474 (21)
1203 (17)
4 (3-6)

1481 (44)
684 (20)
2485 (74)
2694 (80)
3261 (97)
544 (16)
589 (18)
4 (2-6)

74 (37)
68 (34)
118 (59)
136 (68)
194 (97)
46 (23)
18 (9)
3 (2-5)

97 (53)
73 (40)
113 (62)
128 (70)
174 (95)
58 (32)
18 (10)
4 (3-6)

40 (39)
39 (38)
60 (59)
60 (59)
98 (96)
22 (22)
14 (14)
4 (2-5)

92 (50)
84 (46)
114 (62)
116 (63)
176 (96)
60 (33)
24 (13)
4 (3-7)

1049 (61)
481 (28)
1307 (76)
1425 (83)
1668 (97)
390 (23)
342 (20)
5 (3-7)

228 (42)
179 (33)
364 (67)
376 (69)
530 (97)
139 (26)
86 (16)
4 (2-6)

395 (55)
289 (40)
493 (69)
505 (70)
700 (97)
215 (30)
112 (16)
5 (3-7)

1286 (18)
142 (2)
4872 (70)
37 (1)
675 (10)

689 (21)
52 (2)
2235 (67)
21 (1)
365 (11)

50 (25)
8 (4)
126 (63)
2 (1)
15 (7)

30 (16)
2 (1)
137 (75)
2 (1)
12 (7)

21 (21)
1 (1)
70 (69)
0 (0)
10 (10)

19 (10)
4 (2)
148 (80)
1 (1)
12 (7)

290 (17)
32 (2)
1211 (71)
6 (0)
176 (10)

77 (14)
16 (3)
410 (75)
5 (1)
37 (7)

110 (15)
27 (4)
535 (74)
0 (0)
48 (7)

27 (21)

26 (20)

28 (22)

31 (22)

26 (20)

29 (20)

31 (22)

26 (19)

28 (20)

1864 (27)
3549 (51)
1547 (22)
52 (1)

1151 (34)
1271 (38)
900 (27)
40 (1)

24 (12)
139 (69)
36 (18)
2 (1)

26 (14)
125 (68)
31 (17)
1 (1)

7 (7)
87 (85)
8 (8)
0 (0)

13 (7)
158 (86)
13 (7)
0 (0)

444 (26)
847 (49)
420 (25)
4 (0)

115 (21)
356 (65)
70 (13)
4 (1)

84 (12)
566 (79)
69 (10)
1 (0)

6126 (87)
3577 (51)
1808 (26)
24 (0)
5779 (82)
40 (1)
5880 (84)
4093 (58)
1352 (19)
607 (9)
3919 (56)
1186 (17)
1507 (22)

2777 (83)
1455 (43)
842 (25)
7 (0)
2823 (84)
17 (1)
2826 (84)
1819 (54)
632 (19)
275 (8)
1832 (55)
496 (15)
609 (18)

163 (81)
94 (47)
39 (19)
2 (1)
151 (75)
3 (1)
165 (82)
111 (55)
30 (15)
16 (8)
102 (51)
32 (16)
42 (21)

171 (93)
126 (69)
53 (29)
1 (1)
142 (78)
3 (2)
152 (83)
118 (65)
32 (18)
13 (7)
114 (62)
38 (21)
57 (31)

91 (89)
44 (43)
15 (15)
1 (1)
81 (79)
0 (0)
81 (79)
59 (58)
11 (11)
6 (6)
55 (54)
21 (21)
20 (20)

174 (95)
117 (64)
49 (27)
2 (1)
142 (77)
2 (1)
148 (80)
125 (68)
39 (21)
12 (7)
118 (64)
41 (22)
44 (24)

1626 (95)
1009 (59)
482 (28)
2 (0)
1434 (84)
14 (1)
1454 (85)
1093 (64)
344 (20)
213 (12)
919 (54)
308 (18)
454 (27)

454 (83)
256 (47)
124 (23)
4 (1)
434 (80)
0 (0)
449 (82)
299 (55)
99 (18)
30 (6)
312 (57)
86 (16)
79 (15)

670 (93)
476 (66)
204 (28)
5 (1)
572 (79)
1 (0)
605 (84)
469 (65)
165 (23)
42 (6)
467 (65)
164 (23)
202 (28)

146 (17)
79 (11)
29 (6)
2 (2)

147 (17)
78 (11)
29 (6)
2 (2)

149 (17)
83 (11)
26 (5)
2 (2)

149 (17)
82 (10)
27 (6)
3 (2)

152 (19)
86 (12)
25 (5)
2 (2)

148 (16)
85 (9)
27 (6)
3 (2)

143 (16)
77 (10)
30 (7)
3 (2)

149 (17)
84 (10)
28 (6)
2 (2)

147 (16)
83 (10)
28 (6)
3 (2)

AVF: arteriovenous fistula; AVG: ateriovenous graft; BMI: body mass index; CCI Score:
Charlson comorbidity index; CVA: cerebrovascular accident; DBP: diastolic blood
pressure; eGFR: estimated glomerular filtration rate; H2 receptors: histamine 2 receptors;
IQR: interquartile range; PTSD: post-traumatic stress disorder; SBP: systolic blood
pressure; SD: standard deviation; TIA: Transient Ischemic Attack.
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Table 3.2: Association of CVA events in Cox proportional regression with
urine toxicology groups in the main analysis.

UTOX groups
1-7 vs 0*
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

Unadjusted
HR (95% CI)

P-value

Adjusted (IPTW wts)
HR (95% CI)

P-value

0.88 (0.7, 1.09)
0.63 (0.48, 0.81)
0.79 (0.6, 1.02)
0.7 (0.52, 0.95)
0.96 (0.84, 1.09)
1 (0.81, 1.23)
0.91 (0.72, 1.14)

0.2
0.0005
0.1
0.021
0.5
1
0.4

0.94 (0.71, 1.25)
0.58 (0.4, 0.84)
0.73 (0.57, 0.93)
0.69 (0.47, 1.01)
1.04 (0.89, 1.22)
0.92 (0.74, 1.13)
0.86 (0.66, 1.11)

0.7
0.0037
0.012
0.1
0.6
0.4
0.2

*For description of UTOX groups 0-7, see Figure 2.3. HR: Hazard ratios; CI: Confidence
intervals.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 3.1.

The unadjusted hazard ratios (95% CI, p-values for comparison with the UTOX
group 0 reference) in the respective exposure groups were:
• Group 1 [0.88 (0.7, 1.09) , P=0.2].
• Group 2 [0.63 (0.48, 0.81), P=0.0005].
• Group 3 [0.79 (0.6, 1.02), P=0.1].
• Group 4 [0.7 (0.52, 0.95), P=0.02].
In the main adjusted analysis (with weights) a similar trend was observed, with
only the associations of UTOX groups 2 and 3 being statistically significant. The adjusted
hazard ratios (95% CI) of the respective exposure groups (vs group 0 reference) were:
• Group 1 [0.94 (0.71, 1.25), P=0.7].
• Group 2 [0.58 (0.4, 0.84), P=0.0037].
• Group 3 [0.73 (0.57, 0.93), P=0.01]
• Group 4 [0.69 (0.47, 1.01), P=0.1].
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UTOX groups 5-7 vs group 0
The association between UTOX groups 5-7 and CVA events is shown in Table 3.2. UTOX
groups 5-7 (vs group 0 reference) were not associated with CVA events in either the unadjusted or adjusted (with weights) analysis.
Unadjusted hazard ratios (95% CI) were:
• Group 5 [0.96 (0.84, 1.09), P=0.5].
• Group 6 [1 (0.81, 1.23), P=1.0].
• Group 7 [0.91 (0.72, 1.14), P=0.4].
Adjusted hazard ratios (95% CI) were:
• Group 5 [1.04 (0.89, 1.22), P=0.6].
• Group 6 [0.92 (0.74, 1.13), P=0.4].
• Group 7 [0.86 (0.66, 1.11), P=0.2].
In incremental analysis (Table 3.3) and in doubly robust analysis (Table 3.4), only
UTOX group 2 (vs group 0 reference) was significantly associated with a lower CVA risk.
However, in the analysis adjusted for winsorized IPTW weights, UTOX groups 24 (vs group 0 reference) were significantly associated with lower CVA risk (Table 3.4).
In analyses with Bonferroni correction, only UTOX group 2 was associated with a lower
risk of CVA. This association was statistically significant both in the unadjusted analysis
and after adjustment (with winsorized weights and doubly robust estimation). However,
none of the pair-wise associations between different UTOX groups and CVA events were
statistically significant (Figure 3.2).

Association with CVA Events Competing with Death
UTOX groups 1-4 vs group 0
Table 3.5 shows the association between UTOX groups 1-4 and CVA events in competing
risk models. In the unadjusted model, UTOX groups 1-4 were associated with lower risk
of CVA events. However, only the associations of UTOX groups 2 and 4 were statistically
significant.
The unadjusted subhazard ratios (95% CI, p-values for comparison with the UTOX
group 0 reference) in the respective exposure groups were:
• Group 1 [0.82 (0.67, 1.02), P=0.1].
• Group 2 [0.65 (0.51, 0.83), P=0.0007].
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Table 3.3: Association of CVA events in Cox proportional regression with
urine toxicology groups in the incrementally adjusted analysis.
UTOX groups

Model 2

Model 3

Model 4

Model 5

1-7 vs 0*

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

P-value

Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

0.9 (0.72, 1.13)
0.65 (0.49, 0.85)
0.81 (0.61, 1.08)
0.72 (0.52, 0.98)
0.97 (0.85, 1.1)
1.01 (0.82, 1.26)
0.93 (0.73, 1.19)

1.02 (0.81, 1.27)
0.68 (0.52, 0.9)
0.93 (0.7, 1.23)
0.75 (0.53, 1.06)
0.96 (0.84, 1.1)
1.07 (0.86, 1.32)
0.94 (0.75, 1.17)

1.03 (0.82, 1.29)
0.68 (0.51, 0.9)
0.92 (0.71, 1.2)
0.74 (0.52, 1.06)
0.97 (0.85, 1.1)
1.08 (0.87, 1.32)
0.95 (0.77, 1.17)

0.96 (0.76, 1.23)
0.64 (0.46, 0.89)
0.87 (0.66, 1.15)
0.73 (0.51, 1.05)
1.01 (0.88, 1.16)
1.02 (0.82, 1.27)
0.94 (0.76, 1.17)

0.8
0.0088
0.3
0.1
0.9
0.8
0.6

*For description of UTOX groups 0-7, see Figure 2.3. HR: Hazard ratios; CI: Confidence
intervals.
Model 1: Unadjusted analysis shown in Table 3.2.
Models 2-5 presented here are incrementally adjusted, as follows : Model 2: Model 1 +
demographics (sex, race, age). Model 3: Model 2 + comorbidities (chronic pulmonary
disease, liver disease, diabetes, hyperlipidemia, hypertension, post-traumatic stress
disorder, and history of transient ischemic attack) + access type + smoking. Model 4:
Model 3+ use of medications (analgesics, psychiatric drugs, antimicrobials,
antiretrovirals, cardiovascular meds, chemotherapeutic inhibitors, diuretics, proton pump
inhibitors, H2 receptor blockers, warfarin, anticoagulants, and benzodiazepines). Model
5: Model 4 + vital signs (mean systolic blood pressure, mean diastolic blood pressure,
mean body mass index, and mean pain score) + baseline eGFR (eGFR intercept).
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Table 3.4: Association of CVA events in Cox proportional regression with
urine toxicology groups in the DRE analysis.
UTOX groups
1-7 vs 0*
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

DRE
HR (95% CI)

P-value

Adjusted
(winsorized IPTW wts)
HR (95%CI)

P-value

DRE
(winsorized IPTW wts)
HR (95%CI)

P-value

0.93 (0.67, 1.28)
0.55 (0.38, 0.8)
0.77 (0.59, 1)
0.74 (0.47, 1.16)
1.08 (0.92, 1.26)
0.89 (0.73, 1.08)
0.82 (0.65, 1.05)

0.6
0.0015
0.053
0.2
0.4
0.2
0.1

0.95 (0.72, 1.25)
0.58 (0.4, 0.84)
0.77 (0.6, 0.99)
0.71 (0.51, 1)
1.04 (0.89, 1.21)
0.98 (0.79, 1.21)
0.86 (0.67, 1.11)

0.7
0.0037
0.042
0.047
0.6
0.8
0.3

0.95 (0.7, 1.3)
0.55 (0.38, 0.8)
0.82 (0.63, 1.07)
0.72 (0.47, 1.08)
1.08 (0.92, 1.26)
0.93 (0.76, 1.13)
0.84 (0.67, 1.05)

0.8
0.0019
0.1
0.1
0.4
0.5
0.1

*For description of UTOX groups 0-7, see Figure 2.3. HR: Hazard ratios; CI: Confidence
intervals.
DRE: Doubly robust estimation; "doubly robust" means the model includes all the
variables used to calculate IPTW weights and includes weights, too.
Winsorized weights: Weights adjusted at 90 percentiles, respectively, for each group.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 3.1.

• Group 3 [0.81 (0.63, 1.04), P=0.09].
• Group 4 [0.66 (0.47, 0.93), P=0.02].
In the main adjusted analysis (with weights) a similar trend was observed. However, only the associations of UTOX groups 2 and 3 were statistically significant. The adjusted subhazard ratios (95% CI) of the respective exposure groups (vs group 0 reference)
were:
• Group 1 [0.85 (0.65, 1.12), P=0.3].
• Group 2 [0.61 (0.42, 0.87), P=0.0058].
• Group 3 [0.75 (0.59, 0.96), P=0.019].
• Group 4 [0.7 (0.48, 1.02), P=0.062].
UTOX groups 5-7 vs group 0
The association between UTOX groups 5-7 and CVA events in competing risk models is
shown in Table 3.5. UTOX groups 5-7 (vs group 0 reference) were not associated with CVA
events in either the unadjusted or the adjusted (with weights) analysis:
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Figure 3.2: Association of CVA events with urine toxicology groups
using Tukey’s adjustment for pair-wise comparisons adjusted with
IPTW weights. *For description of UTOX groups 0-7, see Figure 2.3. CI:
Confidence intervals.The displayed confidence intervals have a 95%
family-wise confidence level and are corrected for the number of all
pair-wise comparisons using Tukey’s method. Point estimates/Hazard
ratios of respective pair-wise comparisons (vertical scale) are shown as
solid circles. Confidence intervals that include zero (dotted line)
correspond to statistically non-significant associations.

Unadjusted subhazard ratios (95% CI) were:
• Group 5 [0.98 (0.87, 1.11), P=0.8].
• Group 6 [1 (0.82, 1.22), P=1.0].
• Group 7 [0.93 (0.74, 1.17), P=0.5].
Adjusted subhazard ratios (95% CI) were:
• Group 5 [1.07 (0.92, 1.24), P=0.4].
• Group 6 [0.93 (0.76, 1.14), P=0.5].
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Table 3.5: Association of CVA events in competing risk regression with
urine toxicology groups in the main analysis.

UTOX groups
1-7 vs 0*

Unadjusted
SHR (95% CI)

P-value

Adjusted (IPTW wts)
SHR (95% CI)

P-value

Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

0.82 (0.67, 1.02)
0.65 (0.51, 0.83)
0.81 (0.63, 1.04)
0.66 (0.47, 0.93)
0.98 (0.87, 1.11)
1 (0.82, 1.22)
0.93 (0.74, 1.17)

0.1
0.0007
0.090
0.017
0.8
1
0.5

0.85 (0.65, 1.12)
0.61 (0.42, 0.87)
0.75 (0.59, 0.96)
0.7 (0.48, 1.02)
1.07 (0.92, 1.24)
0.93 (0.76, 1.14)
0.89 (0.69, 1.14)

0.3
0.0058
0.019
0.062
0.4
0.5
0.4

*For description of UTOX groups 0-7, see Figure 2.3. SHR: Subazard ratios; CI:
Confidence intervals.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 3.1.

• Group 7 [0.89 (0.69, 1.14), P=0.4].
In all sensitivity analyses (incremental analysis, winsorized weights, and doubly
robust models (Table 3.6 and Table 3.7), only UTOX group 2 (vs group 0 reference) was
significantly associated with a lower CVA event risk in competing risk analyses.
In analyses with Bonferroni correction, only UTOX group 2 was associated with a
lower risk of CVA events. This association was statistically significant both in unadjusted
and adjusted analysis (with winsorized weights and doubly robust estimation analysis;
Table 3.7) .

Discussion
In this large national cohort of US veterans with advanced CKD who transitioned to dialysis, we observed a significant association between combined use of cannabis with opioids (UTOX group 2 vs 0 reference) and lower risk of CVA events/CVA events competing
with death in both unadjusted and adjusted analyses, independent of the statistical model
used. However, we did not find a significant association between cannabis use/combined
cannabis use with other drugs (UTOX group 1, 3 and 4 vs 0 reference), or between opioid use, other drug use, combined opioid use with other drugs (UTOX groups 5-7 vs 0
reference) and risk of CVA events/CVA events competing with death.

Chapter 3. ASSOCIATION OF CANNABIS USE WITH CEREBROVASCULAR
OUTCOMES IN VETERANS WITH ADVANCED CHRONIC KIDNEY DISEASE
(CKD) TRANSITIONING TO DIALYSIS

63

Table 3.6: Association of CVA events in competing risk regression with
urine toxicology groups in the incrementally adjusted analysis.
UTOX groups

Model 2

Model 3

Model 4

Model 5

1-7 vs 0*

SHR (95% CI)

SHR (95% CI)

SHR (95% CI)

SHR (95% CI)

P-value

Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

0.84 (0.67, 1.05)
0.67 (0.52, 0.87)
0.82 (0.63, 1.07)
0.67 (0.48, 0.95)
0.99 (0.87, 1.12)
1 (0.82, 1.24)
0.94 (0.75, 1.19)

0.93 (0.74, 1.18)
0.7 (0.54, 0.91)
0.92 (0.71, 1.2)
0.71 (0.5, 1.02)
0.98 (0.87, 1.11)
1.05 (0.85, 1.29)
0.95 (0.77, 1.17)

0.96 (0.77, 1.19)
0.7 (0.53, 0.92)
0.91 (0.71, 1.18)
0.72 (0.5, 1.03)
0.98 (0.87, 1.12)
1.06 (0.86, 1.3)
0.96 (0.79, 1.17)

0.91 (0.73, 1.14)
0.67 (0.49, 0.91)
0.87 (0.66, 1.13)
0.71 (0.49, 1.02)
1.04 (0.91, 1.19)
1.01 (0.82, 1.24)
0.97 (0.79, 1.18)

0.4
0.011
0.3
0.065
0.6
0.9
0.7

*For description of UTOX groups 0-7, see Figure 2.3. SHR: Subazard ratios; CI:
Confidence intervals.
Model 1: Unadjusted analysis shown in Table 3.5.
Models 2-5 presented here are incrementally adjusted, as follows : Model 2: Model 1 +
demographics (sex, race, age). Model 3: Model 2 + comorbidities (chronic pulmonary
disease, liver disease, diabetes, hyperlipidemia, hypertension, post-traumatic stress
disorder, and history of transient ischemic attack) + access type + smoking. Model 4:
Model 3+ use of medications (analgesics, psychiatric drugs, antimicrobials,
antiretrovirals, cardiovascular meds, chemotherapeutic inhibitors, diuretics, proton pump
inhibitors, H2 receptor blockers, warfarin, anticoagulants, and benzodiazepines). Model
5: Model 4 + vital signs (mean systolic blood pressure, mean diastolic blood pressure,
mean body mass index, and mean pain score) + baseline eGFR (eGFR intercept).
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Table 3.7: Association of CVA events in competing risk regression with
urine toxicology groups in the DRE analysis.
UTOX groups
1-7 vs 0*

DRE
SHR (95% CI)

P-value

Adjusted
(winsorized IPTW wts)
SHR (95%CI)

P-value

DRE
(winsorized IPTW wts)
SHR (95%CI)

P-value

Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

0.84 (0.62, 1.14)
0.58 (0.41, 0.83)
0.78 (0.6, 1.02)
0.73 (0.47, 1.12)
1.09 (0.93, 1.27)
0.89 (0.74, 1.07)
0.85 (0.67, 1.06)

0.3
0.0028
0.071
0.1
0.3
0.2
0.1

0.8 (0.66, 0.98)
0.57 (0.4, 0.82)
1.28 (0.78, 2.11)
0.69 (0.49, 0.96)
1.02 (0.87, 1.18)
1.05 (0.84, 1.32)
0.89 (0.7, 1.13)

0.0
0.0025
0.300
0.029
0.8
0.7
0.3

0.86 (0.64, 1.16)
0.59 (0.41, 0.84)
0.83 (0.65, 1.07)
0.69 (0.46, 1.03)
1.09 (0.93, 1.26)
0.93 (0.77, 1.12)
0.86 (0.7, 1.06)

0.3
0.0034
0.1
0.072
0.3
0.4
0.2

*For description of UTOX groups 0-7, see Figure 2.3. SHR: Subazard ratios; CI:
Confidence intervals.
DRE: Doubly robust estimation; "doubly robust" means the model includes all the
variables used to calculate IPTW weights and includes weights, too.
Winsorized weights: Weights adjusted at 90 percentiles, respectively, for each group.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 3.1.

To our knowledge, this is the first study to use urine toxicology tests (UTOX) to ascertain cannabis, opioid, or other drugs use in order to examine the association between
various combinations of exposures and cerebrovascular outcomes, mainly risk of CVA (ischemic stroke and transient ischemic attack (TIA)) events and the risk of CVA events competing with death. In addition, this is the first study to examine these associations based
on urine toxicology tests in patients with advanced chronic kidney disease.
Previous epidemiological research has reported contradictory results in the association between cannabis use and stroke risk. In a cross-sectional analysis from the Nationwide Inpatient Sample (NIS), Rumalla, Reddy, and Mittal (2016a) examined the association between cannabis use and risk of stroke in patients who were 15-54 years old, using
ICD-9 diagnostic codes to identify cannabis use and the occurrence of ischemic stroke.
The prevalence of cannabis use was 2.4%, and cannabis use was associated with higher
odds of stroke. The study by Rumalla, Reddy, and Mittal (2016a) adjusted for comorbid
risk factors like hypertension but not for smoking status, an important unmeasured confounder. Westover, McBride, and Haley (2007) conducted a retrospective cross-sectional
analysis using administrative data of hospital discharge patients in the age range of 18-44
years in the state of Texas. They examined the association between cannabis, alcohol, tobacco, amphetamines, cocaine, opioids, and stroke, adjusted for risk factors like smoking,
substance abuse, and comorbid risk factors like hypertension. The prevalence of cannabis
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use was 1%, and cannabis exposure was associated with higher risk of ischemic stroke.
Hemachandra et al. (2016), in a cross-sectional study using data from the Personality and
Total Health (PATH) Through Life Study, examined the association of self-reported use of
cannabis with stroke, with adjustment for covariates like smoking, alcohol use, and comorbid risk factors like hypertension and diabetes. The prevalence of cannabis use was 14%,
and cannabis use was associated with a higher risk of stroke. In another cross-sectional
study using data from NIS, Kalla et al. (2018) examined the association between cannabis
use and CVA events with adjustment for covariates like smoking, alcohol use, and risk
factors like diabetes and hypertension. The prevalence of cannabis use was 1.5%, and a
higher risk of CVA was noted in cannabis users.
Contrasting the studies describing a higher risk of stroke associated with cannabis
use, four other epidemiological studies observed no association between cannabis use and
stroke (Sidney et al., 1997; Sidney, 2002; Barber et al., 2013; Falkstedt et al., 2017; Reis et al.,
2017). Sidney et al. (1997) conducted a retrospective cohort study using Kaiser Permanente
Northern California data in patients of age range 15-49 years. They used self-reported
cannabis use and examined its association with the risk of hospitalization for stroke, with
adjustment for covariates like age, race, education, BMI, hypertension, smoking, and alcohol use. The prevalence of current cannabis users was 22%, and the prevalence of former
users was 20%. The authors observed that neither current nor former cannabis use was
associated with higher risk of stroke.
Barber et al. (2013) conducted a case-control study using data from a New Zealand
hospital with patients in the age range 18-55 years, with adjustment for smoking status
but not for comorbidities like hypertension. This was the only study that used UDTs to
identify cannabis use. The prevalence of cannabis use based on UDTs was 15.6% among
the stroke/TIA patients and 8.1% in control patients. The prevalence of smoking was 88%
in cannabis users and 28% in cannabis-nonusers. When adjusting for tobacco use, the
association between cannabis use and stroke was attenuated and was not statistically significant. Falkstedt et al. (2017) used a retrospective cohort study of Swedish men with an
age range of 20-59 years and examined the association between self-reported cannabis use
and stroke, with adjustment for smoking and comorbid risk factors like diabetes and hypertension. The prevalence of cannabis use was 1.5% in this study. The authors did not
find an association between cannabis use and stroke in this group of young adults. Reis
et al. (2017) used data from a prospective cohort study from the Coronary Artery Risk Development in Young Adults (CARDIA) study. The study population age range was 18-55
years. The prevalence of self-reported cannabis use (both recent and cumulative lifetime
use) was 83%, and the authors did not observe a statistically significant association between cannabis use and CVA events when adjusted for sociodemographic characteristics,
comorbid risk factors like hypertension, diabetes, smoking, and alcohol use.
Experimental studies have observed a neuroprotective effect for cannabis in ischemic stroke. Cannabinoids can be neuroprotective by acting on oxidative stress and
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neuroinflammation (Choi, Mou, and Silva, 2019). Experimental studies have shown that
blocking the CB1 receptor is neuroprotective (Kolb et al., 2019). An increase in CB1 receptor expression has been observed in the ischemic regions of the brain tissue in a human
autopsy studies, and in a mouse model of experimental ischemia which was treated with
CB1 receptor blockade. Similarly, a CB2 receptor agonist used in a rat model of stroke
was neuroprotective (Kolb et al., 2019). Cannabis consists of more than 120 cannabinoids,
yet the cannabinoids studied in most settings were THC and CBD, and the importance
and role of the majority of other cannabinoids is yet to be known (Choi, Mou, and Silva,
2019). Summarizing preclinical data on this topic, England et al. (2015), in a systematic
review and meta-analysis based on 34 preclinical studies, concluded that cannabinoids
could have a neuroprotective effect in stroke.
In ischemic stroke, acute excitotoxicity results in N-Methyl-D-aspartate (NMDA)
receptor stimulation, which leads to glutamate release and intracellular calcium influx.
Further, this leads to oxidative stress, which can result in microvascular injury, dysfunction of the blood-brain barrier, and ischemic inflammation (Hayakawa, Mishima, and Fujiwara, 2010). Also, sigma 1 receptors are associated with activation of the NMDA receptor
and aid in worsening the adverse effects of NMDA receptor activity in ischemic stroke
(Rodriguez-Munoz et al., 2018). However, in animal studies, THC was neuroprotective
but only as pre-ischemic treatment as THC inhibits excitotoxicity of glutamate. Conversely,
CBD is neuroprotective both in pre- and post-treatment scenarios in mice. Furthermore,
repeated treatment with CBD for 14 days resulted in improved outcomes in mice with
ischemic stroke (Hayakawa, Mishima, and Fujiwara, 2010). In an animal study, administration of CBD-enhanced morphine evoked antinociception and displayed antagonist-like
activity on the sigma 1 receptor to reduce the NMDA receptor’s adverse effects in ischemic
stroke (Rodriguez-Munoz et al., 2018). The beneficial effects of CBD can be related to its
mechanisms of action, as CBD acts indirectly on the CB receptors (CB1 and CB2) and does
not bind to them directly, which is in contrast to other experimental agonists and antagonists. Experimental studies have observed that CBD was neuroprotective (Kolb et al.,
2019), as mentioned above (Rodriguez-Munoz et al., 2018). On the contrary, THC exerts
its neuroprotective effects by blocking CB1 receptors via an inverse agonist mechanism.
This blockade of CB1 receptors by THC reduces calcium influx, glutamate release, and
enhances cerebrovascular blood flow (Choi, Mou, and Silva, 2019).
Our study is the first epidemiological or clinical study to examine the association
between combined use of cannabis with opioids and their association with CVA events.
The combined use of cannabis with opioids may result in potential pharmacodynamic and
pharmacokinetic interactions like synergistic analgesia, as observed by Rodriguez-Munoz
et al. (2018). In the current study, we also observed a significant association between combined use of cannabis with opioids (UTOX group 2 vs 0 reference) and lower risk of CVA
events, similar to the synergistic effects seen in the above-mentioned experimental studies.
We did not find a significant association between cannabis use (UTOX group 1 vs 0

Chapter 3. ASSOCIATION OF CANNABIS USE WITH CEREBROVASCULAR
OUTCOMES IN VETERANS WITH ADVANCED CHRONIC KIDNEY DISEASE
(CKD) TRANSITIONING TO DIALYSIS

67

reference) and risk of CVA events. Our finding was consistent with some of the previous
studies (Sidney et al., 1997; Sidney, 2002; Barber et al., 2013; Falkstedt et al., 2017; Reis et al.,
2017). Similarly, we found a significant association between cannabis use combined with
other drugs (UTOX group 3 and 4 vs 0 reference) and CVA. In Tukey adjusted pair-wise
comparisons (Figure 3.2), we did not find a significant association between CVA events
and various pair-wise comparisons of UTOX groups.
Previous research has not mentioned an increased risk of stroke with the use of
opioids. Khodneva et al. (2016) examined the association between prescription opioid use
(POU) and risk of stroke in the prospective cohort study REGARDS (Risk of Coronary
Heart Disease, Stroke, and Cardiovascular Death Among Adults). The authors found that
POU was not associated with the risk of stroke. Also, a recent systematic review based
on 21 studies did not find any association between opioid use and risk of stroke (Wong
and Ranapurwala, 2019). We saw a similar lack of association between opioid use (UTOX
groups 5 vs 0 reference) and CVA events in our study.
Previous research has shown that the use of illicit/other drugs like cocaine and amphetamines was associated with an increased risk of stroke. While Westover, McBride,
and Haley (2007) did not find a significant association between amphetamine use and ischemic stroke, cocaine use was associated with a higher risk of ischemic stroke. On the
other hand, the association between ecstasy, opiates, phencyclidine, lysergic acid diethylamide (LSD), and risk of stroke is unclear (Esse et al., 2011). We did not observe a significant association between other drugs use alone or combined use of other drugs with
opioids (UTOX groups 6 and 7 vs 0 reference) and risk of CVA events. As we combined
amphetamines, barbiturates, benzodiazepines, cocaine, heroin, PCP, and LSD use into a
single “other drugs” category, this could have diluted the individual effects of single drugs
on stroke. Another reason for our results differing from those reported previously is the
difference in the study population/design of previous research from our study. Previous
research was mostly cross-sectional in design. Most of the earlier studies were based on
hospital discharges, and they may not have had information about baseline characteristics or history of stroke. Most of these studies’ exposure was identified by self-reported
use or by ICD-9 diagnostic codes. Most of the studies used logistic regression to examine
the association between cannabis, opioids, other drugs use, and stroke instead of using
time-to-event analyses.
Our study has several strengths. First, we examined, for the first time, the association between recurrent stroke and non-synthetic cannabis, opioids, other drug use or
combination of these in patients with advanced kidney disease transitioning to dialysis.
Second, we used UDTs or urine toxicology tests to ascertain the use of cannabis, opioids,
and other illicit drugs. Finally, we used IPTW weights to balance all the groups on potential confounders.
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Our study also has limitations that should be acknowledged. First, there is a possibility of misclassification of exposure with UDTs: 1) A test can be negative because the
UDTs were not performed in the window of detection of particular use to cannabis (3 days
for single-use, 14 for moderate use, and around 30 days for heavy use), opioids or other
drugs; and 2) a test can be positive because of a false-positive test result. To minimize
misclassification, we assessed only the current use of cannabis but allowed for lifetime
use for opioids and other drugs when defining exposure. Second, we were not able to
evaluate the risk of hemorrhagic stroke due to low numbers in certain exposure groups.
Third, due to the small number of patients, we did not include interactions or subgroup
analyses. Fourth, we adjusted for several confounders, but there is a possibility of residual
confounding. Fifth, as we used observational data for this study, we cannot infer causality. Finally, the study cohort was restricted to predominantly male US veterans; thus, our
study findings may have limited generalizability.

Conclusion
In summary, this study shows that combined cannabis use with opioids was associated
with a significantly lower risk of CVA events. Combined cannabis use with opioids may
be neuroprotective and may aid in synergistic analgesia. The current socio-legal environment of the opioid epidemic and decriminalization of cannabis may result in an increasing
number of people becoming exposed to cannabis. Restrictions on opioids and expected
increased use of cannabis demand future clinical trials and further epidemiological studies that help provide a clear understanding of the cerebrovascular effects of combined
cannabis and opioids use in the general population and in people with compromised kidney function.
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Chapter 4
ASSOCIATION OF CANNABIS USE WITH
MORTALITY AFTER DIALYSIS INITIATION IN
VETERANS WITH ADVANCED CHRONIC KIDNEY
DISEASE (CKD) TRANSITIONING TO DIALYSIS

Introduction
We examined the association between cannabis use and kidney function and cerebrovascular outcomes in Chapters 2 and 3, respectively.
The research presented in chapter 4 was based on Aim 3, mentioned in the Research
Aims section of chapter 1, that examined the association between cannabis use and mortality outcomes in the study population.
In the United States, the prevalence of CKD (stages 1-5) among adults is approximately 15% (CDC, 2019b; Saran et al., 2019). Patients with CKD are at high risk of adverse
events and suffer from a high burden of comorbidities such as chronic pain, cardiovascular
disease (CVD), and mortality (Tonelli et al., 2015). The prevalence of CVD in CKD patients
is two times higher than in the general population, with a linearly increasing risk of CVD
seen with decreasing kidney function (Levin, 2003; Herzog et al., 2011; Gansevoort et al.,
2013).
The final stage of CKD is end-stage renal disease (ESRD). Based on data from the
United States Renal Data Systems (USRDS) in 2016, there were 726,331 prevalent ESRD
cases and 124,675 incident ESRD patients in the US. In the last decade, an increase in the
incident ESRD rate has been observed (Saran et al., 2019). The only available treatment for
ESRD is renal replacement therapy (RRT). RRT can be dialysis or transplantation (Levey,
Stevens, and Coresh, 2009). Due to many barriers to obtaining a kidney transplant, most
Americans rely on dialysis as their modality of RRT (Beyar, 2011; Saran et al., 2019). Patients on RRT, especially those receiving dialysis, are at higher risk of mortality. There have
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been several improvements in the dialysis procedure, which led to a decrease in mortality rate (2007-2016) in dialysis patients by about 18%. However, the five-year mortality
of patients on dialysis remains very high, ranging from 42-52%, with death due to CVD
being the most common cause of death (Saran et al., 2019). The use of opioids has been
associated with higher mortality in patients on dialysis (Kimmel et al., 2017).
As already discussed in chapters 1, 2 and 3), pain is common among patients with
CKD and end-stage renal disease (ESRD). Use of analgesics in patients with CKD/ESRD is
associated with multiple difficulties and a higher risk of mortality associated with opioid
use. This suggests that alternative modes of analgesia are needed to treat pain in this patient population. In many US states, cannabis is currently legalized for medicinal and/or
recreational use (Park et al., 2017), and it may aid as an alternative analgesic to treat pain in
these patients (Davison and Davison, 2011; National Academies of Sciences and Medicine,
2017; Abrams, 2018; Coluzzi, 2018; Ishida et al., 2018).
It is crucial that the safety and efficacy of cannabis be proven before it is used as an
alternative analgesic. As mentioned in the earlier chapters (1, 2 and 3), one of the ways
cannabis exerts its effects is by acting on cannabinoid (CB) receptors CB1 or CB2 (Park
et al., 2017). CB receptors are expressed in multiple tissues, including the brain, cardiovascular system, and kidneys. CB receptors can be activated by cannabinoids present in
cannabis. The endocannabinoid system (ECS) is composed of cannabinoid receptors, their
endogenous ligands, and the machinery involved in their synthesis and breakdown. The
ECS plays a significant role in maintaining renal homeostasis. Experimental studies have
observed disturbance in CB receptors in acute and chronic kidney disease (Park et al.,
2017). Previous research has shown that CB1 receptors present in the myocardium and
vascular tissue, in combination with exo/endocannabinoids, influence blood pressure and
have a cardio-repressor effect (Pacher, Batkai, and Kunos, 2005; Malinowska, BaranowskaKuczko, and Schlicker, 2012). In pathophysiological conditions, increased expression of
CB1 receptors has been observed in the brain, cardiovascular, and renal systems. Research
has shown that activation of CB1 receptors may lead to oxidative stress, inflammation, and
fibrosis (Mukhopadhyay et al., 2010c; Rajesh et al., 2012; Chua et al., 2019).
A report by the National Academies of Sciences and Medicine (NASM) showed
that cannabis is effective in treating chronic pain. In the same report, based on previous
research, NASM mentioned that there is insufficient evidence regarding the existence of an
association between self-reported cannabis use and mortality (National Academies of Sciences and Medicine, 2017). However, prior studies that examined the association between
cannabis use and mortality in the NASM report were based on observations from the general population. Only one study examined the association between self-reported cannabis
use and mortality in patients with compromised kidney function; it found no significant
association (Ishida et al., 2017). In the same study, the authors observed a significant association between illicit drug use and mortality (Ishida et al., 2017). A similar risk of increased
mortality was observed with illegal drug use in another study whose study population

Chapter 4. ASSOCIATION OF CANNABIS USE WITH MORTALITY AFTER DIALYSIS
INITIATION IN VETERANS WITH ADVANCED CHRONIC KIDNEY
71
DISEASE (CKD) TRANSITIONING TO DIALYSIS
consisted of individuals with compromised kidney function (Grubbs et al., 2016). Only
one study examined the association between cannabis use and cause-specific death in the
general population and found no association with CVD mortality (Reis et al., 2017). These
cited studies did not examine the association between the combined use of cannabis with
opioids and/or other drugs and mortality.
There is a scarcity of studies examining the association between cannabis use and
all-cause/cause-specific mortality in individuals with compromised kidney function. It
was our hypothesis that cannabis use is associated with an increased risk of death. To address this gap, we used UDTs to determine the use of cannabis, opioids, and other drugs
(also, the combined use of opioids/other drugs with cannabis) for classification of individuals into specific urine toxicology groups (UTOX groups) based on their exposure status.
We examined the association between different exposure status and mortality using Cox
proportional hazard models and Fine and Grey competing risk regression for the association between UTOX groups and cause-specific CVD mortality.

Methods
Study Population
Description of the study population was provided in the Methods section of chapter 2. For
the current analysis, our study sample was 7,146 patients (6,476 who tested negative for
cannabis and 670 who tested positive for cannabis, Figure 4.1).

Exposure Ascertainment
Details of the exposure ascertainment were provided in the Methods section of chapter 2.
Exposure ascertainment lead to categorization into 8 urine toxicology (UTOX) exposure
groups (Figure 2.3 and Figure 4.1).

Outcome Ascertainment
Our co-primary outcomes of interest were all-cause and cardiovascular mortality. The
start of the follow-up period for mortality analyses started at dialysis initiation, and patients were censored at either death, loss of follow-up, end of the respective follow-up
periods, kidney transplantation, or the last date of available follow-up (September 1, 2015
and July 30, 2015 for all-cause and cardiovascular mortality, respectively), whichever occurred first. Information about all-cause mortality, censoring events, and associated dates
were obtained from VA and USRDS data sources. Cardiovascular mortality data was obtained from USRDS. The difference in the last date of available follow-up between all-cause
and cause-specific mortality was due to different sources of information, i.e., the VA and
USRDS, respectively (Soohoo et al., 2019).
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Figure 4.1: Study population for mortality outcome. *469 patients tested
positive for cannabis any time before 365 days of dialysis initiation or after
dialysis initiation.
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Confounders/Covariates
Description of the confounders/covariates was provided in the Methods section of chapter
2.

Statistical Analysis
Overall description of the statistical analysis was provided in the Methods section of chapter 2. We estimated the association between UTOX groups and all-cause mortality events
using Cox proportional hazards models. We used Fine and Grey competing risk regression
for the association of UTOX groups with CV mortality as the event of interest competes
with other causes of death. The proportionality hazard (PH) assumption was tested by
Kolmogorov-type Supremum Test (Hiller, Marshall, and Dunn, 2015). The PH assumption
was satisfied. To correctly interpret IPTW weights as probability weights, we used survey
packages for Cox regression and Fine and Grey competing risk regression. Different levels
of adjustment were performed, as follows:
1. Main analysis:
(a) Unadjusted model/ Model 1: Only UTOX groups (UTOX group 0 reference).
(b) Adjusted model: Model 1 + IPTW weights.
2. Sensitivity analyses:
(a) Incremental analysis:
i. Model 2-Model 1 + demographic variables.
ii. Model 3-Model 2 + comorbidities + smoking status + vascular access.
iii. Model 4- Model 3 + medications.
iv. Model 5- Model 4 + vital signs + baseline eGFR .
(b) Doubly robust model: Model 5 + IPTW weights.
(c) Adjusted model with winsorized weights: Model 1 + winsorized IPTW weights.
(d) Doubly robust model with winsorized weights: Model 5 + winsorized IPTW
weights.
We used a two-sided p-value of <0.05 as a threshold of statistical significance for
all analyses. We also performed additional analyses to control for multiple comparisons
between the 8 UTOX groups. First, we applied Bonferroni correction to avoid type I error
(Armstrong, 2014). The Bonferroni correction sets the significance at a more conservative
value, which is represented by α/n. In the current study α=0.05 and n= 8 UTOX groups
which involves seven comparisons and results in α-threshold of 0.007 (0.05/7). Second, we
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performed multiple pair-wise comparisons among the 8 UTOX groups (total of 28 pairwise comparisons) using Tukey’s method. We considered these additional analyses, as
Bonferroni correction is not routinely recommended and Tukey’s adjustment is a post hoc
analysis (Lee and Lee, 2018). All analyses were conducted in SAS Enterprise Guide v7.1
(SAS Institute; Cary, NC), STATA/MP Version 15 (STATA Corporation, College Station,
TX) and R-Studio 1.0.153. The study was approved by the Institutional Review Boards
of the Memphis and Long Beach, VA, Medical centers, with exemption from informed
consent.

Results
Mortality Outcome
Baseline characteristics of the cohort were as follows: The mean (SD) age of the sample
was 60 years (10); 97% were males; 46% were African Americans; 97% had hypertension;
77% had hyperlipidemia; 72% were diabetic; 51% were current smokers; 87% were analgesics users; 84% were diuretics users, and 51% were psychiatric medication users. Except
patients in UTOX groups 0 and 5, patients in the other groups (1-4 & 6, 7) were more likely
to be younger, less likely to be white, and more likely to be smokers (Table 4.1).
During a median 1.8-year (IQR) (0.8, 3.5) follow-up period after dialysis initiation,
there were 4,023 deaths (56%) in the overall cohort (crude incidence rate 242 per 1000
patient-years; 95% CI 235-249, with a total of 16,629 patient-years of follow-up).

Association with All-Cause Mortality
UTOX groups 1-4 vs group 0
Table 4.2 shows the association between UTOX groups 1-4 and all-cause mortality. In the
unadjusted model, UTOX groups 1-4 (vs group 0) did not show significant association with
all-cause mortality.
The unadjusted hazard ratios (95% CI, p-values for comparison with the UTOX
group 0 reference) in the respective exposure groups were:
• Group 1 [0.94 (0.78, 1.14) , P=0.5].
• Group 2 [1.16 (0.95, 1.41), P=0.1].
• Group 3 [0.9 (0.69, 1.17), P=0.4].
• Group 4 [1.13 (0.94, 1.37), P=0.2].
The main adjusted analysis (with weights) showed similar results. The adjusted
hazard ratios (95% CI) of the respective exposure groups (vs group 0 reference) were:
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Table 4.1: Baseline characteristics of the overall mortality outcome cohort
and urine toxicology (UTOX) groups.
Variables

Demographics
Mean age (SD), years
Males, n (%)
Race, n (%)
Whites
African Americans
Other
Comorbidities, n (%)
Chronic pulmonary disease
Liver disease
Diabetes
Hyperlipidemia
Hypertension
PTSD
CCI Score (IQR)
Access type, n (%)
AVF
AVG
Catheter
Other
Missing
Baseline eGFR
(mL/min/1.73m2 /year),
Mean (SD)
Smoking, n (%)
Never
Current
Past
Missing
Medication use, n (%)
Analgesics
Psychiatric meds
Antimicrobials
Antiretrovirals
Cardiovascular meds
Chemotherapeutics
Diuretics
Proton pump inhibitors
H2 receptor blockers
Warfarin
Anticoagulants
Antihistamines
Benzodiazepines
Vital signs, Mean (SD)
SBP
DBP
BMI
Pain

All
(N=7,146)

Tested negative
for all tests
(N=3,394)

Cannabis
(N=201)

Cannabis
+ opioids
(N=183)

Cannabis
+ other drugs
(N=102)

Cannabis
+ opioids
+ other drugs
(N=184)

Opioids
(N=1,715)

other drugs
(N=566)

Opioids
+ other drugs
(N=765)

60 (10)
6932 (97)

62 (10)
3285 (97)

57 (8)
192 (96)

57 (8)
180 (98)

57 (6)
100 (98)

56 (7)
179 (97)

62 (9)
1711 (98)

58 (8)
545 (96)

57 (7)
740 (97)

3608 (51)
3313 (46)
225 (3)

1877 (55)
1362 (40)
155 (5)

91 (45)
107 (53)
3 (1)

99 (54)
76 (42)
8 (4)

26 (26)
76 (75)
0 (0)

56 (30)
124 (67)
4 (2)

1101 (63)
614 (35)
36 (2)

140 (25)
416 (74)
10 (2)

218 (29)
538 (70)
9 (1)

3508 (49)
1945 (27)
5135 (72)
5524 (77)
6926 (97)
1504 (21)
4 (3-6)

1488 (44)
689 (20)
2506 (74)
2719 (80)
3292 (97)
547 (16)
4 (2-6)

74 (37)
68 (34)
118 (59)
136 (68)
194 (97)
46 (23)
3 (2-5)

97 (53)
73 (40)
113 (62)
128 (70)
174 (95)
58 (32)
4 (3-6)

40 (39)
39 (38)
60 (59)
60 (59)
98 (96)
22 (22)
4 (2-5)

92 (50)
84 (46)
114 (62)
116 (63)
176 (96)
60 (33)
4 (3-7)

1064 (61)
494 (28)
1329 (76)
1445 (83)
1701 (97)
398 (23)
5 (3-7)

235 (42)
189 (33)
377 (67)
389 (69)
550 (97)
146 (26)
4 (2-6)

418 (55)
309 (40)
518 (68)
531 (69)
741 (97)
227 (30)
5 (3-7)

1310 (18)
146 (2)
4964 (70)
37 (1)
689 (10)

694 (20)
52 (2)
2259 (67)
21 (1)
368 (11)

50 (25)
8 (4)
126 (63)
2 (1)
15 (7)

30 (16)
2 (1)
137 (75)
2 (1)
12 (7)

21 (21)
1 (1)
70 (69)
0 (0)
10 (10)

19 (10)
4 (2)
148 (80)
1 (1)
12 (7)

295 (17)
35 (2)
1238 (71)
6 (0)
177 (10)

81 (14)
16 (3)
425 (75)
5 (1)
39 (7)

120 (16)
28 (4)
561 (73)
0 (0)
56 (7)

28 (21)

26 (20)

28 (22)

31 (22)

26 (20)

29 (20)

31 (23)

26 (19)

28 (20)

1882 (26)
3635 (51)
1577 (22)
52 (1)

1158 (34)
1285 (38)
911 (27)
40 (1)

24 (12)
139 (69)
36 (18)
2 (1)

26 (14)
125 (68)
31 (17)
1 (1)

7 (7)
87 (85)
8 (8)
0 (0)

13 (7)
158 (86)
13 (7)
0 (0)

451 (26)
864 (49)
432 (25)
4 (0)

116 (21)
373 (66)
73 (13)
4 (1)

87 (11)
604 (79)
73 (10)
1 (0)

6239 (87)
3652 (51)
1838 (26)
25 (0)
5870 (82)
40 (1)
5983 (84)
4177 (59)
1371 (19)
615 (9)
3990 (56)
1210 (17)
1538 (22)

2803 (83)
1469 (43)
848 (25)
7 (0)
2846 (84)
17 (1)
2851 (84)
1837 (54)
636 (19)
277 (8)
1850 (55)
501 (15)
617 (18)

163 (81)
94 (47)
39 (19)
2 (1)
151 (75)
3 (1)
165 (82)
111 (55)
30 (15)
16 (8)
102 (51)
32 (16)
42 (21)

171 (93)
126 (69)
53 (29)
1 (1)
142 (78)
3 (2)
152 (83)
118 (65)
32 (18)
13 (7)
114 (62)
38 (21)
57 (31)

91 (89)
44 (43)
15 (15)
1 (1)
81 (79)
0 (0)
81 (79)
59 (58)
11 (11)
6 (6)
55 (54)
21 (21)
20 (20)

174 (95)
117 (64)
49 (27)
2 (1)
142 (77)
2 (1)
148 (80)
125 (68)
39 (21)
12 (7)
118 (64)
41 (22)
44 (24)

1654 (95)
1029 (59)
492 (28)
2 (0)
1457 (83)
14 (1)
1482 (85)
1114 (64)
350 (20)
215 (12)
937 (54)
317 (18)
463 (26)

472 (83)
269 (48)
126 (22)
4 (1)
448 (79)
0 (0)
464 (82)
312 (55)
101 (18)
30 (5)
322 (57)
87 (15)
83 (15)

711 (93)
504 (66)
216 (28)
6 (1)
603 (79)
1 (0)
640 (84)
501 (66)
172 (23)
46 (6)
492 (64)
173 (23)
212 (28)

146 (17)
79 (11)
29 (6)
2 (2)

147 (17)
78 (11)
29 (6)
2 (2)

149 (17)
83 (11)
26 (5)
2 (2)

149 (17)
82 (10)
27 (6)
3 (2)

152 (19)
86 (12)
25 (5)
2 (2)

148 (16)
85 (9)
27 (6)
3 (2)

143 (16)
77 (10)
30 (7)
3 (2)

149 (17)
84 (10)
28 (6)
2 (2)

147 (16)
83 (10)
28 (6)
3 (2)

AVF: arteriovenous fistula; AVG: ateriovenous graft; BMI: body mass index; CCI Score:
Charlson comorbidity index; CVA: cerebrovascular accident; DBP: diastolic blood
pressure; eGFR: estimated glomerular filtration rate; H2 receptors: histamine 2 receptors;
IQR: interquartile range; PTSD: post-traumatic stress disorder; SBP: systolic blood
pressure; SD: standard deviation.
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Table 4.2: Association of mortality in Cox proportional regression with
urine toxicology groups in the main analysis.

UTOX groups
1-7 vs 0*
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

Unadjusted
HR (95% CI)

P-value

Adjusted (IPTW wts)
HR (95% CI)

P-value

0.94 (0.78, 1.14)
1.16 (0.95, 1.41)
0.9 (0.69, 1.17)
1.13 (0.94, 1.37)
1.19 (1.1, 1.28)
0.84 (0.74, 0.95)
0.9 (0.81, 1)

0.5
0.1000
0.4
0.200
<0.0001
0.0043
0.04

0.95 (0.78, 1.15)
0.96 (0.74, 1.25)
0.94 (0.72, 1.23)
1.2 (0.92, 1.56)
0.96 (0.87, 1.06)
0.95 (0.82, 1.09)
0.87 (0.75, 1)

0.6
0.8
0.6
0.2
0.4
0.5
0.057

*For description of UTOX groups 0-7, see Figure 2.3. HR: Hazard ratios; CI: Confidence
intervals.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 4.1.

• Group 1 [0.95 (0.78, 1.15), P=0.6].
• Group 2 [0.96 (0.74, 1.25), P=0.8].
• Group 3 [0.94 (0.72, 1.23), P=0.5].
• Group 4 [1.2 (0.92, 1.56), P=0.2].
UTOX groups 5-7 vs group 0
The association between UTOX groups 5-7 and all-cause mortality is shown in Table 4.2.
In the unadjusted analysis, UTOX group 5 was associated with a higher risk of all-cause
mortality. On the other hand, groups 6 and 7 were associated with a lower risk of all-cause
mortality. The unadjusted hazard ratios (95% CI, p-values for comparison with the UTOX
group 0 reference) in the respective exposure groups were:
• Group 5 [1.19 (1.1, 1.28), P=<0.0001].
• Group 6 [0.84 (0.74, 0.95), P=0.0043].
• Group 7 [0.9 (0.81, 1), P=0.04].
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Table 4.3: Association of mortality in Cox proportional regression with
urine toxicology groups in the incrementally adjusted analysis.
UTOX groups

Model 2

Model 3

Model 4

Model 5

1-7 vs 0*

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

P-value

Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

1.22 (1.01, 1.48)
1.42 (1.16, 1.73)
1.22 (0.93, 1.58)
1.63 (1.34, 1.98)
1.18 (1.1, 1.28)
1.14 (1.01, 1.3)
1.23 (1.1, 1.37)

1.14 (0.94, 1.38)
1.23 (1, 1.5)
1.12 (0.86, 1.46)
1.23 (1.01, 1.5)
1.04 (0.96, 1.12)
1 (0.88, 1.13)
0.95 (0.84, 1.06)

1.13 (0.93, 1.37)
1.2 (0.98, 1.47)
1.11 (0.85, 1.45)
1.22 (1, 1.48)
1.01 (0.93, 1.09)
0.99 (0.87, 1.13)
0.91 (0.81, 1.02)

1.1 (0.91, 1.35)
1.05 (0.85, 1.3)
1.05 (0.8, 1.4)
1.11 (0.9, 1.36)
0.94 (0.86, 1.02)
1.01 (0.88, 1.15)
0.84 (0.74, 0.95)

0.3
0.7
0.7
0.3
0.1
0.9
0.0045

*For description of UTOX groups 0-7, see Figure 2.3. HR: Hazard ratios; CI: Confidence
intervals.
Model 1: Unadjusted analysis shown in Table 4.2.
Models 2-5 presented here are incrementally adjusted, as follows : Model 2: Model 1 +
demographics (sex, race, age). Model 3: Model 2 + comorbidities (chronic pulmonary
disease, liver disease, diabetes, hyperlipidemia, hypertension, and post-traumatic stress
disorder) + access type + smoking. Model 4: Model 3+ use of medications (analgesics,
psychiatric drugs, antimicrobials, antiretrovirals, cardiovascular meds, chemotherapeutic
inhibitors, diuretics, proton pump inhibitors, H2 receptor blockers, warfarin,
anticoagulants, and benzodiazepines). Model 5: Model 4 + vital signs (mean systolic
blood pressure, mean diastolic blood pressure, mean body mass index, and mean pain
score) + baseline eGFR (eGFR intercept).

However, in adjusted analyses (with weights), UTOX groups 5-7 showed no significant association with all-cause mortality. The adjusted hazard ratios (95% CI, p-values for
comparison with the UTOX group 0 reference) in the respective exposure groups were:
• Group 5 [0.96 (0.87, 1.06), P=0.4].
• Group 6 [0.95 (0.82, 1.09), P=0.5].
• Group 7 [0.87 (0.75, 1), P=0.057].
In sensitivity analyses (incremental analysis (Table 4.3), doubly robust analysis, and
adjusted analysis with winsorized weights (Table 4.4), UTOX groups 1-6 (vs group 0 reference) did not show significant associations with all-cause mortality. However, group 7
(vs group 0 reference) was significantly associated with a lower risk of all-cause mortality. In analyses with Bonferroni adjustment, none of the groups (1-7, vs group 0 reference)
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Table 4.4: Association of mortality in Cox proportional regression with
urine toxicology groups in the DRE analysis.
UTOX groups
1-7 vs 0*
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

DRE
HR (95% CI)

P-value

Adjusted
(winsorized IPTW wts)
HR (95%CI)

P-value

DRE
(winsorized IPTW wts)
HR (95%CI)

P-value

1.12 (0.91, 1.37)
1 (0.76, 1.3)
1.15 (0.87, 1.51)
1.23 (0.91, 1.65)
0.93 (0.83, 1.03)
1.04 (0.88, 1.23)
0.82 (0.68, 0.98)

0.3
1.0
0.3
0.2
0.1
0.6
0.032

0.95 (0.79, 1.15)
1.03 (0.8, 1.33)
0.92 (0.72, 1.19)
1.12 (0.89, 1.42)
1.01 (0.92, 1.1)
0.92 (0.8, 1.06)
0.87 (0.77, 0.99)

0.6
0.8
0.5
0.3
0.9
0.3
0.030

1.13 (0.92, 1.39)
1.05 (0.81, 1.35)
1.12 (0.86, 1.46)
1.12 (0.86, 1.46)
0.94 (0.85, 1.03)
1.04 (0.88, 1.22)
0.86 (0.74, 1)

0.2
0.7
0.4
0.4
0.2
0.7
0.051

*For description of UTOX groups 0-7, see Figure 2.3. HR: Hazard ratios; CI: Confidence
intervals.
DRE: Doubly robust estimation; "doubly robust" means the model includes all the
variables used to calculate IPTW weights and includes weights, too.
Winsorized weights: Weights adjusted at 90 percentiles, respectively, for each group.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 4.1.

showed significant associations with all-cause mortality. Similarly, none of the associations were statistically significant between UTOX groups and mortality in pair-wise comparisons (Figure 4.2). In incremental analysis (Model 5), the adjusted hazard ratios for
smokers (95% CI, p-values for comparison with the non-smoker group) were: [1.25 (1.15,
1.36), P= <.0001] for current smokers and [1.10 (1.00, 1.21), P=0.06] for past smokers.

Association with Cardiovascular Mortality
A total of 1,047 (14.7%) cardiovascular deaths were observed during the follow up period
(crude mortality rate 63 per 1,000 patient years; 95% CI, 59-67).
UTOX groups 1-4 vs group 0
Table 4.5 shows the association between UTOX groups 1-4 and CV mortality. In the unadjusted model, UTOX groups 1-4 (vs group 0) did not show a significant association with
cardiovascular (CV) mortality.
The unadjusted subhazard ratios (95% CI, p values for comparison with the UTOX
group 0 reference) in the respective exposure groups were:
• Group 1 [0.81 (0.55, 1.19), P=0.3].

Chapter 4. ASSOCIATION OF CANNABIS USE WITH MORTALITY AFTER DIALYSIS
INITIATION IN VETERANS WITH ADVANCED CHRONIC KIDNEY
79
DISEASE (CKD) TRANSITIONING TO DIALYSIS

Figure 4.2: Association of mortality with urine toxicology groups using
Tukey’s adjustment for pair-wise comparisons adjusted with IPTW
weights. *For description of UTOX groups 0-7, see Figure 2.3. CI:
Confidence intervals.The displayed confidence intervals have a 95%
family-wise confidence level and are corrected for the number of all
pair-wise comparisons using Tukey’s method. Point estimates/Hazard
ratios of respective pair-wise comparisons (vertical scale) are shown as
solid circles. Confidence intervals that include zero (dotted line)
correspond to statistically non-significant associations.
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Table 4.5: Association of CV mortality in competing risk regression with
urine toxicology groups in the main analysis.

UTOX groups
1-7 vs 0*

Unadjusted
SHR (95% CI)

P-value

Adjusted (IPTW wts)
SHR (95% CI)

P-value

Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

0.81 (0.55, 1.19)
0.63 (0.39, 1.01)
0.58 (0.31, 1.07)
1.05 (0.73, 1.51)
0.96 (0.82, 1.11)
0.8 (0.63, 1.01)
0.75 (0.61, 0.93)

0.3
0.054
0.080
0.8
0.5
0.062
0.0094

0.83 (0.54, 1.27)
0.54 (0.29, 0.98)
0.52 (0.26, 1.03)
1.73 (1.08, 2.78)
0.9 (0.76, 1.07)
0.89 (0.66, 1.19)
0.7 (0.53, 0.93)

0.4
0.043
0.062
0.023
0.2
0.4
0.013

*For description of UTOX groups 0-7, see Figure 2.3. SHR: Subazard ratios; CI:
Confidence intervals.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 4.1.

• Group 2 [0.63 (0.39, 1.01), P=0.054].
• Group 3 [0.58 (0.31, 1.07), P=0.080].
• Group 4 [1.05 (0.73, 1.51), P=0.8].
In the main adjusted analysis (with weights), UTOX group 2 was associated with
significantly lower risk of CV mortality, and UTOX group 4 was associated with significantly higher risk of CV mortality, while the associations of UTOX groups 1 and 3 with CV
mortality were not statistically significant. The adjusted subhazard ratios (95% CI) of the
respective exposure groups (vs group 0 reference) were:
• Group 1 [0.83 (0.54, 1.27), P=0.4].
• Group 2 [0.54 (0.29, 0.98), P=0.043].
• Group 3 [0.52 (0.26, 1.03), P=0.062].
• Group 4 [1.73 (1.08, 2.78), P=0.023].
UTOX groups 5-7 vs group 0
The association between UTOX groups 5-7 and CV mortality is shown in Table 4.5. In the
unadjusted analysis, UTOX groups 5 and 6 (vs group 0 reference) were not associated with

Chapter 4. ASSOCIATION OF CANNABIS USE WITH MORTALITY AFTER DIALYSIS
INITIATION IN VETERANS WITH ADVANCED CHRONIC KIDNEY
81
DISEASE (CKD) TRANSITIONING TO DIALYSIS
CV mortality. However, UTOX group 7 was associated with significantly lower risk of CV
mortality.
The unadjusted subhazard ratios (95% CI) were:
• Group 5 [0.96 (0.82, 1.11), P=0.5].
• Group 6 [0.8 (0.63, 1.01), P=0.062].
• Group 7 [0.75 (0.61, 0.93), P=0.0094].
In the main adjusted analysis (Table 4.5), similar trends of association were observed.
The adjusted subhazard ratios (95% CI) were:
• Group 5 [0.9 (0.76, 1.07), P=0.2].
• Group 6 [0.89 (0.66, 1.19), P=0.4].
• Group 7 [0.7 (0.53, 0.93), P=0.013].
In sensitivity analyses shown in Table 4.6 and Table 4.7 (incremental analysis, doubly robust analysis, and adjusted analysis with winsorized weights) only UTOX group 7
(vs group 0 reference) was significantly associated with a lower risk of CV mortality. In
analyses with Bonferroni correction, none of the groups (1-7 vs group 0 reference) demonstrated a significant association with CV mortality.

Discussion
In this large, nationally representative cohort of US veterans with advanced CKD who
transitioned to dialysis, we did not observe a significant association between cannabis use
(alone or in combination with opioids/other drugs) and all-cause or CV mortality. We detected similar nonsignificant associations between opioid use, other drugs use, combined
opioid use, and other drug use (UTOX groups 5-7 vs 0 reference) versus the risk of all-cause
and CV mortality. Our finding of a significant association between current smoking status
(vs nonsmokers) and increased risk of mortality serves as a positive control and provides
assurance for the robustness of the observed results. In Tukey- adjusted pair-wise comparisons (Figure 4.2), we did not find a significant association between mortality and various
pair-wise comparisons of UTOX groups. To our knowledge, this is the first study that investigated exposure to cannabis, opioids, or other drug use (and their combinations) based
on urine toxicology tests (UTOX) and their association in patients with advanced CKD and
their effects on all-cause/CV mortality outcomes.
The NASM report about the association between self-reported cannabis use and
mortality was based on epidemiological studies whose populations were individuals with
normal kidney function/general population (Andreasson and Allebeck, 1990; Sidney et
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Table 4.6: Association of CV mortality in competing risk regression with
urine toxicology groups in the incrementally adjusted analysis.
UTOX groups

Model 2

Model 3

Model 4

Model 5

1-7 vs 0*

SHR (95% CI)

SHR (95% CI)

SHR (95% CI)

SHR (95% CI)

P-value

Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

0.94 (0.64, 1.38)
0.69 (0.43, 1.11)
0.72 (0.39, 1.33)
1.32 (0.91, 1.91)
0.94 (0.81, 1.09)
0.97 (0.76, 1.24)
0.92 (0.74, 1.15)

0.99 (0.67, 1.46)
0.69 (0.43, 1.11)
0.75 (0.4, 1.39)
1.25 (0.86, 1.82)
0.89 (0.76, 1.03)
0.95 (0.74, 1.21)
0.88 (0.7, 1.1)

0.99 (0.67, 1.47)
0.7 (0.43, 1.13)
0.74 (0.4, 1.38)
1.26 (0.86, 1.83)
0.88 (0.75, 1.03)
0.94 (0.74, 1.21)
0.89 (0.71, 1.12)

0.95 (0.62, 1.44)
0.66 (0.39, 1.1)
0.6 (0.3, 1.21)
1.16 (0.78, 1.72)
0.86 (0.73, 1.02)
0.96 (0.74, 1.25)
0.86 (0.67, 1.1)

0.8
0.1
0.2
0.5
0.079
0.8
0.2

*For description of UTOX groups 0-7, see Figure 2.3. SHR: Subazard ratios; CI:
Confidence intervals.
Model 1: Unadjusted analysis shown in Table 4.5.
Models 2-5 presented here are incrementally adjusted, as follows : Model 2: Model 1 +
demographics (sex, race, age). Model 3: Model 2 + comorbidities (chronic pulmonary
disease, liver disease, diabetes, hyperlipidemia, hypertension, and post-traumatic stress
disorder) + access type + smoking. Model 4: Model 3+ use of medications (analgesics,
psychiatric drugs, antimicrobials, antiretrovirals, cardiovascular meds, chemotherapeutic
inhibitors, diuretics, proton pump inhibitors, H2 receptor blockers, warfarin,
anticoagulants, and benzodiazepines). Model 5: Model 4 + vital signs (mean systolic
blood pressure, mean diastolic blood pressure, mean body mass index, and mean pain
score) + baseline eGFR (eGFR intercept).
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Table 4.7: Association of CV mortality in competing risk regression with
urine toxicology groups in the DRE analysis.
UTOX groups
1-7 vs 0*

DRE
SHR (95% CI)

P-value

Adjusted
(winsorized IPTW wts)
SHR (95%CI)

P-value

DRE
(winsorized IPTW wts)
SHR (95%CI)

P-value

Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

0.95 (0.57, 1.59)
0.56 (0.29, 1.07)
0.56 (0.26, 1.18)
1.67 (1.01, 2.76)
0.88 (0.73, 1.06)
0.95 (0.7, 1.3)
0.69 (0.5, 0.95)

0.9
0.080
0.1
0.046
0.2
0.8
0.023

0.83 (0.55, 1.26)
0.57 (0.32, 1.04)
0.53 (0.27, 1.06)
1.47 (0.94, 2.28)
0.92 (0.78, 1.08)
0.85 (0.64, 1.11)
0.73 (0.57, 0.94)

0.4
0.066
0.073
0.090
0.3
0.2
0.015

0.99 (0.61, 1.63)
0.59 (0.31, 1.12)
0.58 (0.28, 1.22)
1.45 (0.88, 2.38)
0.89 (0.74, 1.06)
0.93 (0.69, 1.26)
0.79 (0.59, 1.05)

1.0
0.1
0.1
0.1
0.2
0.6
0.1

*For description of UTOX groups 0-7, see Figure 2.3. SHR: Subazard ratios; CI:
Confidence intervals.
DRE: Doubly robust estimation; "doubly robust" means the model includes all the
variables used to calculate IPTW weights and includes weights, too.
Winsorized weights: Weights adjusted at 90 percentiles, respectively, for each group.
IPTW wts: Inverse probability treatment weights; calculated from the variables shown in
Table 4.1.

al., 1997; Sidney, 2002; Calabria et al., 2010; Muhuri and Gfroerer, 2011; Manrique-Garcia
et al., 2016; National Academies of Sciences and Medicine, 2017). In a prospective cohort
study of 45,540 Swedish males in the military followed for 15 years, Andreasson and Allebeck (1990) examined the association between cannabis use and mortality. The authors
observed a significantly higher risk of mortality in heavy cannabis users (defined as individuals who smoked cannabis more than 50 times) (vs nonusers) in unadjusted analyses.
However, once confounders like tobacco smoking and alcohol use were accounted for,
the association became nonsignificant. A similar nonsignificant association was observed
between mild/moderate cannabis use and risk of mortality. Limitations of this Swedish
study were its reliance on self-reported cannabis use for determining exposure and lack of
data on cannabis use in the follow-up period.
In a retrospective cohort study using Kaiser Permanente Northern California data
in patients in the age range of 15-49 years, Sidney et al. (1997) and Sidney (2002) examined
the association between self-reported cannabis use and mortality. The authors observed
a significantly higher risk of mortality in cannabis users (vs nonusers) after adjusting for
potential confounders like smoking, alcohol use, and sociodemographic characteristics.
However, this association was present only in men with acquired immunodeficiency syndrome (AIDS). The authors suggested that the observed association might be attributable
to uncontrolled confounding factors like risk of infection. Other limitations of this study
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were the absence of biological validation to assess cannabis use, the absence of information on post-baseline use of cannabis, lack of information on other substance use (residual
confounding), and the young age of the study population.
In a study using data from the National Health Interview Survey’s (NHIS) Drug
and Alcohol Use supplemental questionnaire (DAU), Muhuri and Gfroerer (2011) examined the association between cannabis/other illegal drug use and all-cause mortality. In
this study, the authors classified their primary exposure variable into five mutually exclusive groups, with one of them being cannabis. The authors found no association between
cannabis use (vs nonuse of all substances) and the risk of all-cause mortality after adjusting
for confounders like smoking and alcohol use. A strength of this study was the use of mutually exclusive exposure groups (marijuana only, heroin (regardless of use of marijuana,
cocaine, hallucinogens, or inhalants), cocaine, no heroin (regardless of use of marijuana,
hallucinogens, or inhalants), hallucinogens/inhalants, no heroin or cocaine (regardless of
marijuana use), and nonuse of drugs from any of the five classes). Limitations were the
use of self-reported cannabis use and lack of information about follow-up cannabis use.
Manrique-Garcia et al. (2016) conducted a follow-up study of the Andreasson and
Allebeck (1990) study described above. The authors examined the association between
cannabis use and mortality in a longitudinal cohort of 50,373 Swedish males in the military
followed for approximately 40 years. Like Andreasson and Allebeck (1990), they observed
a similar significantly higher risk of mortality in heavy cannabis users (vs nonusers) after adjusting for confounders like smoking, alcohol, and illicit drug use. Limitations of
the Manrique-Garcia et al. study were the use of baseline cannabis exposure with no information about cannabis use in the 40 years of the follow-up period and the absence of
information on confounders in the follow-up period. Another limitation was the use of
self-reported cannabis use. In a systematic review, Calabria et al. (2010) described only
two long-term cohort studies, Sidney et al. (1997) and Andreasson and Allebeck (1990).
Based on these studies, the authors emphasized the lack of evidence regarding the effects
of cannabis use on mortality. In all studies mentioned above, the study populations were
composed of individuals with normal kidney function.
Three recent studies examined individuals with compromised kidney function or
with CVD (Grubbs et al., 2016; Reis et al., 2017; Bundy et al., 2018). In a retrospective cohort
study using USRDS data, Grubbs et al. (2016) examined the association between illicit drug
use and mortality in 511,821 incident hemodialysis patients above the age of 20 years. In
this study, the authors observed a higher risk of mortality associated with illicit drug use
after adjusting for potential confounders but without adjustment for smoking or alcohol
consumption. Another shortcoming of this study was that the primary exposure was all
illicit drug use, which included cannabis. Reis et al. (2017) used data from a prospective
cohort study from the Coronary Artery Risk Development in Young Adults (CARDIA)
study consisting of a study population with an age range of 18-55 years. The authors found
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no association between self-reported cannabis use (both recent and cumulative cannabis
use adjusted for smoking and alcohol consumption) and CVD mortality.
Bundy et al. (2018) used data from the Chronic Renal Insufficiency Cohort (CRIC, a
prospective longitudinal cohort) composed of 3,939 patients with mild to moderate CKD
in the age range of 21-74 years. They observed that cannabis use (adjusted for smoking
and alcohol consumption) was not associated with the progression of CKD. However, in
the same study they observed a higher risk of all-cause mortality associated with illicit
drug use. In our current study, cannabis use alone (UTOX group 1 vs 0 reference) was not
associated with higher risk of all-cause/CV mortality, in line with Bundy et al. (2018) and
Reis et al. (2017). We observed a similar, nonsignificant association between combined use
of cannabis with opioids, other drugs, or a combination of the same (UTOX groups 2-4 vs 0
reference), and all-cause mortality/CV mortality. None of the previous studies examined
the association between combined cannabis use and mortality.
As mentioned above, Muhuri and Gfroerer (2011) (in a general population-based
cohort), Grubbs et al. (2016) (in patients with ESRD), and Bundy et al. (2018) (in patients
with CKD) observed a higher risk of mortality with illicit drug use. We did not observe a
significant association between other drugs use alone or combined use of other drugs with
opioids (UTOX groups 6 and 7 vs 0 reference) and risk of all-cause/CV mortality. Potential
reasons for this discrepancy are the smaller sample size of our study and the fact that we
combined amphetamines, barbiturates, benzodiazepines, cocaine, heroin, PCP, and LSD
use into a single “other drugs” category. This could have diluted the individual effects of
single drugs on mortality.
Our study has several distinctive features and strengths. First, we ascertained exposure to cannabis, opioids, other/illicit drugs, and the combination of these using UDT,
which would presumably capture a larger population of users (both prescription and nonprescription use). Second, we examined for the first time the association between UTOX
groups and all-cause/CV mortality in individuals with compromised kidney function.
Third, a control group composed of patients who tested negative for all substances was
available in our analysis. Fourth, we adjusted for a variety of potential confounders. This
adjustment increased the robustness of our results in comparison to previous studies that
did not always account for potential confounders. Finally, IPTW was used to balance all
the UTOX groups on all the potential confounders available (mentioned in the Methods
section of chapter 2), which is a superior method of adjustment and which was not applied in previous studies.
Our study also has limitations that should be mentioned. First, misclassification is
possible in identifying exposure based on UDTs, as a result of false-positive test results
(e.g., in the case of interfering substances or medications). Also, a test can be negative
because the UDTs were not performed in the window of detection of particular use for
cannabis (3 days for single-use, 14 for moderate use, and around 30 days for heavy use),
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opioids, or other drugs. As discussed above in detail, we assessed only current use of
cannabis but allowed for lifetime use for opioids and other drugs when defining exposure to minimize misclassification. Second, we did not include interactions or subgroup
analyses due to the small number of patients. Third, the study cohort was restricted to
predominantly male US veterans (and predominantly black, whereas other studies used
whites); thus, our study findings may have limited generalizability. Fourth, we adjusted
for several confounders, but there is a possibility of residual confounding. Finally, as we
used observational data for this study, we cannot infer causality.

Conclusion
In summary, this study shows that cannabis use alone or combined use of cannabis with
opioids or with other drugs was not significantly associated with all-cause or CV mortality. Our study results suggest the absence of a harmful association between exposure
to cannabis and mortality. The current socio-legal environment of cannabis legalization
may result in an increasing number of people exposed to cannabis, which includes individuals with compromised kidney function. Our findings regarding a lack of association
with mortality are reassuring to this population, although larger and more diverse observational studies and clinical trials are warranted to assure the safety of cannabis and
cannabinoids in regard to mortality. In addition to our findings on cannabis, we observed
that the exposure to opioids alone and other drugs (alone or in combination) was not significantly associated with the risk of all-cause/CV mortality. Further studies are required
to confirm these findings.
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Chapter 5
DISCUSSION

The comprehensive goal of the current study was to investigate the association between
cannabis use and renal, cerebrovascular, and mortality outcomes in US veterans with advanced CKD transitioning to dialysis. Previous research examining the association between cannabis use and aforementioned outcomes relied on self-reported cannabis consumption (Vupputuri et al., 2004; Grubbs et al., 2016; Ishida et al., 2017; National Academies
of Sciences and Medicine, 2017; Bundy et al., 2018; Lu et al., 2018), whereas our study used
urine drug testing (UDT) to ascertain the various types of exposure. Research has shown
that self-reported illicit drug use (at federal level cannabis use is still considered illicit) in
patients with chronic pain is not reliable (Reisfield, Salazar, and Bertholf, 2007).
Only one previous study by Barber et al. (2013) used UDTs to identify cannabis use.
The majority of previous studies looked at the effects of the individual drugs (cannabis,
opioids, etc.) but not in combination with each other (Vupputuri et al., 2004; Grubbs et al.,
2016; Novick et al., 2016; Ishida et al., 2017; Kimmel et al., 2017; National Academies of
Sciences and Medicine, 2017; Bundy et al., 2018; Lu et al., 2018; Novick et al., 2019).
In the current study, we used UDTs to ascertained and categorize the exposure into
mutually exclusive urine toxicology (UTOX) groups. This categorization into groups was
done to capture the unique behavioral characteristics of drug use. Also, this categorization
allowed for the differentiation of patients based on characteristics that may be difficult to
ascertain in a retrospective observational study especially patients who were positive only
for cannabis or combined cannabis use with opioids that might be predominantly receiving
them for medicinal purposes, while patients who were positive for illicit drugs alone or in
any combination might be more likely to use the drugs for recreational purposes.
First, we observed that cannabis use was not associated with steeper slopes of estimated glomerular filtration rate (eGFR) and risk of acute kindey injury (AKI). Secondly,
cannabis use was not associated with higher risk of stroke. Lastly, we observed that
cannabis use was not associated with a higher risk of mortality.
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UTOX Groups 1-4 vs Group 0
Renal Outcomes
We found no significant association between cannabis use (UTOX group 1) and steeper
estimated glomerular filtration rate (eGFR) slopes. Perturbations in the endocannabinoid
system (composed of cannabinoid receptors, endogenous ligands, and the machinery involved in their synthesis and breakdown) can play a role in the pathogenesis of CKD (decrease in kidney function) and AKI. Only four epidemiological studies have thus far examined the association between self-reported cannabis use and kidney function or change
in eGFR (Vupputuri et al., 2004; Ishida et al., 2017; Bundy et al., 2018; Lu et al., 2018).
However, these studies did not find any association between cannabis use and change in
kidney function. Our study results are in agreement with previous studies.
Experimental studies have observed that CB1 receptor blockade and activation of
CB2 receptors may have beneficial effects on renal structure and function (Park et al., 2017;
Barutta et al., 2018b; Chua et al., 2019). It should be noted that these studies heavily relied
on pharmacologic means that are highly specific for each receptor in isolation. This is
in contrast to natural cannabinoids (examined in the current study) that are capable of
activating both CB receptors and, therefore the net renal effect, which may be indicative of
the balance between activation of both receptors. This may be one of the reasons we did
not observe a significant association between cannabis use and change in kidney function.
An association between cannabis use and AKI has only been reported in case reports
(Ishida et al., 2017; Park et al., 2017). However, these associations were from cases of
synthetic cannabinoid use. A structural difference exists between synthetic cannabinoids
and natural cannabis (Ho, Martinusen, and Lo, 2019). Our study results did not find a
significant association between cannabis use and risk of AKI. The difference in the risk
of AKI with synthetic cannabinoids and natural cannabinoids may be attributed to the
structural differences between the two exposures. Also, due to the relatively low numbers
of cannabis users in our study, we may not have observed a significant association between
cannabis use and AKI.
We also did not observe a significant association between combined use of cannabis
and steeper eGFR slopes or with the risk of AKI. None of the previous studies examined
this association, and our study is the only one to investigate this association. However,
based on our results, we can interpret that the lack of association between cannabis in
combination with other drug and kidney function can be explained by the properties mentioned above of natural cannabinoids. Besides, we can hypothesize that the use of cannabis
in combination with opioids or other drugs or both may have influenced the dose/quantity
prescribed/taken by the patient. This combined use may result in consumption of a lower
dosage of each of them and subsequently may have led to a lack of harm. We did not find
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a significant association between risk of AKI and various pair-wise comparisons in UTOX
groups 1-4.

Cerebrovascular Outcomes
The cerebrovascular outcomes we examined was a cerebrovascular accident (CVA) event,
i.e., de novo incidence or recurrence of ischemic stroke or transient ischemic attack (TIA).
We did not observe a significant association between cannabis use (UTOX group 1) and
risk of CVA events. Previous literature shows that cannabis use may increase (Westover,
McBride, and Haley, 2007; Hemachandra et al., 2016; Rumalla, Reddy, and Mittal, 2016b;
Rumalla, Reddy, and Mittal, 2016a; Kalla et al., 2018) or decrease (Sidney et al., 1997; Sidney, 2002; Barber et al., 2013; Reis et al., 2017) the risk of stroke incidence. Our findings are
in agreement with other studies that observed no association between cannabis use and
stroke (Sidney et al., 1997; Sidney, 2002; Barber et al., 2013; Reis et al., 2017). Notably, both
the current study and the Barber et al. (2013) study examined exposure to cannabis based
on UDTs.
Combined cannabis use with opioids (UTOX group 2) was associated with a significantly lower risk of CVA events. Our study is the first epidemiological or clinical study
to examine the association between combined use of cannabis with opioids and their association with CVA events. Previous research based on preclinical studies indicates that
cannabinoids have therapeutic value in stroke (Choi, Mou, and Silva, 2019). The neuroprotective effects of cannabinoids are mediated through both CB receptors (Choi, Mou,
and Silva, 2019). Experimental studies have observed that THC exerts its neuroprotective
effects by blocking CB1 receptors via an inverse agonist mechanism (Choi, Mou, and Silva,
2019). On the other hand, CBD’s beneficial effects can be related to its unique mechanisms
of action, including acting indirectly on the CB receptors. Also, a preclinical study showed
that CBD could enhance morphine-evoked antinociception and reduce adverse effects in
ischemic stroke (Rodriguez-Munoz et al., 2018), providing a potential explanation for the
beneficial associations described in our study for combined cannabis and opioid users.
We did not observe a significant association between combined use of cannabis
(UTOX groups 3-4) and the risk of CVA events. None of the previous studies examined
this association. As mentioned above, combined cannabis use may aid in dose reduction
of the combined drugs and cannabis. We did not find a significant association between
risk of CVA events and various pair-wise comparisons of UTOX groups 1-4.

Mortality Outcomes
Cannabis use alone or combined use of cannabis with opioids or with other drugs (UTOX
groups 1-4) was not significantly associated with all-cause or cardiovascular (CV) mortality. Also, we did not find a significant association between risk of mortality and various
pair-wise comparisons of UTOX groups 1-4.
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Prior studies that examined the association between cannabis use and mortality
were based on observations from the general population. The only study that examined
the association between self-reported cannabis use and mortality in patients with compromised kidney function found no significant association (Ishida et al., 2017). Similarly, the
only study that assessed the association between cannabis use and cause-specific mortality in the general population found no association with CVD mortality (Reis et al., 2017).
These studies did not examine the association between the combined use of cannabis with
opioids and/or other drug and mortality. A study by Manrique-Garcia et al. (2016) investigated the association between cannabis use and mortality in patients with normal kidney
function and observed a significantly higher risk of mortality in heavy cannabis users (vs
non-users). Our findings are not indicative of an association between cannabis use and
mortality. This could be due to the difference in the study population (general population
vs patients with compromised kidney function) or by the different exposure ascertainment
of cannabis use (self-reported vs UDTs).

UTOX Groups 5-7 vs Group 0
Renal Outcomes
We found a significant association between combined use of opioids and other drugs
(UTOX group 7) with steeper eGFR slopes. An association between lifetime opiate use
and reduced eGFR has been previously described (Novick et al., 2016). Prior research also
has shown that the use of illicit drugs may increase the risk of CKD progression (Vupputuri et al., 2004; Bundy et al., 2018). However, the association between the combined use of
opioids with other/illicit drugs and renal outcomes has not been previously investigated.
We did not find a significant association between opioid use (UTOX group 5)/other drug
use (UTOX group 6) and steeper eGFR slopes.
While we found a significant association between combined use of opioids and
other drugs (UTOX group 7) and risk of AKI, this was not observed when examining opioid use or other drug use in isolation. Similarly, we did not find an association between
UTOX groups 5-7 and risk of AKI in various pair-wise comparisons of UTOX groups. The
association between opioid overdose and higher incidence of AKI is known (Mallappallil
et al., 2017). Previous research has shown that illicit drug use was associated with the risk
of AKI (Vupputuri et al., 2004; Bundy et al., 2018). The difference between the current
study and previous research examining the association between steeper eGFR slopes/risk
of AKI and opioids/other drug use could be due to the use of self-reported exposure vs
UDTs. Also, this discrepancy in the results may be due to a difference in the cohorts studied, especially the advanced CKD nature of our cohort.
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Cerebrovascular Outcomes
We did not find a significant association between opioids, other drugs, or combination of
both and risk of CVA events. A similar lack of associations was observed in various pairwise comparisons. Previous research has not observed an increased risk of stroke with the
use of opioids. Khodneva et al. (2016) observed that prescription opioid use (POU) did not
increase the risk of stroke. We found a similar nonsignificant association between opioid
use and CVA events, despite the difference in exposure ascertainment between the two
studies
Previous research has shown that the use of illicit/other drug was associated with
an increased risk of stroke (Westover, McBride, and Haley, 2007; Esse et al., 2011). However, we did not observe a significant association between other drug use and risk of CVA
events. This may be explained by use of self-reported exposure in previous studies vs.
UDTs in the current study. Our study is the first of its kind to examine the association
between combined use of opioids and other drugs and risk of CVA events.

Mortality Outcomes
We observed that the exposure to opioids alone and other drugs (alone or in combination) was not significantly associated with the risk of all-cause/CV mortality. A similar
lack of associations was observed in various pair-wise comparisons. Kimmel et al. (2017)
observed that opioid use was associated with higher risk of mortality among dialysis patients. One potential reason for this discrepancy was a difference in the method used to
ascertain opioid use: We defined opioid use based on UDTs, while Kimmel et al. (2017)
identified opioid use based on pharmacy prescriptions, which would have missed illicit
opioid users. However, our finding of a significant association between current smoking
status (vs nonsmokers) and increased risk of mortality serves as a positive control provides
assurance for the robustness of the observed results.
Previous research observed increased mortality risk with illicit/other drug use (Muhuri
and Gfroerer, 2011; Grubbs et al., 2016; Bundy et al., 2018). Our study results might be different from previous studies due to 1) smaller sample size of our study and 2) the fact that
we combined several illicit drugs into an “other drug” category, which could have diluted
the individual effects of single drugs on mortality. Besides, previous research used selfreport of other drugs and our study ascertained use of other drugs based on UDTs. To our
knowledge, our study is the only study that examined the association between combined
use of opioids/other drugs, and mortality.

Strengths and Recommendations of the Study
This study has several unique features:
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1. We used UDT’s to ascertain the use of cannabis, opioids, other/illicit drugs, or the
combination of these.
2. We categorized patients into mutually exclusive UTOX groups. An advantage of
this grouping is that patients in the various UTOX groups are unique, based on
cannabis/drug usage.
3. We used a control group composed of patients who tested negative for all substances.
4. We examined the association between various UTOX groups and renal, cerebrovascular/cardiovascular, and mortality outcomes.
In summary, we did not observe conclusive benefits associated with cannabis exposure, but our findings may provide sufficient assurance of a lack of harm in patients with
advanced CKD. However, further, larger and more diverse studies are needed to validate
our findings.
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Chapter 6
CONCLUSION

Summary of Findings
In the current study using retrospective cohort data of US veterans with advanced CKD
who transitioned to dialysis and had undergone urine drug tests (UDTs), we identified
users of cannabis alone (2.8%) or in combination with other drugs (9.4%). We examined
associations between the use of cannabis, opioids, other drugs, or a combination of these
(a total of 7 drug exposure categories vs group that tested negative for all tests) with the
following outcomes:
• Renal outcomes (Chapter 2).
• Cerebrovascular outcomes (Chapter 3).
• Mortality outcomes (Chapter 4).
First, we examined the associations of seven different drug exposure categories with
renal outcomes (vs reference), including progression of CKD (quantified as steeper eGFR
slope) and risk of AKI. We found no significant association between cannabis use and
steeper eGFR slopes or risk of AKI after adjusting for potential confounders. As a comparative control, however, we observed a significant statistical association between other
drug use in combination with opioids and both renal outcomes.
Second, we investigated associations with cerebrovascular outcomes, defined as the
de novo incidence or recurrence of ischemic stroke or transient ischemic attack (TIA). Of
the seven different exposure categories (vs reference), only the combined use of cannabis
and opioids was associated with significantly lower risk of cerebrovascular outcomes after
adjusting for potential confounders.
Finally, we examined associations with mortality, including both all-cause and cardiovascular mortality. None of the seven drug exposure groups (vs reference) was associated with significantly higher risk of all-cause or CV mortality after adjustments for
confounders.
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Implications for Practice, Policy, and Future Research
The current socio-legal environment of cannabis legalization may result in an increasing
number of people who consume and hence are exposed to cannabis. Our understanding of the risks associated with the use of tobacco or alcohol is more complete than our
knowledge cannabis the health effects. This knowledge gap demands better discernment
of the short- and long-term effects of cannabis use on health (either detrimental or protective). In this regard, the National Academy of Sciences and Medicine (NASM) has published a report titled “The Health Effects of Cannabis and Cannabinoids: The Current
State of Evidence and Recommendations for Research" (National Academies of Sciences
and Medicine, 2017). According to NASM, the current socio-legal climate of cannabis legalization “.. is a pivotal time in the world of cannabis policy and research. Shifting public
sentiment, conflicting and impeded scientific research, and legislative battles have fueled
the debate about what, if any, harms or benefits can be attributed to the use of cannabis or
its derivatives" (p. 9). Previous research showed that in states where medical marijuana is
legalized, there is a reduction in utilization of prescribed opioids and deaths due to opioid
overdose (Shah et al., 2019)
The first research gap mentioned by NASM (National Academies of Sciences and
Medicine, 2017) in clinical and observational research was a lack of studies examining the
health effects of cannabis use in at-risk or under-researched populations, especially in the
elderly. Even though NASM has not mentioned adults with compromised kidney function,
this group falls under the category of at-risk populations. Our study addresses this gap
in knowledge, and our results suggest that exposure to cannabis in this population is not
associated with worse renal, cardiovascular, or mortality outcomes. While we did not
observe conclusive benefits associated with cannabis exposure, our findings may provide
sufficient assurance of a lack of harm to foster future research dedicated to the examination
of potential health benefits of cannabis and/or its derivatives in this population, or to
promote the clinical use of these substances.
Regarding clinical applications, the NASM report emphasizes that cannabis is effective in treating chronic pain. Based on our study, cannabis use alone or in combination
with opioids may not be harmful in patients with compromised kidney function. This may
be relevant given that clinicians may choose to prescribe cannabis alone or in combination
with opioids for medicinal purposes to treat pain in patients with advanced CKD. Notably,
combined cannabis use with opioids may have a synergistic, analgesic effect. Synergistic
analgesia may further help in reducing the dose of both cannabis and opioids needed for
optimal pain relief. Our current study may also aid policymakers as they look for clinical
evidence to guide their decisions regarding further legalization of cannabis.
Notwithstanding our results, future studies are needed to expand further our understanding of the diverse health effects of cannabis use in the general population as well
as patients with CKD. The prevalence of CVD in CKD patients is two times higher than
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that of the general population (Levin, 2003). In the current study, one of our main focuses
was the association between cerebrovascular outcomes and cannabis use, based on preclinical studies indicating that cannabinoids may have a therapeutic potential in stroke.
Especially, there are reports on neuroprotective properties of tetrahydrocannabinol (THC)
and cannabidiol (CBD) that exert their effects by directly or indirectly acting on cannabinoid (CB) receptors CB1 or CB2 (Park et al., 2017; Chua et al., 2019). Given the diverse
physiologic effects of the endocannabinoid system and the ubiquity of CB1 and/or CB2
receptors in various organ systems, it is plausible to postulate that numerous other cardiovascular and noncardiovascular outcomes could be examined in relationship to cannabis
exposure in the CKD (and other) populations. Cardiovascular outcomes such as congestive heart failure, peripheral vascular disease, and coronary artery disease are common
among patients with advanced CKD and are associated with worse morbidity and mortality and could represent future targets of cannabis research.
Among the various noncardiovascular outcomes representing potential targets for
future cannabis-related research, chronic obstructive pulmonary disease is a common comorbidity that is also a risk factor for CKD (Chen and Liao, 2016). The NASM report
mentioned a research gap in studies examining the association between cannabis use (especially smoking) and respiratory outcomes. Chronic tobacco/cannabis smoking worsen
respiratory function. However, previous research observed moderate evidence of a statistical association between cannabis smoking and improved respiratory function through
airway dynamics (National Academies of Sciences and Medicine, 2017). Both CB receptors
CB1 and CB2 are expressed in the lungs and bronchial tissue (Turcotte et al., 2016). Previous research in vitro/preclinical studies showed the deleterious effect of THC on airway
epithelial cells and how it may be mediated through CB2 receptors (Turcotte et al., 2016).
Another potential area for future research is psychiatric conditions, which are common in patients with CKD/ESRD (De Sousa, 2008). According to the NASM report (National Academies of Sciences and Medicine, 2017), there is a research gap in the evidence
about the association between cannabis use and mental health outcomes, especially posttraumatic stress disorder symptoms (PTSD). Previous studies showed how increased expression of CB1 receptors in patients with PTSD was associated with anxious arousal. Also,
there have been observations regarding the potential role of THC and CBD in alleviating
symptoms of PTSD (Abizaid, Merali, and Anisman, 2019). In a pilot study, Roitman et
al. (2014) administered 5 mg of THC as an add on therapy to 10 patients with PTSD and
observed a statistically significant improvement in different PTSD symptoms like global
symptom severity, nightmares, hyperarousal symptoms, and sleep quality.
Future studies of all of the above-mentioned clinical outcomes are needed. These
studies can address the pathophysiologic mechanisms using basic science experiments as
well as epidemiological studies and clinical trials. Also, these studies should clarify questions (among others) about the risks and benefits of medical and recreational cannabis
consumption. It is also imperative that key information be forthcoming regarding optimal
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dosage and route of administration, chemical components and structures of content, and
toxicity profile delineation of each component in order to maximize health benefits and
minimize adverse effects.
The current study can inspire future studies that use UDTs for exposure ascertainment and foster the use of different biological means ascertainment of exposure instead of
self-reported use. Finally, based on our study, future studies could utilize data from UDTs
to examine the association between combined use of exposures and various outcomes in
addition to the individual exposures.

Conclusion
In summary, this study in patients with advanced CKD transitioning to dialysis shows
that:
1. Cannabis use alone or in combination with opioids or other drugs is not associated
with worse renal, cardiovascular, or mortality outcomes.
2. Use of cannabis in combination with opioids may lower the risk of cerebrovascular
events.
3. Combined use of opioids with other drugs may increase the risk of adverse renal
outcomes.
The preponderance of evidence in the population we studied suggests a lack of
detrimental associations between cannabis exposure and renal, cardiovascular, and mortality outcomes. The study results call for future research to broaden understanding of the
health effects of cannabis use across various populations in order to guide policy decision
making.
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